Page last updated: 2024-12-05

masoprocol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

nordihydroguaretic acid: antioxidant compound found in the creosote bush (Larrea tridentata) [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Masoprocol: A potent lipoxygenase inhibitor that interferes with arachidonic acid metabolism. The compound also inhibits formyltetrahydrofolate synthetase, carboxylesterase, and cyclooxygenase to a lesser extent. It also serves as an antioxidant in fats and oils. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

masoprocol : The meso-form of nordihydroguaiaretic acid. An antioxidant found in the creosote bush, Larrea divaricata, it is a potent lipoxygenase inhibitor that interferes with arachidonic acid metabolism. It also inhibits (though to a lesser extent) formyltetrahydrofolate synthetase, carboxylesterase, and cyclooxygenase. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

FloraRankFlora DefinitionFamilyFamily Definition
Larrea divaricataspecies[no description available]ZygophyllaceaeA plant family of the order Sapindales, subclass Rosidae, class Magnoliopsida which is a small family of small trees and shrubs growing in arid and warm regions.[MeSH]

Cross-References

ID SourceID
PubMed CID4534
CHEMBL ID52
CHEBI ID7625
SCHEMBL ID135976
MeSH IDM0014961
PubMed CID71398
CHEMBL ID313972
CHEBI ID73468
SCHEMBL ID3818
MeSH IDM0014961

Synonyms (225)

Synonym
4,4'-(2,3-dimethyl-1,4-butanediyl)bis(1,2-benzenediol)
einecs 207-903-0
2,3-dimethyl-1,4-bis(3,4-dihydroxyphenyl)butane
ai3-23059
nsc 4291
beta,gamma-dimethyl-alpha,delta-bis(3,4-dihydroxyphenyl)butane
norhydroguaiaretic acid
4,4'-(2,3-dimethyl-1,4-butanediyl)bis-1,2-benzenediol
butane, 1,4-bis(3,4-dihydroxyphenyl)-2,3-dimethyl-
2,3-bis(3,4-dihydroxyphenylmethyl)butane
ccris 1399
4,4'-(2,3-dimethyltetramethylene)dipyrocatechol
nsc 682984
4,4'-(2,3-dimethyl-1,4-butanediyl)bis(pyrocatechol)
norguaiaretic acid, dihydro
MLS002153435
norguaiaretic acid, dihydro-
.beta.,.delta.-bis(3,4-dihydroxyphenyl)butane
butane,4-bis(3,4-dihydroxyphenyl)-2,3-dimethyl-
dinorguaiaretic acid, dihydro-
pyrocatechol,4'- (2,3-diemthyltetramethylene) di-
dihydronorguaiaretic acid
pyrocatechol,4'-(2,3-dimethyltetramethylene)di-
nsc4291
4,3-dimethyl-1,4-butanediyl)bis(pyrocatechol)
wln: qr bq d1y1&y1&1r cq dq
1, 4,4'-(2,3-dimethyl-1,4-butanediyl)bis-
4,3-dimethyltetramethylene)dipyrocatechol
pyrocatechol, 4,4'-(2,3-dimethyltetramethylene)di-
4-[4-(3,4-dihydroxyphenyl)-2,3-dimethyl-butyl]benzene-1,2-diol
nsc682984
1,2-benzenediol, 4,4'-(2,3-dimethyl-1,4-butanediyl)bis-
KBIO1_000999
DIVK1C_000999
NCI60_003992
actinex
SPECTRUM_001146
nordihydroguaretic acid
SMP2_000272
SPECTRUM5_000735
IDI1_000999
OPREA1_368609
500-38-9
nordihydroguaiaretic acid ,
ndga
CMAP_000026
MLS000069451 ,
smr000059049
KBIOSS_001626
KBIO3_002828
KBIO2_002349
KBIOGR_002349
KBIO2_001626
KBIO2_007485
KBIOSS_002352
KBIO2_006762
KBIO2_004917
KBIO2_004194
NINDS_000999
NCGC00089785-02
NCGC00089785-03
N-8500
nordihydroguajaretic acid
nordihydroguaiaretic acid, >=90% (hplc), from larrea divaricata (creosote bush)
nordihydroguaiaretic acid, >=97.0% (hplc)
D0800
chebi:7625 ,
CHEMBL52 ,
HMS503G19
AKOS003367978
hczkyjdfepmadg-uhfffaoysa-
inchi=1/c18h22o4/c1-11(7-13-3-5-15(19)17(21)9-13)12(2)8-14-4-6-16(20)18(22)10-14/h3-6,9-12,19-22h,7-8h2,1-2h3
4-[4-(3,4-dihydroxyphenyl)-2,3-dimethylbutyl]benzene-1,2-diol
NCGC00015741-06
dtxcid702437
tox21_302171
NCGC00255380-01
dtxsid5022437 ,
cas-500-38-9
HMS2232L16
S3984
NCGC00015741-04
NCGC00015741-05
NCGC00015741-08
CS-1431
FT-0606781
4,4'-(2,3-dimethylbutane-1,4-diyl)dibenzene-1,2-diol
1,4-bis(3,4-dihydroxyphenyl)-2,3-dimethylbutane
HMS3370G10
gtpl4265
nordihydroguiaretic acid
CCG-207935
HY-N0198
MLS006011710
SCHEMBL135976
4,4'-(2,3-dimethylbutane-1,4-diyl)bis(benzene-1,2-diol)
cid_4534
nordihydroguaiaretic acid (ndga)
lox inhibitor, n/a
4-[4-[3,4-bis(oxidanyl)phenyl]-2,3-dimethyl-butyl]benzene-1,2-diol
4-[4-(3,4-dihydroxyphenyl)-2,3-dimethyl-butyl]pyrocatechol
bdbm32020
.beta.,.gamma.-dimethyl-.alpha.,.delta.-bis(3,4-dihydroxyphenyl)butane
AC-24202
HMS3649M15
mfcd00002206
AS-58406
4,4'-(2,3-dimethylbutane-1,4-diyl)di(benzene-1,2-diol)
bp_36
ndga - cas 500-38-9
F17140
rel-4,4'-((2r,3s)-2,3-dimethylbutane-1,4-diyl)bis(benzene-1,2-diol)
NCGC00015741-09
sr-01000003007
SR-01000003007-2
ndga;masoprocol
BCP08590
Q7050774
SDCCGSBI-0050852.P002
STL570288
chx 100; masoprocol; meso-ndga
NCGC00015741-13
A913176
XN163193
nordihydroguaiareticacid-d6
ndga (nordihydroguaiaretic acid)
Z2065671207
BIDD:ER0127
nordihydroguaiaretic acid, (r*,s*)-isomer
chebi:73468 ,
insm-18
nsc-682984
nsc-4291
chx-100
LOPAC0_000877
4-[(2s,3r)-3-[(3,4-dihydroxyphenyl)methyl]-2-methylbutyl]benzene-1,2-diol
bdbm22372
4-[(2r,3s)-4-(3,4-dihydroxyphenyl)-2,3-dimethylbutyl]benzene-1,2-diol
chembl313972 ,
EU-0100877
lopac-n-5023
NCGC00015741-02
tnp00263
NCGC00015741-01
4-[(2r,3s)-4-(3,4-dihydroxyphenyl)-2,3-dimethyl-butyl]benzene-1,2-diol
meso-ndga
1,2-benzenediol, 4,4'-(2,3-dimethyl-1,4-butanediyl)bis-, (r*,s*)-
27686-84-6
masoprocol
meso-nordihydroguaiaretic acid
chx 100
meso-4,4'-(2,3-dimethyltetramethylene)dipyrocatechol
D04862
masoprocol (usan/inn)
actinex (tn)
erythro-nordihydroguaiaretic acid
meso-beta,gamma-dimethyl-alpha,delta-bis(3,4-dihydroxyphenyl)butan
meso-4,4'-(2,3-dimethyl-1,4-butanediyl)bis(pyrocatechol)
meso-4-[4-(3,4-dihydroxyphenyl)-2,3-dimethylbutyl]benzene-1,2-diol
meso-2,3-bis(3,4-dihydroxyphenylmethyl)butane
meso-1,4-bis(3,4-dihydroxyphenyl)-2,3-dimethylbutane
DB00179
nordihydroguaiaretic acid (meso-form)
c18h22o4
einecs 248-606-6
(r*,s*)-4,4'-(2,3-dimethylbutane-1,4-diyl)bispyrocatechol
masoprocol [usan:inn]
masoprocolum [inn-latin]
NCGC00094201-02
NCGC00015741-03
nordihydroguaiaretic acid from larrea divaricata (creosote bush)
NCGC00094201-01
meso nordihydroguaiaretic acid
acid, meso-nordihydroguaiaretic
N 5023 ,
NCGC00094201-04
4-[(2s,3r)-4-(3,4-dihydroxyphenyl)-2,3-dimethylbutyl]benzene-1,2-diol
NCGC00094201-03
NCGC00094201-05
HMS3262P15
dtxsid5045178 ,
tox21_110210
dtxcid3025178
cas-27686-84-6
CCG-204959
AKOS016014015
NCGC00015741-07
1,2-benzenediol, 4,4'-((2r,3s)-2,3-dimethyl-1,4-butanediyl)bis-, rel-
masoprocolum
unii-7bo8g1byqu
7bo8g1byqu ,
LP00877
4-((2r,3s)-4-(3,4-dihydroxyphenyl)-2,3-dimethylbutyl)benzene-1,2-diol
nordihydroguaiaretic acid [inci]
masoprocol [mart.]
nordihydroguaiaretic acid [who-dd]
masoprocol [vandf]
oristar nhga
nordihydroguaiaretic acid [mi]
masoprocol [orange book]
masoprocol [who-dd]
masoprocol [usan]
insm18
masoprocol [inn]
SCHEMBL3818
NCGC00261562-01
tox21_500877
nordihydroguaiaretsaure
4,4'-((2r,3s)-2,3-dimethylbutane-1,4-diyl)bis(benzene-1,2-diol)
sr-01000076028
SR-01000076028-1
HY-109500
ncgc00015741-06!nordihydroguaiaretic acid
4,4'-((2r,3s)-2,3-dimethylbutane-1,4-diyl)dibenzene-1,2-diol
1050512-02-1
Q6783851
NCGC00094201-06
1,2-benzenediol, 4,4'-[(2r,3s)-2,3-dimethyl-1,4-butanediyl]bis-, rel-
EN300-18167073
CS-0031186
masoprocol (mart.)
meso-4-(4-(3,4-dihydroxyphenyl)-2,3-dimethylbutyl)benzene-1,2-diol
ndhga
masoprocolum (inn-latin)
l01xx10

Research Excerpts

Toxicity

ExcerptReferenceRelevance
"5 million adverse drug reaction (ADR) reports for 8620 drugs/biologics that are listed for 1191 Coding Symbols for Thesaurus of Adverse Reaction (COSTAR) terms of adverse effects."( Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL, 2004
)
0.32
" In this study, we tested inhibitors of arachidonate metabolism for possible protection against the toxic effects of the cytokine combination of tumor necrosis factor (TNF, 100 U/ml) and interferon-gamma (IFN-gamma, 100 U/ml) in rat islet cell monolayer cultures, using a 51Cr release cytotoxicity assay to measure islet cell lysis (% 51Cr release)."( Cytotoxic effects of cytokines on islet beta-cells: evidence for involvement of eicosanoids.
Baquerizo, H; Rabinovitch, A; Sumoski, W, 1990
)
0.28
" 7,12-Dimethylbenz(a)anthracene (DMBA) and 7-hydroxymethyl-12-methylbenz(a)anthracene (7-OHM-12-MBA), but not benzo(a)pyrene (BP), selectively produce necrosis in the two inner zones of the rat adrenal cortex and are toxic to cultured rat adrenocortical cells."( Influence of effectors of prostaglandin metabolism on the toxicity induced by 7-hydroxymethyl-12-methylbenz(a)anthracene in cultured rat adrenal cells.
Hallberg, E; Rydström, J, 1990
)
0.28
" The results suggest that the antioxidant properties of these substances interfere with the rapidly occurring toxic effects of HU and that this may account for amelioration of HU developmental toxicity."( Ethoxyquin and nordihydroguaiaretic acid reduce hydroxyurea developmental toxicity.
DeSesso, JM; Goeringer, GC, 1990
)
0.28
" Our data show that NDGA can abrogate the toxic and tumour-promoting effects of Fe-NTA in liver and kidney of mice and can serve as a potent chemopreventive agent to suppress oxidant-induced tissue injury and tumorigenesis."( Nordihydroguairetic acid is a potent inhibitor of ferric-nitrilotriacetate-mediated hepatic and renal toxicity, and renal tumour promotion, in mice.
Ansar, S; Athar, M; Iqbal, M, 1999
)
0.3
" In summary, the inhibitors that provided protection from toxic lymph appear to work at the membrane and are involved in limiting membrane peroxidation."( The role of oxidant-mediated pathways in the cytotoxicity of endothelial cells exposed to mesenteric lymph from rats subjected to trauma-hemorrhagic shock.
Dayal, S; Deitch, EA; Lu, Q; Lukose, B; Osband, AJ; Xu, DZ; Zaets, S, 2003
)
0.32
" There were no serious adverse events (SAEs) and possible treatment-related Adverse Events (AEs) reported were mild and self-limiting."( Phase I/II clinical safety studies of terameprocol vaginal ointment.
Arnold, S; Dalby, R; Frazer, N; Khanna, N; Stern, J; Tan, M, 2007
)
0.34
" There is a need to explore intensely stable therapeutic compounds, potent enough to restrict, disrupt or wipe out such toxic aggregates."( Repositioning nordihydroguaiaretic acid as a potent inhibitor of systemic amyloidosis and associated cellular toxicity.
Ajmal, MR; Islam, S; Khan, RH; Nusrat, S; Santra, MK; Siddiqi, MK; Zaidi, N; Zaman, M, 2016
)
0.43

Pharmacokinetics

ExcerptReferenceRelevance
" The terminal half-life of NDGA was 135."( Pharmacokinetic analysis by high-performance liquid chromatography of intravenous nordihydroguaiaretic acid in the mouse.
Dorr, RT; Lambert, JD; Meyers, RO; Timmermann, BN, 2001
)
0.31

Compound-Compound Interactions

ExcerptReferenceRelevance
" We observed no such synergism when M4N was used in combination with cisplatin, another chemotherapeutic agent, but not a Pgp substrate, as analyzed by the combination index and isobologram methods."( Reversal of multidrug resistance by two nordihydroguaiaretic acid derivatives, M4N and maltose-M3N, and their use in combination with doxorubicin or paclitaxel.
Chang, CC; Chou, TC; Hsu, CI; Huang, RC; Klutz, A; Lee, YC; Liang, YC; Lin, CF; Mold, DE, 2006
)
0.33
"The ability of Tetra-O-methyl nordihydroguaiaretic acid (M4N) to induce rapid cell death in combination with Etoposide, Rapamycin, or UCN-01 was examined in LNCaP cells, both in cell culture and animal experiments."( Tetra-O-Methyl Nordihydroguaiaretic Acid Broadly Suppresses Cancer Metabolism and Synergistically Induces Strong Anticancer Activity in Combination with Etoposide, Rapamycin and UCN-01.
Huang, RC; Kimura, K, 2016
)
0.43

Bioavailability

ExcerptReferenceRelevance
" Bioavailability and selectivity were assessed by ex vivo RIA of TXB2, LTB4, and 12-HETE from ionophore-challenged blood."( Simple procedure for measuring the pharmacodynamics and analgesic potential of lipoxygenase inhibitors.
Carey, F; Edmonds, AE; Forder, RA; Haworth, D, 1988
)
0.27
" administration to ICR mice indicated an absolute bioavailability for oral M4N of approximately 88%."( Systemic treatment with tetra-O-methyl nordihydroguaiaretic acid suppresses the growth of human xenograft tumors.
Chang, CC; Chung, Y; Henry, RA; Huang, RC; Liang, YC; Lin, E; Mold, DE; Park, R, 2005
)
0.33
" The latter is an important factor to assure the bioavailability of plant extracts intended to be administered via the oral route."( Stability of an Aqueous Extract of Larrea divaricata Cav. during a Simulated Digestion Process.
Alonso, MR; Anesini, C; Martino, R; Monti, D; Peralta, I, 2017
)
0.46
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

ExcerptRelevanceReference
" Dose-response curves for the inhibitory effects of the anti-oxidants on DNA synthesis and ODC activity at 48 h after mitogen addition were very similar."( Effects of anti-oxidants on ornithine decarboxylase in mitogenically-activated T lymphocytes.
Fragonas, JC; Hunt, NH, 1992
)
0.28
" Our data suggest that both the route of drug administration and dosing regimen employed affect the antiinflammatory potency and/or efficacy of compounds on colitis induced by acetic acid in the rat."( Antiinflammatory effects of various drugs on acetic acid induced colitis in the rat.
Bostwick, JS; Decktor, DL; Fitzpatrick, LR; Pendleton, RG; Renzetti, M, 1990
)
0.28
" CDE had a similar effect on peroxide production, but the dose-response curves suggested that only the high-molecular-weight polymers of tannin present in the CDE were able to enhance peroxide production."( Modulation of inflammatory cell function by cotton bract tannin: changes in the capacity of alveolar macrophages and neutrophils to produce hydrogen peroxide.
Rohrbach, MS; Vuk-Pavlović, Z, 1990
)
0.28
" In the presence of 10(-4) acetylsalicylic acid (ASA), cumulative dose-response curves of phasic and tonic contractions for LTC4 were shifted to the right of controls, whereas curves of the phasic motility for LTD4 remained unaltered."( On the inotropic effects of leukotrienes in the isolated urinary bladder of guinea pigs and rats.
Chaud, MA; Gimeno, AL; Gimeno, MF; Viggiano, JM, 1985
)
0.27
" The dose-response curves of NA were shifted to the right."( Vasoconstriction induced by noradrenaline and angiotensin II is antagonized by eicosapentaenoic acid independent of formation of trienoic eicosanoids.
Juan, H; Sametz, W, 1986
)
0.27
" However, in the presence of the EDRF stimulator acetylcholine, the dose-response curve to SNP was shifted to right in the aorta as well."( Endothelium-derived relaxant factor inhibits effects of nitrocompounds in isolated arteries.
Busse, R; Pohl, U, 1987
)
0.27
" A dose-response relationship revealed that I5-HT was activated with an ED50 of 30 nM."( Whole-cell recordings of inwardly rectifying K+ currents activated by 5-HT1A receptors on dorsal raphe neurones of the adult rat.
Fox, AP; Kelly, JS; Penington, NJ, 1993
)
0.29
" Such a complex dose-response effect may have significant impact in explaining the pathologic effects of NO2."( Dual effect of nitrogen dioxide on rat alveolar macrophage arachidonate metabolism.
Forman, HJ; Robison, TW,
)
0.13
" AA reduced the maximum amplitude of nIACh estimated from the dose-response relationship without causing an appreciable change in the apparent dissociation constant."( Inhibitory effects of arachidonic acid on nicotinic transmission in bullfrog sympathetic neurons.
Minota, S; Watanabe, S, 1997
)
0.3
" Our data suggested that a high dosage of systemic expression of CTLA4Ig was effective to enhance xenograft survival and that in it was reinforced by a combination with the macrophage inhibitor NDGA."( Enhancing engraftment of neonatal porcine xenoislet with CTLA4Ig and nordihydroguaiaretic acid.
Chen, YT; Chiang, CH; Fu, SH; Hsu, BR, 2006
)
0.33
" Treatment consisted of continuous oral daily dosing according to a planned dose escalation of 750, 1250, 1750, 2250 and 2500 mg of NDGA."( A pilot dose-escalation study of the effects of nordihydroguareacetic acid on hormone and prostate specific antigen levels in patients with relapsed prostate cancer.
Claros, C; Goldfine, ID; Harzstark, AH; Kerner, JF; Lin, A; Rosenberg, J; Ryan, CJ; Small, EJ; Youngren, JF, 2008
)
0.35
"Continuous daily dosing with NDGA is reasonably well tolerated but is associated with transaminitis in some patients, that occurs after several months on therapy."( A pilot dose-escalation study of the effects of nordihydroguareacetic acid on hormone and prostate specific antigen levels in patients with relapsed prostate cancer.
Claros, C; Goldfine, ID; Harzstark, AH; Kerner, JF; Lin, A; Rosenberg, J; Ryan, CJ; Small, EJ; Youngren, JF, 2008
)
0.35
" Cumulative levobupivacaine dose-response curves over a range of 10(-6) to 3 x 10(-4) M were constructed in 1) aortic rings with no drug pretreatment; 2) endothelium-denuded rings pretreated with quinacrine dihydrochloride (nonspecific phospholipase A(2) inhibitor: 2 x 10(-5), 4 x 10(-5) M), nordihydroguaiaretic acid (NDGA) (lipoxygenase inhibitor: 10(-5), 3 x 10(-5) M), indomethacin (nonspecific cyclooxygenase inhibitor: 10(-5) M), AA-861 (5-lipoxygenase inhibitor: 10(-5), 5 x 10(-5) M), fluconazole (cytochrome P450 epoxygenase inhibitor: 10(-5) M), verapamil (10(-5) M), or calcium-free solution; and 3) endothelium-intact rings pretreated with N(omega)-nitro-L-arginine methyl ester (L-NAME) (nitric oxide synthase inhibitor: 5 x 10(-5) M), indomethacin, or fluconazole."( The direct effect of levobupivacaine in isolated rat aorta involves lipoxygenase pathway activation and endothelial nitric oxide release.
Choi, YS; Hah, YS; Hwang, EM; Jeong, YS; Lee, SH; Ok, SH; Park, JY; Shin, IW; Sohn, JT, 2010
)
0.36
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (8)

RoleDescription
antioxidantA substance that opposes oxidation or inhibits reactions brought about by dioxygen or peroxides.
plant metaboliteAny eukaryotic metabolite produced during a metabolic reaction in plants, the kingdom that include flowering plants, conifers and other gymnosperms.
ferroptosis inhibitorAny substance that inhibits the process of ferroptosis (a type of programmed cell death dependent on iron and characterized by the accumulation of lipid peroxides) in organisms.
geroprotectorAny compound that supports healthy aging, slows the biological aging process, or extends lifespan.
antineoplastic agentA substance that inhibits or prevents the proliferation of neoplasms.
lipoxygenase inhibitorA compound or agent that combines with lipoxygenase and thereby prevents its substrate-enzyme combination with arachidonic acid and the formation of the icosanoid products hydroxyicosatetraenoic acid and various leukotrienes.
hypoglycemic agentA drug which lowers the blood glucose level.
metaboliteAny intermediate or product resulting from metabolism. The term 'metabolite' subsumes the classes commonly known as primary and secondary metabolites.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (4)

ClassDescription
catecholsAny compound containing an o-diphenol component.
tetrolA polyol that contains 4 hydroxy groups.
lignanAny phenylpropanoid derived from phenylalanine via dimerization of substituted cinnamic alcohols, known as monolignols, to a dibenzylbutane skeleton. Note that while individual members of the class have names ending ...lignane, ...lignene, ...lignadiene, etc., the class names lignan, neolignan, etc., do not end with an "e".
nordihydroguaiaretic acidA tetrol that is butane which is substituted at positions 2 and 3 by 3,4-dihydroxybenzyl groups. Masoprocol, the meso-form found in the leaves of the creosote bush (Larrea divaricata), is a potent lipoxygenase inhibitor.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (2)

PathwayProteinsCompounds
phospholipases1410
dopamine degradation431

Protein Targets (175)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency31.62280.003245.467312,589.2998AID2517
Chain A, TYROSYL-DNA PHOSPHODIESTERASEHomo sapiens (human)Potency2.81840.004023.8416100.0000AID485290
Chain A, Putative fructose-1,6-bisphosphate aldolaseGiardia intestinalisPotency22.33420.140911.194039.8107AID2451
Chain A, HADH2 proteinHomo sapiens (human)Potency7.94330.025120.237639.8107AID893
Chain B, HADH2 proteinHomo sapiens (human)Potency7.94330.025120.237639.8107AID893
Chain A, JmjC domain-containing histone demethylation protein 3AHomo sapiens (human)Potency22.38720.631035.7641100.0000AID504339
Chain A, 2-oxoglutarate OxygenaseHomo sapiens (human)Potency28.93420.177814.390939.8107AID2147
Chain A, ATP-DEPENDENT DNA HELICASE Q1Homo sapiens (human)Potency16.57520.125919.1169125.8920AID2549; AID2708
LuciferasePhotinus pyralis (common eastern firefly)Potency40.02710.007215.758889.3584AID1224835; AID624030
acetylcholinesteraseHomo sapiens (human)Potency64.63670.002541.796015,848.9004AID1347397; AID1347398
thioredoxin reductaseRattus norvegicus (Norway rat)Potency19.95260.100020.879379.4328AID588453
15-lipoxygenase, partialHomo sapiens (human)Potency0.10000.012610.691788.5700AID887
WRNHomo sapiens (human)Potency17.78280.168331.2583100.0000AID651768
phosphopantetheinyl transferaseBacillus subtilisPotency59.62170.141337.9142100.0000AID1490
hypoxia-inducible factor 1 alpha subunitHomo sapiens (human)Potency57.13253.189029.884159.4836AID1224846; AID1224894
RAR-related orphan receptor gammaMus musculus (house mouse)Potency7.42800.006038.004119,952.5996AID1159521; AID1159523
USP1 protein, partialHomo sapiens (human)Potency10.00000.031637.5844354.8130AID504865
GLS proteinHomo sapiens (human)Potency9.10640.35487.935539.8107AID624170
TDP1 proteinHomo sapiens (human)Potency11.46420.000811.382244.6684AID686978; AID686979
GLI family zinc finger 3Homo sapiens (human)Potency10.84120.000714.592883.7951AID1259369; AID1259392
Microtubule-associated protein tauHomo sapiens (human)Potency21.45090.180013.557439.8107AID1460
AR proteinHomo sapiens (human)Potency41.09140.000221.22318,912.5098AID1259243; AID1259247; AID743035; AID743054; AID743063
apical membrane antigen 1, AMA1Plasmodium falciparum 3D7Potency7.07950.707912.194339.8107AID720542
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency19.09190.011212.4002100.0000AID1030
hypoxia-inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor)Homo sapiens (human)Potency5.01190.00137.762544.6684AID914; AID915
PINK1Homo sapiens (human)Potency44.66842.818418.895944.6684AID624263
estrogen receptor 2 (ER beta)Homo sapiens (human)Potency49.61370.000657.913322,387.1992AID1259377; AID1259378
hypothetical protein, conservedTrypanosoma bruceiPotency30.25860.223911.245135.4813AID624173
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency54.48270.001022.650876.6163AID1224839
progesterone receptorHomo sapiens (human)Potency61.13060.000417.946075.1148AID1346795
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency51.82700.000214.376460.0339AID720691; AID720692; AID720719
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency0.80030.003041.611522,387.1992AID1159552; AID1159555
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency58.16870.001530.607315,848.9004AID1224841; AID1224848; AID1224849; AID1259401; AID1259403
pregnane X nuclear receptorHomo sapiens (human)Potency21.68990.005428.02631,258.9301AID1346982
estrogen nuclear receptor alphaHomo sapiens (human)Potency39.78580.000229.305416,493.5996AID1259248; AID743069; AID743075; AID743077; AID743078; AID743079
ParkinHomo sapiens (human)Potency44.66840.819914.830644.6684AID624263
peroxisome proliferator-activated receptor deltaHomo sapiens (human)Potency21.87240.001024.504861.6448AID743215
peroxisome proliferator activated receptor gammaHomo sapiens (human)Potency38.25100.001019.414170.9645AID743140; AID743191
aryl hydrocarbon receptorHomo sapiens (human)Potency10.87070.000723.06741,258.9301AID743122
activating transcription factor 6Homo sapiens (human)Potency33.50990.143427.612159.8106AID1159516; AID1159519
nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105), isoform CRA_aHomo sapiens (human)Potency54.941019.739145.978464.9432AID1159509
v-jun sarcoma virus 17 oncogene homolog (avian)Homo sapiens (human)Potency48.96620.057821.109761.2679AID1159526
Histone H2A.xCricetulus griseus (Chinese hamster)Potency39.34070.039147.5451146.8240AID1224845; AID1224896
cellular tumor antigen p53 isoform aHomo sapiens (human)Potency31.62280.316212.443531.6228AID902
polyunsaturated fatty acid lipoxygenase ALOX12Homo sapiens (human)Potency14.12541.000012.232631.6228AID1452
15-hydroxyprostaglandin dehydrogenase [NAD(+)] isoform 1Homo sapiens (human)Potency13.35730.001815.663839.8107AID894
vitamin D3 receptor isoform VDRAHomo sapiens (human)Potency44.66840.354828.065989.1251AID504847
chromobox protein homolog 1Homo sapiens (human)Potency17.78280.006026.168889.1251AID540317
parathyroid hormone/parathyroid hormone-related peptide receptor precursorHomo sapiens (human)Potency28.18383.548119.542744.6684AID743266
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency6.01180.000323.4451159.6830AID743065; AID743067
heat shock protein beta-1Homo sapiens (human)Potency28.63370.042027.378961.6448AID743210; AID743228
mitogen-activated protein kinase 1Homo sapiens (human)Potency39.81070.039816.784239.8107AID995
flap endonuclease 1Homo sapiens (human)Potency22.38720.133725.412989.1251AID588795
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency30.63790.000627.21521,122.0200AID743202
peptidyl-prolyl cis-trans isomerase NIMA-interacting 1Homo sapiens (human)Potency89.12510.425612.059128.1838AID504891
DNA polymerase eta isoform 1Homo sapiens (human)Potency28.18380.100028.9256213.3130AID588591
DNA polymerase iota isoform a (long)Homo sapiens (human)Potency44.66840.050127.073689.1251AID588590
urokinase-type plasminogen activator precursorMus musculus (house mouse)Potency1.99530.15855.287912.5893AID540303
plasminogen precursorMus musculus (house mouse)Potency1.99530.15855.287912.5893AID540303
urokinase plasminogen activator surface receptor precursorMus musculus (house mouse)Potency1.99530.15855.287912.5893AID540303
gemininHomo sapiens (human)Potency3.43970.004611.374133.4983AID624296; AID624297
DNA polymerase kappa isoform 1Homo sapiens (human)Potency3.89520.031622.3146100.0000AID588579
peripheral myelin protein 22Rattus norvegicus (Norway rat)Potency15.22890.005612.367736.1254AID624032; AID624044
cytochrome P450 3A4 isoform 1Homo sapiens (human)Potency12.58930.031610.279239.8107AID884; AID885
Gamma-aminobutyric acid receptor subunit piRattus norvegicus (Norway rat)Potency12.58931.000012.224831.6228AID885
Polyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)Potency1.58490.316212.765731.6228AID881
Rap guanine nucleotide exchange factor 3Homo sapiens (human)Potency50.11876.309660.2008112.2020AID720709
Cellular tumor antigen p53Homo sapiens (human)Potency64.86010.002319.595674.0614AID651631; AID720552
Gamma-aminobutyric acid receptor subunit beta-1Rattus norvegicus (Norway rat)Potency12.58931.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit deltaRattus norvegicus (Norway rat)Potency12.58931.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)Potency12.58931.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-5Rattus norvegicus (Norway rat)Potency12.58931.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-3Rattus norvegicus (Norway rat)Potency12.58931.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-1Rattus norvegicus (Norway rat)Potency12.58931.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-2Rattus norvegicus (Norway rat)Potency12.58931.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-4Rattus norvegicus (Norway rat)Potency12.58931.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-3Rattus norvegicus (Norway rat)Potency12.58931.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-6Rattus norvegicus (Norway rat)Potency12.58931.000012.224831.6228AID885
Histamine H2 receptorCavia porcellus (domestic guinea pig)Potency1.58490.00638.235039.8107AID881
Spike glycoproteinSevere acute respiratory syndrome-related coronavirusPotency39.81070.009610.525035.4813AID1479145
Gamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)Potency12.58931.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-3Rattus norvegicus (Norway rat)Potency12.58931.000012.224831.6228AID885
Guanine nucleotide-binding protein GHomo sapiens (human)Potency50.11871.995325.532750.1187AID624288
Gamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)Potency12.58931.000012.224831.6228AID885
TAR DNA-binding protein 43Homo sapiens (human)Potency12.58931.778316.208135.4813AID652104
GABA theta subunitRattus norvegicus (Norway rat)Potency12.58931.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit epsilonRattus norvegicus (Norway rat)Potency12.58931.000012.224831.6228AID885
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency17.78280.003245.467312,589.2998AID2517
Chain A, Putative fructose-1,6-bisphosphate aldolaseGiardia intestinalisPotency12.55940.140911.194039.8107AID2451
Chain A, HADH2 proteinHomo sapiens (human)Potency1.21260.025120.237639.8107AID886; AID893
Chain B, HADH2 proteinHomo sapiens (human)Potency1.21260.025120.237639.8107AID886; AID893
Chain A, 2-oxoglutarate OxygenaseHomo sapiens (human)Potency14.12540.177814.390939.8107AID2147
Chain A, ATP-DEPENDENT DNA HELICASE Q1Homo sapiens (human)Potency6.86600.125919.1169125.8920AID2353; AID2549
Chain A, Ferritin light chainEquus caballus (horse)Potency12.58935.623417.292931.6228AID2323
thioredoxin reductaseRattus norvegicus (Norway rat)Potency17.78060.100020.879379.4328AID488773; AID588453
ClpPBacillus subtilisPotency0.63101.995322.673039.8107AID651965
15-lipoxygenase, partialHomo sapiens (human)Potency0.94500.012610.691788.5700AID2157; AID887
ATAD5 protein, partialHomo sapiens (human)Potency20.58780.004110.890331.5287AID493107
Fumarate hydrataseHomo sapiens (human)Potency33.17340.00308.794948.0869AID1347053
USP1 protein, partialHomo sapiens (human)Potency89.12510.031637.5844354.8130AID504865
NFKB1 protein, partialHomo sapiens (human)Potency7.94330.02827.055915.8489AID895; AID928
GLS proteinHomo sapiens (human)Potency0.63100.35487.935539.8107AID624146
TDP1 proteinHomo sapiens (human)Potency18.29910.000811.382244.6684AID686978; AID686979
ThrombopoietinHomo sapiens (human)Potency5.01190.02517.304831.6228AID917; AID918
AR proteinHomo sapiens (human)Potency29.95610.000221.22318,912.5098AID743035; AID743042; AID743054; AID743063
Smad3Homo sapiens (human)Potency3.16230.00527.809829.0929AID588855
DNA polymerase III, partialBacillus subtilisPotency11.91731.062114.152826.6795AID485295
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency1.19860.011212.4002100.0000AID1030; AID493210
hypoxia-inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor)Homo sapiens (human)Potency7.94330.00137.762544.6684AID914; AID915
hypothetical protein, conservedTrypanosoma bruceiPotency11.99550.223911.245135.4813AID624147
regulator of G-protein signaling 4Homo sapiens (human)Potency15.00300.531815.435837.6858AID504845
EWS/FLI fusion proteinHomo sapiens (human)Potency15.42350.001310.157742.8575AID1259252; AID1259253; AID1259255; AID1259256
nonstructural protein 1Influenza A virus (A/WSN/1933(H1N1))Potency5.01190.28189.721235.4813AID2326
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency30.10650.000214.376460.0339AID720692
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency25.49050.001530.607315,848.9004AID1224819; AID1224820
estrogen nuclear receptor alphaHomo sapiens (human)Potency14.96010.000229.305416,493.5996AID743079
polyproteinZika virusPotency33.17340.00308.794948.0869AID1347053
ParkinHomo sapiens (human)Potency13.27790.819914.830644.6684AID720572; AID720573
peroxisome proliferator activated receptor gammaHomo sapiens (human)Potency28.42240.001019.414170.9645AID743140
arylsulfatase AHomo sapiens (human)Potency21.33131.069113.955137.9330AID720538
alpha-galactosidaseHomo sapiens (human)Potency11.22024.466818.391635.4813AID2107
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency2.38770.035520.977089.1251AID504332
aryl hydrocarbon receptorHomo sapiens (human)Potency29.84930.000723.06741,258.9301AID743085
Bloom syndrome protein isoform 1Homo sapiens (human)Potency22.38720.540617.639296.1227AID2364; AID2528
cytochrome P450 2D6 isoform 1Homo sapiens (human)Potency32.46480.00207.533739.8107AID891
hexokinase-4 isoform 1Homo sapiens (human)Potency7.07952.511913.800328.1838AID743205
peripheral myelin protein 22 isoform 1Homo sapiens (human)Potency84.921423.934123.934123.9341AID1967
cellular tumor antigen p53 isoform aHomo sapiens (human)Potency22.53580.316212.443531.6228AID902; AID924
polyunsaturated fatty acid lipoxygenase ALOX12Homo sapiens (human)Potency2.81841.000012.232631.6228AID1452
cytochrome P450 2C19 precursorHomo sapiens (human)Potency11.07920.00255.840031.6228AID899
cytochrome P450 2C9 precursorHomo sapiens (human)Potency7.08710.00636.904339.8107AID883
D(1A) dopamine receptorHomo sapiens (human)Potency8.84220.02245.944922.3872AID488981; AID488982
15-hydroxyprostaglandin dehydrogenase [NAD(+)] isoform 1Homo sapiens (human)Potency3.16230.001815.663839.8107AID894
vitamin D3 receptor isoform VDRAHomo sapiens (human)Potency35.48130.354828.065989.1251AID504847
chromobox protein homolog 1Homo sapiens (human)Potency31.62280.006026.168889.1251AID488953
potassium voltage-gated channel subfamily H member 2 isoform dHomo sapiens (human)Potency35.48130.01789.637444.6684AID588834
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency8.17740.000323.4451159.6830AID743065; AID743067
glucokinase regulatory proteinHomo sapiens (human)Potency7.07952.511913.800328.1838AID743205
DNA polymerase betaHomo sapiens (human)Potency0.79430.022421.010289.1251AID485314
mitogen-activated protein kinase 1Homo sapiens (human)Potency12.58930.039816.784239.8107AID995
flap endonuclease 1Homo sapiens (human)Potency15.39070.133725.412989.1251AID488816; AID588795
ubiquitin carboxyl-terminal hydrolase 2 isoform aHomo sapiens (human)Potency31.62280.65619.452025.1189AID927
ras-related protein Rab-9AHomo sapiens (human)Potency91.99970.00022.621531.4954AID485297
serine/threonine-protein kinase mTOR isoform 1Homo sapiens (human)Potency18.49270.00378.618923.2809AID2668
peptidyl-prolyl cis-trans isomerase NIMA-interacting 1Homo sapiens (human)Potency30.13130.425612.059128.1838AID504536
DNA polymerase eta isoform 1Homo sapiens (human)Potency3.16230.100028.9256213.3130AID588591
DNA polymerase iota isoform a (long)Homo sapiens (human)Potency29.00620.050127.073689.1251AID588590
gemininHomo sapiens (human)Potency7.07950.004611.374133.4983AID463097
DNA polymerase kappa isoform 1Homo sapiens (human)Potency12.03530.031622.3146100.0000AID588579
cytochrome P450 3A4 isoform 1Homo sapiens (human)Potency0.10000.031610.279239.8107AID884; AID885
M-phase phosphoprotein 8Homo sapiens (human)Potency24.44850.177824.735279.4328AID488949
histone acetyltransferase KAT2A isoform 1Homo sapiens (human)Potency28.18380.251215.843239.8107AID504327
muscarinic acetylcholine receptor M1Rattus norvegicus (Norway rat)Potency0.02820.00106.000935.4813AID943
lethal factor (plasmid)Bacillus anthracis str. A2012Potency15.84890.020010.786931.6228AID912
lamin isoform A-delta10Homo sapiens (human)Potency7.94330.891312.067628.1838AID1487
Gamma-aminobutyric acid receptor subunit piRattus norvegicus (Norway rat)Potency0.10001.000012.224831.6228AID885
Polyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)Potency2.21060.316212.765731.6228AID2537; AID881
Integrin beta-3Homo sapiens (human)Potency25.11890.316211.415731.6228AID924
Integrin alpha-IIbHomo sapiens (human)Potency25.11890.316211.415731.6228AID924
Gamma-aminobutyric acid receptor subunit beta-1Rattus norvegicus (Norway rat)Potency0.10001.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit deltaRattus norvegicus (Norway rat)Potency0.10001.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)Potency0.10001.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-5Rattus norvegicus (Norway rat)Potency0.10001.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-3Rattus norvegicus (Norway rat)Potency0.10001.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-1Rattus norvegicus (Norway rat)Potency0.10001.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-2Rattus norvegicus (Norway rat)Potency0.10001.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-4Rattus norvegicus (Norway rat)Potency0.10001.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-3Rattus norvegicus (Norway rat)Potency0.10001.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-6Rattus norvegicus (Norway rat)Potency0.10001.000012.224831.6228AID885
Alpha-synucleinHomo sapiens (human)Potency29.09290.56239.398525.1189AID652106
Histamine H2 receptorCavia porcellus (domestic guinea pig)Potency6.10590.00638.235039.8107AID881; AID883
Gamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)Potency0.10001.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-3Rattus norvegicus (Norway rat)Potency0.10001.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)Potency0.10001.000012.224831.6228AID885
Disintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)Potency31.62281.584913.004325.1189AID927
Inositol monophosphatase 1Rattus norvegicus (Norway rat)Potency19.95261.000010.475628.1838AID1457
GABA theta subunitRattus norvegicus (Norway rat)Potency0.10001.000012.224831.6228AID885
Ataxin-2Homo sapiens (human)Potency22.38720.011912.222168.7989AID588378
Gamma-aminobutyric acid receptor subunit epsilonRattus norvegicus (Norway rat)Potency0.10001.000012.224831.6228AID885
Single-stranded DNA cytosine deaminaseHomo sapiens (human)Potency44.668428.183860.145389.1251AID1347427
ATP-dependent phosphofructokinaseTrypanosoma brucei brucei TREU927Potency4.77550.060110.745337.9330AID485368
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
RNA polymerase beta subunit (EC 2.7.7.6), partialEscherichia coliIC50 (µMol)12.436211.687217.090023.7759AID826
90-kda heat shock protein beta HSP90 beta, partialHomo sapiens (human)IC50 (µMol)16.31160.17369.803229.2701AID712; AID754
Estrogen receptor 1Homo sapiens (human)IC50 (µMol)22.19372.161613.689226.3472AID713
glucose-6-phosphate dehydrogenase-6-phosphogluconolactonasePlasmodium bergheiIC50 (µMol)50.83330.889021.028671.5000AID504765; AID540252; AID540269
Replicase polyprotein 1abBetacoronavirus England 1IC50 (µMol)10.00000.00403.43889.5100AID1640022
glucose-6-phosphate 1-dehydrogenase isoform bHomo sapiens (human)IC50 (µMol)80.00008.870012.851817.8000AID504792
heat shock protein HSP 90-alpha isoform 2Homo sapiens (human)IC50 (µMol)16.31160.17369.803229.2701AID712; AID754
14-3-3 protein gammaHomo sapiens (human)IC50 (µMol)50.00000.78120.78120.7812AID711
Polyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)IC50 (µMol)12.30000.03201.46494.8000AID1617776; AID309801
Lipoxygenase Solanum tuberosum (potato)IC50 (µMol)10.00003.00003.50004.0000AID261406
Prostaglandin G/H synthase 1 Bos taurus (cattle)IC50 (µMol)32.00000.00051.41288.2000AID160706; AID347221
Prostaglandin G/H synthase 2 Bos taurus (cattle)IC50 (µMol)14.00000.00050.57393.4000AID160706
Proto-oncogene c-FosHomo sapiens (human)IC50 (µMol)0.00790.00790.10890.2100AID1178344
Transcription factor AP-1Homo sapiens (human)IC50 (µMol)0.00790.00790.39202.0300AID1178344
Insulin-like growth factor 1 receptorHomo sapiens (human)IC50 (µMol)0.90000.00030.43088.0000AID308042
Seed linoleate 13S-lipoxygenase-1Glycine max (soybean)IC50 (µMol)11.78290.07002.12673.5000AID1802593; AID254899; AID254906; AID261407; AID284858; AID3068; AID633798
Polyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)IC50 (µMol)3.18390.00011.68479.3200AID1406145; AID160519; AID1736439; AID286228; AID339217; AID345787; AID400125; AID485951; AID499651; AID630132; AID630142; AID6951
Replicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2IC50 (µMol)2.59000.00022.45859.9600AID1640021
Androgen receptorHomo sapiens (human)IC50 (µMol)32.93330.00000.875310.0000AID633579; AID633582; AID633583
AromataseHomo sapiens (human)IC50 (µMol)0.01100.00001.290410.0000AID479369
Polyunsaturated fatty acid 5-lipoxygenaseRattus norvegicus (Norway rat)IC50 (µMol)0.75200.00462.018210.0000AID179757; AID6790; AID6804; AID6809; AID6820; AID6825; AID6855; AID6859; AID7079; AID7096
Polyunsaturated fatty acid lipoxygenase ALOX15Oryctolagus cuniculus (rabbit)IC50 (µMol)0.11000.11003.26419.0330AID242641
17-beta-hydroxysteroid dehydrogenase type 1Homo sapiens (human)IC50 (µMol)5.50000.00751.36125.5000AID1364656
Cytochrome P450 11B1, mitochondrialRattus norvegicus (Norway rat)IC50 (µMol)30.00000.49503.52895.0000AID179759
Polyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)IC50 (µMol)1.51140.04002.099810.0000AID1138903; AID2919; AID308044; AID309799; AID354432; AID485950; AID611380
Polyunsaturated fatty acid lipoxygenase ALOX12Homo sapiens (human)IC50 (µMol)2.77800.10002.452310.0000AID309798; AID3108; AID354433; AID485949; AID611381
Sodium- and chloride-dependent GABA transporter 1Rattus norvegicus (Norway rat)IC50 (µMol)30.00000.00132.22068.3000AID179759
Caspase-1Homo sapiens (human)IC50 (µMol)10.00000.00201.70138.8000AID1801388
Sodium- and chloride-dependent GABA transporter 2Rattus norvegicus (Norway rat)IC50 (µMol)30.00000.00321.79008.3000AID179759
Sodium- and chloride-dependent GABA transporter 3Rattus norvegicus (Norway rat)IC50 (µMol)30.00000.00321.54318.3000AID179759
Prostaglandin G/H synthase 2Homo sapiens (human)IC50 (µMol)50.00000.00010.995010.0000AID347222
Prostaglandin G/H synthase 2 Rattus norvegicus (Norway rat)IC50 (µMol)40.00000.00291.786810.0000AID161024; AID179759
17-beta-hydroxysteroid dehydrogenase type 2Homo sapiens (human)IC50 (µMol)0.38000.09603.94009.9000AID1364654
Alpha-synucleinHomo sapiens (human)IC50 (µMol)0.21500.19003.82049.8000AID1695728; AID1695730
Sodium- and chloride-dependent betaine transporterRattus norvegicus (Norway rat)IC50 (µMol)30.00000.00321.54318.3000AID179759
Polyunsaturated fatty acid 5-lipoxygenaseMus musculus (house mouse)IC50 (µMol)0.40000.00800.15750.4000AID630143
Leukotriene B4 receptor 1Homo sapiens (human)IC50 (µMol)0.08500.00080.30913.2500AID101297
Lipoxygenase Glycine max (soybean)IC50 (µMol)23.34600.50004.86509.2300AID1163384; AID1173943; AID1180076; AID1498922; AID1624746
Prostaglandin G/H synthase 1 Rattus norvegicus (Norway rat)IC50 (µMol)40.00000.00291.823210.0000AID161024; AID179759
5-lipoxygenase Bos taurus (cattle)IC50 (µMol)0.70000.18001.75824.0000AID54297; AID6882
large T antigenBetapolyomavirus macacaeIC50 (µMol)21.86000.160024.9724100.0000AID1903
Prostaglandin G/H synthase 1Ovis aries (sheep)IC50 (µMol)6.75000.00032.177410.0000AID1798182
Seed linoleate 13S-lipoxygenase-1Glycine max (soybean)IC50 (µMol)6.75000.07002.12673.5000AID1798182
Prostaglandin G/H synthase 2Homo sapiens (human)IC50 (µMol)6.75000.00010.995010.0000AID1798182
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Hsf1 proteinMus musculus (house mouse)EC50 (µMol)2.31900.160024.4900236.5000AID435004
POsterior SegregationCaenorhabditis elegansEC50 (µMol)26.11102.201047.1808186.6810AID1964
Transient receptor potential cation channel subfamily A member 1Homo sapiens (human)EC50 (µMol)25.12710.00033.166210.0000AID1549771; AID1549787
TransthyretinHomo sapiens (human)EC50 (µMol)9.46675.60007.54298.6000AID1169291; AID1169297; AID1169298
Sodium-dependent noradrenaline transporter Homo sapiens (human)EC50 (µMol)8.75500.082031.0243168.9080AID1960
Zinc finger protein mex-5Caenorhabditis elegansEC50 (µMol)8.75500.082033.5679168.9080AID1960
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (646)

Processvia Protein(s)Taxonomy
lipid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
phospholipid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
apoptotic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of cell population proliferationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
positive regulation of macrophage derived foam cell differentiationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
arachidonic acid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of cell migrationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
prostate gland developmentPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
regulation of epithelial cell differentiationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
positive regulation of chemokine productionPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
positive regulation of peroxisome proliferator activated receptor signaling pathwayPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
positive regulation of keratinocyte differentiationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of cell cyclePolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of growthPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
hepoxilin biosynthetic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
endocannabinoid signaling pathwayPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
cannabinoid biosynthetic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipoxin A4 biosynthetic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
linoleic acid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipid oxidationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipoxygenase pathwayPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
response to oxidative stressProstaglandin G/H synthase 1 Bos taurus (cattle)
cellular oxidant detoxificationProstaglandin G/H synthase 1 Bos taurus (cattle)
meiotic spindle organizationProstaglandin G/H synthase 2 Bos taurus (cattle)
prostaglandin biosynthetic processProstaglandin G/H synthase 2 Bos taurus (cattle)
ovarian cumulus expansionProstaglandin G/H synthase 2 Bos taurus (cattle)
positive regulation of protein phosphorylationProstaglandin G/H synthase 2 Bos taurus (cattle)
response to oxidative stressProstaglandin G/H synthase 2 Bos taurus (cattle)
cyclooxygenase pathwayProstaglandin G/H synthase 2 Bos taurus (cattle)
positive regulation of embryonic developmentProstaglandin G/H synthase 2 Bos taurus (cattle)
cellular response to interleukin-1Prostaglandin G/H synthase 2 Bos taurus (cattle)
cellular oxidant detoxificationProstaglandin G/H synthase 2 Bos taurus (cattle)
regulation of neuroinflammatory responseProstaglandin G/H synthase 2 Bos taurus (cattle)
positive regulation of oocyte maturationProstaglandin G/H synthase 2 Bos taurus (cattle)
positive regulation of meiotic cell cycle process involved in oocyte maturationProstaglandin G/H synthase 2 Bos taurus (cattle)
monoatomic ion transportTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
intracellular calcium ion homeostasisTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
cell surface receptor signaling pathwayTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
response to coldTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
response to xenobiotic stimulusTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
response to organic substanceTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
response to organic cyclic compoundTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
sensory perception of painTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
calcium-mediated signalingTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
response to painTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
thermoceptionTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
detection of mechanical stimulus involved in sensory perception of painTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
detection of chemical stimulus involved in sensory perception of painTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
protein homotetramerizationTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
cellular response to hydrogen peroxideTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
calcium ion transmembrane transportTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
cellular response to organic substanceTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
angiogenesisRap guanine nucleotide exchange factor 3Homo sapiens (human)
adaptive immune responseRap guanine nucleotide exchange factor 3Homo sapiens (human)
signal transductionRap guanine nucleotide exchange factor 3Homo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwayRap guanine nucleotide exchange factor 3Homo sapiens (human)
associative learningRap guanine nucleotide exchange factor 3Homo sapiens (human)
Rap protein signal transductionRap guanine nucleotide exchange factor 3Homo sapiens (human)
regulation of actin cytoskeleton organizationRap guanine nucleotide exchange factor 3Homo sapiens (human)
negative regulation of syncytium formation by plasma membrane fusionRap guanine nucleotide exchange factor 3Homo sapiens (human)
intracellular signal transductionRap guanine nucleotide exchange factor 3Homo sapiens (human)
positive regulation of GTPase activityRap guanine nucleotide exchange factor 3Homo sapiens (human)
regulation of angiogenesisRap guanine nucleotide exchange factor 3Homo sapiens (human)
positive regulation of angiogenesisRap guanine nucleotide exchange factor 3Homo sapiens (human)
positive regulation of protein export from nucleusRap guanine nucleotide exchange factor 3Homo sapiens (human)
positive regulation of stress fiber assemblyRap guanine nucleotide exchange factor 3Homo sapiens (human)
regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionRap guanine nucleotide exchange factor 3Homo sapiens (human)
positive regulation of syncytium formation by plasma membrane fusionRap guanine nucleotide exchange factor 3Homo sapiens (human)
establishment of endothelial barrierRap guanine nucleotide exchange factor 3Homo sapiens (human)
cellular response to cAMPRap guanine nucleotide exchange factor 3Homo sapiens (human)
Ras protein signal transductionRap guanine nucleotide exchange factor 3Homo sapiens (human)
regulation of insulin secretionRap guanine nucleotide exchange factor 3Homo sapiens (human)
conditioned taste aversionProto-oncogene c-FosHomo sapiens (human)
regulation of transcription by RNA polymerase IIProto-oncogene c-FosHomo sapiens (human)
transcription by RNA polymerase IIProto-oncogene c-FosHomo sapiens (human)
inflammatory responseProto-oncogene c-FosHomo sapiens (human)
transforming growth factor beta receptor signaling pathwayProto-oncogene c-FosHomo sapiens (human)
nervous system developmentProto-oncogene c-FosHomo sapiens (human)
female pregnancyProto-oncogene c-FosHomo sapiens (human)
response to xenobiotic stimulusProto-oncogene c-FosHomo sapiens (human)
response to light stimulusProto-oncogene c-FosHomo sapiens (human)
response to gravityProto-oncogene c-FosHomo sapiens (human)
response to toxic substanceProto-oncogene c-FosHomo sapiens (human)
response to activityProto-oncogene c-FosHomo sapiens (human)
skeletal muscle cell proliferationProto-oncogene c-FosHomo sapiens (human)
osteoclast differentiationProto-oncogene c-FosHomo sapiens (human)
response to lipopolysaccharideProto-oncogene c-FosHomo sapiens (human)
response to progesteroneProto-oncogene c-FosHomo sapiens (human)
response to insulinProto-oncogene c-FosHomo sapiens (human)
cellular response to zinc ion starvationProto-oncogene c-FosHomo sapiens (human)
cellular response to reactive oxygen speciesProto-oncogene c-FosHomo sapiens (human)
response to immobilization stressProto-oncogene c-FosHomo sapiens (human)
skeletal muscle cell differentiationProto-oncogene c-FosHomo sapiens (human)
response to muscle stretchProto-oncogene c-FosHomo sapiens (human)
response to ethanolProto-oncogene c-FosHomo sapiens (human)
positive regulation of osteoclast differentiationProto-oncogene c-FosHomo sapiens (human)
positive regulation of DNA-templated transcriptionProto-oncogene c-FosHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIProto-oncogene c-FosHomo sapiens (human)
response to corticosteroneProto-oncogene c-FosHomo sapiens (human)
myoblast proliferationProto-oncogene c-FosHomo sapiens (human)
response to cAMPProto-oncogene c-FosHomo sapiens (human)
SMAD protein signal transductionProto-oncogene c-FosHomo sapiens (human)
cellular response to cadmium ionProto-oncogene c-FosHomo sapiens (human)
cellular response to calcium ionProto-oncogene c-FosHomo sapiens (human)
cellular response to tumor necrosis factorProto-oncogene c-FosHomo sapiens (human)
cellular response to epidermal growth factor stimulusProto-oncogene c-FosHomo sapiens (human)
cellular response to parathyroid hormone stimulusProto-oncogene c-FosHomo sapiens (human)
cellular response to hypoxiaProto-oncogene c-FosHomo sapiens (human)
integrated stress response signalingProto-oncogene c-FosHomo sapiens (human)
positive regulation of miRNA transcriptionProto-oncogene c-FosHomo sapiens (human)
mononuclear cell differentiationProto-oncogene c-FosHomo sapiens (human)
cellular response to phorbol 13-acetate 12-myristateProto-oncogene c-FosHomo sapiens (human)
cellular response to prolactinProto-oncogene c-FosHomo sapiens (human)
signal transductionTransthyretinHomo sapiens (human)
purine nucleobase metabolic processTransthyretinHomo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycle G2/M phase transitionCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
ER overload responseCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
mitophagyCellular tumor antigen p53Homo sapiens (human)
in utero embryonic developmentCellular tumor antigen p53Homo sapiens (human)
somitogenesisCellular tumor antigen p53Homo sapiens (human)
release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
hematopoietic progenitor cell differentiationCellular tumor antigen p53Homo sapiens (human)
T cell proliferation involved in immune responseCellular tumor antigen p53Homo sapiens (human)
B cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
T cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
response to ischemiaCellular tumor antigen p53Homo sapiens (human)
nucleotide-excision repairCellular tumor antigen p53Homo sapiens (human)
double-strand break repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
protein import into nucleusCellular tumor antigen p53Homo sapiens (human)
autophagyCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrestCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediatorCellular tumor antigen p53Homo sapiens (human)
transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
Ras protein signal transductionCellular tumor antigen p53Homo sapiens (human)
gastrulationCellular tumor antigen p53Homo sapiens (human)
neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
protein localizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA replicationCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
determination of adult lifespanCellular tumor antigen p53Homo sapiens (human)
mRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
rRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
response to salt stressCellular tumor antigen p53Homo sapiens (human)
response to inorganic substanceCellular tumor antigen p53Homo sapiens (human)
response to X-rayCellular tumor antigen p53Homo sapiens (human)
response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
positive regulation of gene expressionCellular tumor antigen p53Homo sapiens (human)
cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
viral processCellular tumor antigen p53Homo sapiens (human)
glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
cerebellum developmentCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell growthCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
mitotic G1 DNA damage checkpoint signalingCellular tumor antigen p53Homo sapiens (human)
negative regulation of telomere maintenance via telomeraseCellular tumor antigen p53Homo sapiens (human)
T cell differentiation in thymusCellular tumor antigen p53Homo sapiens (human)
tumor necrosis factor-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
regulation of tissue remodelingCellular tumor antigen p53Homo sapiens (human)
cellular response to UVCellular tumor antigen p53Homo sapiens (human)
multicellular organism growthCellular tumor antigen p53Homo sapiens (human)
positive regulation of mitochondrial membrane permeabilityCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
entrainment of circadian clock by photoperiodCellular tumor antigen p53Homo sapiens (human)
mitochondrial DNA repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
transcription initiation-coupled chromatin remodelingCellular tumor antigen p53Homo sapiens (human)
negative regulation of proteolysisCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assemblyCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
response to antibioticCellular tumor antigen p53Homo sapiens (human)
fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
circadian behaviorCellular tumor antigen p53Homo sapiens (human)
bone marrow developmentCellular tumor antigen p53Homo sapiens (human)
embryonic organ developmentCellular tumor antigen p53Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationCellular tumor antigen p53Homo sapiens (human)
protein stabilizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of helicase activityCellular tumor antigen p53Homo sapiens (human)
protein tetramerizationCellular tumor antigen p53Homo sapiens (human)
chromosome organizationCellular tumor antigen p53Homo sapiens (human)
neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
hematopoietic stem cell differentiationCellular tumor antigen p53Homo sapiens (human)
negative regulation of glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
type II interferon-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
cardiac septum morphogenesisCellular tumor antigen p53Homo sapiens (human)
positive regulation of programmed necrotic cell deathCellular tumor antigen p53Homo sapiens (human)
protein-containing complex assemblyCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stressCellular tumor antigen p53Homo sapiens (human)
thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
necroptotic processCellular tumor antigen p53Homo sapiens (human)
cellular response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
cellular response to xenobiotic stimulusCellular tumor antigen p53Homo sapiens (human)
cellular response to ionizing radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to UV-CCellular tumor antigen p53Homo sapiens (human)
stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
cellular response to actinomycin DCellular tumor antigen p53Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
cellular senescenceCellular tumor antigen p53Homo sapiens (human)
replicative senescenceCellular tumor antigen p53Homo sapiens (human)
oxidative stress-induced premature senescenceCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
oligodendrocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of execution phase of apoptosisCellular tumor antigen p53Homo sapiens (human)
negative regulation of mitophagyCellular tumor antigen p53Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of G1 to G0 transitionCellular tumor antigen p53Homo sapiens (human)
negative regulation of miRNA processingCellular tumor antigen p53Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
negative regulation of pentose-phosphate shuntCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
regulation of fibroblast apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
positive regulation of cellular senescenceCellular tumor antigen p53Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
negative regulation of transcription by RNA polymerase IITranscription factor AP-1Homo sapiens (human)
regulation of transcription by RNA polymerase IITranscription factor AP-1Homo sapiens (human)
transforming growth factor beta receptor signaling pathwayTranscription factor AP-1Homo sapiens (human)
release from viral latencyTranscription factor AP-1Homo sapiens (human)
cellular response to reactive oxygen speciesTranscription factor AP-1Homo sapiens (human)
response to endoplasmic reticulum stressTranscription factor AP-1Homo sapiens (human)
positive regulation of apoptotic processTranscription factor AP-1Homo sapiens (human)
negative regulation of DNA bindingTranscription factor AP-1Homo sapiens (human)
negative regulation by host of viral transcriptionTranscription factor AP-1Homo sapiens (human)
positive regulation by host of viral transcriptionTranscription factor AP-1Homo sapiens (human)
negative regulation of DNA-templated transcriptionTranscription factor AP-1Homo sapiens (human)
positive regulation of DNA-templated transcriptionTranscription factor AP-1Homo sapiens (human)
positive regulation of transcription by RNA polymerase IITranscription factor AP-1Homo sapiens (human)
SMAD protein signal transductionTranscription factor AP-1Homo sapiens (human)
cellular response to cadmium ionTranscription factor AP-1Homo sapiens (human)
integrated stress response signalingTranscription factor AP-1Homo sapiens (human)
positive regulation of miRNA transcriptionTranscription factor AP-1Homo sapiens (human)
positive regulation of vascular associated smooth muscle cell proliferationTranscription factor AP-1Homo sapiens (human)
positive regulation of DNA-templated transcription initiationTranscription factor AP-1Homo sapiens (human)
regulation of cell population proliferationTranscription factor AP-1Homo sapiens (human)
regulation of cell cycleTranscription factor AP-1Homo sapiens (human)
peptidyl-tyrosine autophosphorylationInsulin-like growth factor 1 receptorHomo sapiens (human)
cardiac atrium developmentInsulin-like growth factor 1 receptorHomo sapiens (human)
immune responseInsulin-like growth factor 1 receptorHomo sapiens (human)
signal transductionInsulin-like growth factor 1 receptorHomo sapiens (human)
axonogenesisInsulin-like growth factor 1 receptorHomo sapiens (human)
positive regulation of cell population proliferationInsulin-like growth factor 1 receptorHomo sapiens (human)
insulin receptor signaling pathwayInsulin-like growth factor 1 receptorHomo sapiens (human)
negative regulation of muscle cell apoptotic processInsulin-like growth factor 1 receptorHomo sapiens (human)
cerebellum developmentInsulin-like growth factor 1 receptorHomo sapiens (human)
hippocampus developmentInsulin-like growth factor 1 receptorHomo sapiens (human)
establishment of cell polarityInsulin-like growth factor 1 receptorHomo sapiens (human)
positive regulation of cell migrationInsulin-like growth factor 1 receptorHomo sapiens (human)
positive regulation of cytokinesisInsulin-like growth factor 1 receptorHomo sapiens (human)
response to vitamin EInsulin-like growth factor 1 receptorHomo sapiens (human)
positive regulation of osteoblast proliferationInsulin-like growth factor 1 receptorHomo sapiens (human)
cellular response to zinc ion starvationInsulin-like growth factor 1 receptorHomo sapiens (human)
response to nicotineInsulin-like growth factor 1 receptorHomo sapiens (human)
negative regulation of apoptotic processInsulin-like growth factor 1 receptorHomo sapiens (human)
positive regulation of protein-containing complex disassemblyInsulin-like growth factor 1 receptorHomo sapiens (human)
response to alkaloidInsulin-like growth factor 1 receptorHomo sapiens (human)
negative regulation of MAPK cascadeInsulin-like growth factor 1 receptorHomo sapiens (human)
phosphatidylinositol 3-kinase/protein kinase B signal transductionInsulin-like growth factor 1 receptorHomo sapiens (human)
estrous cycleInsulin-like growth factor 1 receptorHomo sapiens (human)
transcytosisInsulin-like growth factor 1 receptorHomo sapiens (human)
response to ethanolInsulin-like growth factor 1 receptorHomo sapiens (human)
regulation of JNK cascadeInsulin-like growth factor 1 receptorHomo sapiens (human)
protein autophosphorylationInsulin-like growth factor 1 receptorHomo sapiens (human)
insulin-like growth factor receptor signaling pathwayInsulin-like growth factor 1 receptorHomo sapiens (human)
positive regulation of smooth muscle cell proliferationInsulin-like growth factor 1 receptorHomo sapiens (human)
positive regulation of axon regenerationInsulin-like growth factor 1 receptorHomo sapiens (human)
positive regulation of DNA metabolic processInsulin-like growth factor 1 receptorHomo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionInsulin-like growth factor 1 receptorHomo sapiens (human)
cellular response to mechanical stimulusInsulin-like growth factor 1 receptorHomo sapiens (human)
cellular response to estradiol stimulusInsulin-like growth factor 1 receptorHomo sapiens (human)
cellular response to progesterone stimulusInsulin-like growth factor 1 receptorHomo sapiens (human)
cellular response to testosterone stimulusInsulin-like growth factor 1 receptorHomo sapiens (human)
cellular response to dexamethasone stimulusInsulin-like growth factor 1 receptorHomo sapiens (human)
cellular response to transforming growth factor beta stimulusInsulin-like growth factor 1 receptorHomo sapiens (human)
positive regulation of steroid hormone biosynthetic processInsulin-like growth factor 1 receptorHomo sapiens (human)
cellular senescenceInsulin-like growth factor 1 receptorHomo sapiens (human)
dendritic spine maintenanceInsulin-like growth factor 1 receptorHomo sapiens (human)
amyloid-beta clearanceInsulin-like growth factor 1 receptorHomo sapiens (human)
positive regulation of cold-induced thermogenesisInsulin-like growth factor 1 receptorHomo sapiens (human)
response to L-glutamateInsulin-like growth factor 1 receptorHomo sapiens (human)
negative regulation of hepatocyte apoptotic processInsulin-like growth factor 1 receptorHomo sapiens (human)
cellular response to aldosteroneInsulin-like growth factor 1 receptorHomo sapiens (human)
negative regulation of cholangiocyte apoptotic processInsulin-like growth factor 1 receptorHomo sapiens (human)
cellular response to angiotensinInsulin-like growth factor 1 receptorHomo sapiens (human)
cellular response to amyloid-betaInsulin-like growth factor 1 receptorHomo sapiens (human)
cellular response to insulin-like growth factor stimulusInsulin-like growth factor 1 receptorHomo sapiens (human)
multicellular organism developmentInsulin-like growth factor 1 receptorHomo sapiens (human)
positive regulation of kinase activityInsulin-like growth factor 1 receptorHomo sapiens (human)
cellular response to glucose stimulusInsulin-like growth factor 1 receptorHomo sapiens (human)
positive regulation of MAPK cascadeInsulin-like growth factor 1 receptorHomo sapiens (human)
negative regulation of endothelial cell proliferationPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
leukocyte chemotaxis involved in inflammatory responsePolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
leukocyte migration involved in inflammatory responsePolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
leukotriene production involved in inflammatory responsePolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
leukotriene metabolic processPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
humoral immune responsePolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
negative regulation of angiogenesisPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
leukotriene biosynthetic processPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
lipoxygenase pathwayPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
positive regulation of bone mineralizationPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
dendritic cell migrationPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
glucose homeostasisPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
long-chain fatty acid biosynthetic processPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
regulation of fat cell differentiationPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
regulation of inflammatory responsePolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
negative regulation of inflammatory responsePolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
regulation of insulin secretionPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
negative regulation of vascular wound healingPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
negative regulation of wound healingPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
regulation of inflammatory response to woundingPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
regulation of cytokine production involved in inflammatory responsePolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
regulation of cellular response to oxidative stressPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
leukotriene A4 biosynthetic processPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
regulation of reactive oxygen species biosynthetic processPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
negative regulation of response to endoplasmic reticulum stressPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
negative regulation of sprouting angiogenesisPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
positive regulation of leukocyte adhesion to arterial endothelial cellPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
lipoxin biosynthetic processPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
arachidonic acid metabolic processPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
lipid oxidationPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
negative regulation of transcription by RNA polymerase IIAndrogen receptorHomo sapiens (human)
MAPK cascadeAndrogen receptorHomo sapiens (human)
in utero embryonic developmentAndrogen receptorHomo sapiens (human)
regulation of systemic arterial blood pressureAndrogen receptorHomo sapiens (human)
epithelial cell morphogenesisAndrogen receptorHomo sapiens (human)
transcription by RNA polymerase IIAndrogen receptorHomo sapiens (human)
signal transductionAndrogen receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayAndrogen receptorHomo sapiens (human)
cell-cell signalingAndrogen receptorHomo sapiens (human)
spermatogenesisAndrogen receptorHomo sapiens (human)
single fertilizationAndrogen receptorHomo sapiens (human)
positive regulation of cell population proliferationAndrogen receptorHomo sapiens (human)
negative regulation of cell population proliferationAndrogen receptorHomo sapiens (human)
positive regulation of gene expressionAndrogen receptorHomo sapiens (human)
male somatic sex determinationAndrogen receptorHomo sapiens (human)
intracellular estrogen receptor signaling pathwayAndrogen receptorHomo sapiens (human)
androgen receptor signaling pathwayAndrogen receptorHomo sapiens (human)
intracellular receptor signaling pathwayAndrogen receptorHomo sapiens (human)
positive regulation of intracellular estrogen receptor signaling pathwayAndrogen receptorHomo sapiens (human)
Leydig cell differentiationAndrogen receptorHomo sapiens (human)
multicellular organism growthAndrogen receptorHomo sapiens (human)
positive regulation of phosphorylationAndrogen receptorHomo sapiens (human)
positive regulation of MAPK cascadeAndrogen receptorHomo sapiens (human)
positive regulation of insulin-like growth factor receptor signaling pathwayAndrogen receptorHomo sapiens (human)
positive regulation of cell differentiationAndrogen receptorHomo sapiens (human)
negative regulation of integrin biosynthetic processAndrogen receptorHomo sapiens (human)
positive regulation of integrin biosynthetic processAndrogen receptorHomo sapiens (human)
positive regulation of DNA-templated transcriptionAndrogen receptorHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIAndrogen receptorHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIIAndrogen receptorHomo sapiens (human)
insulin-like growth factor receptor signaling pathwayAndrogen receptorHomo sapiens (human)
regulation of developmental growthAndrogen receptorHomo sapiens (human)
animal organ formationAndrogen receptorHomo sapiens (human)
male genitalia morphogenesisAndrogen receptorHomo sapiens (human)
epithelial cell proliferationAndrogen receptorHomo sapiens (human)
negative regulation of epithelial cell proliferationAndrogen receptorHomo sapiens (human)
positive regulation of NF-kappaB transcription factor activityAndrogen receptorHomo sapiens (human)
activation of prostate induction by androgen receptor signaling pathwayAndrogen receptorHomo sapiens (human)
morphogenesis of an epithelial foldAndrogen receptorHomo sapiens (human)
lateral sprouting involved in mammary gland duct morphogenesisAndrogen receptorHomo sapiens (human)
prostate gland growthAndrogen receptorHomo sapiens (human)
prostate gland epithelium morphogenesisAndrogen receptorHomo sapiens (human)
epithelial cell differentiation involved in prostate gland developmentAndrogen receptorHomo sapiens (human)
tertiary branching involved in mammary gland duct morphogenesisAndrogen receptorHomo sapiens (human)
mammary gland alveolus developmentAndrogen receptorHomo sapiens (human)
positive regulation of epithelial cell proliferation involved in prostate gland developmentAndrogen receptorHomo sapiens (human)
cellular response to steroid hormone stimulusAndrogen receptorHomo sapiens (human)
cellular response to estrogen stimulusAndrogen receptorHomo sapiens (human)
cellular response to testosterone stimulusAndrogen receptorHomo sapiens (human)
seminiferous tubule developmentAndrogen receptorHomo sapiens (human)
non-membrane-bounded organelle assemblyAndrogen receptorHomo sapiens (human)
positive regulation of miRNA transcriptionAndrogen receptorHomo sapiens (human)
regulation of protein localization to plasma membraneAndrogen receptorHomo sapiens (human)
negative regulation of extrinsic apoptotic signaling pathwayAndrogen receptorHomo sapiens (human)
male gonad developmentAndrogen receptorHomo sapiens (human)
intracellular steroid hormone receptor signaling pathwayAndrogen receptorHomo sapiens (human)
negative regulation of chronic inflammatory responseAromataseHomo sapiens (human)
steroid biosynthetic processAromataseHomo sapiens (human)
estrogen biosynthetic processAromataseHomo sapiens (human)
androgen catabolic processAromataseHomo sapiens (human)
syncytium formationAromataseHomo sapiens (human)
negative regulation of macrophage chemotaxisAromataseHomo sapiens (human)
sterol metabolic processAromataseHomo sapiens (human)
female genitalia developmentAromataseHomo sapiens (human)
mammary gland developmentAromataseHomo sapiens (human)
uterus developmentAromataseHomo sapiens (human)
prostate gland growthAromataseHomo sapiens (human)
testosterone biosynthetic processAromataseHomo sapiens (human)
positive regulation of estradiol secretionAromataseHomo sapiens (human)
female gonad developmentAromataseHomo sapiens (human)
response to estradiolAromataseHomo sapiens (human)
steroid biosynthetic process17-beta-hydroxysteroid dehydrogenase type 1Homo sapiens (human)
estrogen biosynthetic process17-beta-hydroxysteroid dehydrogenase type 1Homo sapiens (human)
lysosome organization17-beta-hydroxysteroid dehydrogenase type 1Homo sapiens (human)
skeletal muscle tissue development17-beta-hydroxysteroid dehydrogenase type 1Homo sapiens (human)
estrogen metabolic process17-beta-hydroxysteroid dehydrogenase type 1Homo sapiens (human)
gene expression17-beta-hydroxysteroid dehydrogenase type 1Homo sapiens (human)
bone development17-beta-hydroxysteroid dehydrogenase type 1Homo sapiens (human)
adipose tissue development17-beta-hydroxysteroid dehydrogenase type 1Homo sapiens (human)
testosterone biosynthetic process17-beta-hydroxysteroid dehydrogenase type 1Homo sapiens (human)
cellular response to metal ion17-beta-hydroxysteroid dehydrogenase type 1Homo sapiens (human)
ossificationPolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
negative regulation of adaptive immune responsePolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
lipid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
phosphatidylethanolamine biosynthetic processPolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
inflammatory responsePolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
positive regulation of cell-substrate adhesionPolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
arachidonic acid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
lipoxygenase pathwayPolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
fatty acid oxidationPolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
bone mineralizationPolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
positive regulation of actin filament polymerizationPolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
response to endoplasmic reticulum stressPolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
regulation of peroxisome proliferator activated receptor signaling pathwayPolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
cellular response to interleukin-13Polyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
wound healingPolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
long-chain fatty acid biosynthetic processPolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
apoptotic cell clearancePolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
linoleic acid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
regulation of inflammatory responsePolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
hepoxilin biosynthetic processPolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascadePolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
cellular response to calcium ionPolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
regulation of engulfment of apoptotic cellPolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
lipoxin A4 biosynthetic processPolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
lipid oxidationPolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
linoleic acid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX12Homo sapiens (human)
leukotriene A4 metabolic processPolyunsaturated fatty acid lipoxygenase ALOX12Homo sapiens (human)
lipid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX12Homo sapiens (human)
negative regulation of muscle cell apoptotic processPolyunsaturated fatty acid lipoxygenase ALOX12Homo sapiens (human)
arachidonic acid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX12Homo sapiens (human)
lipoxygenase pathwayPolyunsaturated fatty acid lipoxygenase ALOX12Homo sapiens (human)
fatty acid oxidationPolyunsaturated fatty acid lipoxygenase ALOX12Homo sapiens (human)
unsaturated fatty acid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX12Homo sapiens (human)
superoxide anion generationPolyunsaturated fatty acid lipoxygenase ALOX12Homo sapiens (human)
linoleic acid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX12Homo sapiens (human)
hepoxilin biosynthetic processPolyunsaturated fatty acid lipoxygenase ALOX12Homo sapiens (human)
establishment of skin barrierPolyunsaturated fatty acid lipoxygenase ALOX12Homo sapiens (human)
negative regulation of platelet aggregationPolyunsaturated fatty acid lipoxygenase ALOX12Homo sapiens (human)
leukotriene A4 metabolic processPolyunsaturated fatty acid lipoxygenase ALOX12Homo sapiens (human)
lipoxin A4 biosynthetic processPolyunsaturated fatty acid lipoxygenase ALOX12Homo sapiens (human)
lipoxin B4 biosynthetic processPolyunsaturated fatty acid lipoxygenase ALOX12Homo sapiens (human)
lipid oxidationPolyunsaturated fatty acid lipoxygenase ALOX12Homo sapiens (human)
monoamine transportSodium-dependent noradrenaline transporter Homo sapiens (human)
neurotransmitter transportSodium-dependent noradrenaline transporter Homo sapiens (human)
chemical synaptic transmissionSodium-dependent noradrenaline transporter Homo sapiens (human)
response to xenobiotic stimulusSodium-dependent noradrenaline transporter Homo sapiens (human)
response to painSodium-dependent noradrenaline transporter Homo sapiens (human)
norepinephrine uptakeSodium-dependent noradrenaline transporter Homo sapiens (human)
neuron cellular homeostasisSodium-dependent noradrenaline transporter Homo sapiens (human)
amino acid transportSodium-dependent noradrenaline transporter Homo sapiens (human)
norepinephrine transportSodium-dependent noradrenaline transporter Homo sapiens (human)
dopamine uptake involved in synaptic transmissionSodium-dependent noradrenaline transporter Homo sapiens (human)
sodium ion transmembrane transportSodium-dependent noradrenaline transporter Homo sapiens (human)
cellular response to organic substanceCaspase-1Homo sapiens (human)
pattern recognition receptor signaling pathwayCaspase-1Homo sapiens (human)
proteolysisCaspase-1Homo sapiens (human)
apoptotic processCaspase-1Homo sapiens (human)
signal transductionCaspase-1Homo sapiens (human)
osmosensory signaling pathwayCaspase-1Homo sapiens (human)
protein autoprocessingCaspase-1Homo sapiens (human)
positive regulation of interleukin-1 beta productionCaspase-1Homo sapiens (human)
positive regulation of interleukin-18 productionCaspase-1Homo sapiens (human)
defense response to bacteriumCaspase-1Homo sapiens (human)
regulation of apoptotic processCaspase-1Homo sapiens (human)
positive regulation of canonical NF-kappaB signal transductionCaspase-1Homo sapiens (human)
positive regulation of cysteine-type endopeptidase activity involved in apoptotic processCaspase-1Homo sapiens (human)
icosanoid biosynthetic processCaspase-1Homo sapiens (human)
regulation of inflammatory responseCaspase-1Homo sapiens (human)
positive regulation of inflammatory responseCaspase-1Homo sapiens (human)
protein maturationCaspase-1Homo sapiens (human)
defense response to virusCaspase-1Homo sapiens (human)
pyroptosisCaspase-1Homo sapiens (human)
cellular response to lipopolysaccharideCaspase-1Homo sapiens (human)
cellular response to mechanical stimulusCaspase-1Homo sapiens (human)
cellular response to type II interferonCaspase-1Homo sapiens (human)
cytokine precursor processingCaspase-1Homo sapiens (human)
signaling receptor ligand precursor processingCaspase-1Homo sapiens (human)
AIM2 inflammasome complex assemblyCaspase-1Homo sapiens (human)
positive regulation of tumor necrosis factor-mediated signaling pathwayCaspase-1Homo sapiens (human)
prostaglandin biosynthetic processProstaglandin G/H synthase 2Homo sapiens (human)
angiogenesisProstaglandin G/H synthase 2Homo sapiens (human)
response to oxidative stressProstaglandin G/H synthase 2Homo sapiens (human)
embryo implantationProstaglandin G/H synthase 2Homo sapiens (human)
learningProstaglandin G/H synthase 2Homo sapiens (human)
memoryProstaglandin G/H synthase 2Homo sapiens (human)
regulation of blood pressureProstaglandin G/H synthase 2Homo sapiens (human)
negative regulation of cell population proliferationProstaglandin G/H synthase 2Homo sapiens (human)
response to xenobiotic stimulusProstaglandin G/H synthase 2Homo sapiens (human)
response to nematodeProstaglandin G/H synthase 2Homo sapiens (human)
response to fructoseProstaglandin G/H synthase 2Homo sapiens (human)
response to manganese ionProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of vascular endothelial growth factor productionProstaglandin G/H synthase 2Homo sapiens (human)
cyclooxygenase pathwayProstaglandin G/H synthase 2Homo sapiens (human)
bone mineralizationProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of prostaglandin biosynthetic processProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of fever generationProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of synaptic plasticityProstaglandin G/H synthase 2Homo sapiens (human)
negative regulation of synaptic transmission, dopaminergicProstaglandin G/H synthase 2Homo sapiens (human)
prostaglandin secretionProstaglandin G/H synthase 2Homo sapiens (human)
response to estradiolProstaglandin G/H synthase 2Homo sapiens (human)
response to lipopolysaccharideProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of peptidyl-serine phosphorylationProstaglandin G/H synthase 2Homo sapiens (human)
response to vitamin DProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to heatProstaglandin G/H synthase 2Homo sapiens (human)
response to tumor necrosis factorProstaglandin G/H synthase 2Homo sapiens (human)
maintenance of blood-brain barrierProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of protein import into nucleusProstaglandin G/H synthase 2Homo sapiens (human)
hair cycleProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of apoptotic processProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of nitric oxide biosynthetic processProstaglandin G/H synthase 2Homo sapiens (human)
negative regulation of cell cycleProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of vasoconstrictionProstaglandin G/H synthase 2Homo sapiens (human)
negative regulation of smooth muscle contractionProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of smooth muscle contractionProstaglandin G/H synthase 2Homo sapiens (human)
decidualizationProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of smooth muscle cell proliferationProstaglandin G/H synthase 2Homo sapiens (human)
regulation of inflammatory responseProstaglandin G/H synthase 2Homo sapiens (human)
brown fat cell differentiationProstaglandin G/H synthase 2Homo sapiens (human)
response to glucocorticoidProstaglandin G/H synthase 2Homo sapiens (human)
negative regulation of calcium ion transportProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of synaptic transmission, glutamatergicProstaglandin G/H synthase 2Homo sapiens (human)
response to fatty acidProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to mechanical stimulusProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to lead ionProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to ATPProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to hypoxiaProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to non-ionic osmotic stressProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to fluid shear stressProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of transforming growth factor beta productionProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of cell migration involved in sprouting angiogenesisProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of fibroblast growth factor productionProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of brown fat cell differentiationProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of platelet-derived growth factor productionProstaglandin G/H synthase 2Homo sapiens (human)
cellular oxidant detoxificationProstaglandin G/H synthase 2Homo sapiens (human)
regulation of neuroinflammatory responseProstaglandin G/H synthase 2Homo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathway in response to osmotic stressProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to homocysteineProstaglandin G/H synthase 2Homo sapiens (human)
response to angiotensinProstaglandin G/H synthase 2Homo sapiens (human)
in utero embryonic development17-beta-hydroxysteroid dehydrogenase type 2Homo sapiens (human)
placenta development17-beta-hydroxysteroid dehydrogenase type 2Homo sapiens (human)
estrogen biosynthetic process17-beta-hydroxysteroid dehydrogenase type 2Homo sapiens (human)
androgen metabolic process17-beta-hydroxysteroid dehydrogenase type 2Homo sapiens (human)
response to retinoic acid17-beta-hydroxysteroid dehydrogenase type 2Homo sapiens (human)
steroid metabolic process17-beta-hydroxysteroid dehydrogenase type 2Homo sapiens (human)
calcium ion homeostasisAlpha-synucleinHomo sapiens (human)
negative regulation of transcription by RNA polymerase IIAlpha-synucleinHomo sapiens (human)
microglial cell activationAlpha-synucleinHomo sapiens (human)
positive regulation of receptor recyclingAlpha-synucleinHomo sapiens (human)
positive regulation of neurotransmitter secretionAlpha-synucleinHomo sapiens (human)
negative regulation of protein kinase activityAlpha-synucleinHomo sapiens (human)
fatty acid metabolic processAlpha-synucleinHomo sapiens (human)
neutral lipid metabolic processAlpha-synucleinHomo sapiens (human)
phospholipid metabolic processAlpha-synucleinHomo sapiens (human)
activation of cysteine-type endopeptidase activity involved in apoptotic processAlpha-synucleinHomo sapiens (human)
mitochondrial membrane organizationAlpha-synucleinHomo sapiens (human)
adult locomotory behaviorAlpha-synucleinHomo sapiens (human)
response to xenobiotic stimulusAlpha-synucleinHomo sapiens (human)
response to iron(II) ionAlpha-synucleinHomo sapiens (human)
regulation of phospholipase activityAlpha-synucleinHomo sapiens (human)
negative regulation of platelet-derived growth factor receptor signaling pathwayAlpha-synucleinHomo sapiens (human)
regulation of glutamate secretionAlpha-synucleinHomo sapiens (human)
regulation of dopamine secretionAlpha-synucleinHomo sapiens (human)
synaptic vesicle exocytosisAlpha-synucleinHomo sapiens (human)
synaptic vesicle primingAlpha-synucleinHomo sapiens (human)
regulation of transmembrane transporter activityAlpha-synucleinHomo sapiens (human)
negative regulation of microtubule polymerizationAlpha-synucleinHomo sapiens (human)
receptor internalizationAlpha-synucleinHomo sapiens (human)
protein destabilizationAlpha-synucleinHomo sapiens (human)
response to magnesium ionAlpha-synucleinHomo sapiens (human)
negative regulation of transporter activityAlpha-synucleinHomo sapiens (human)
response to lipopolysaccharideAlpha-synucleinHomo sapiens (human)
negative regulation of monooxygenase activityAlpha-synucleinHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylationAlpha-synucleinHomo sapiens (human)
response to type II interferonAlpha-synucleinHomo sapiens (human)
cellular response to oxidative stressAlpha-synucleinHomo sapiens (human)
SNARE complex assemblyAlpha-synucleinHomo sapiens (human)
positive regulation of SNARE complex assemblyAlpha-synucleinHomo sapiens (human)
regulation of locomotionAlpha-synucleinHomo sapiens (human)
dopamine biosynthetic processAlpha-synucleinHomo sapiens (human)
mitochondrial ATP synthesis coupled electron transportAlpha-synucleinHomo sapiens (human)
regulation of macrophage activationAlpha-synucleinHomo sapiens (human)
positive regulation of apoptotic processAlpha-synucleinHomo sapiens (human)
negative regulation of apoptotic processAlpha-synucleinHomo sapiens (human)
negative regulation of cysteine-type endopeptidase activity involved in apoptotic processAlpha-synucleinHomo sapiens (human)
negative regulation of neuron apoptotic processAlpha-synucleinHomo sapiens (human)
positive regulation of endocytosisAlpha-synucleinHomo sapiens (human)
negative regulation of exocytosisAlpha-synucleinHomo sapiens (human)
positive regulation of exocytosisAlpha-synucleinHomo sapiens (human)
regulation of long-term neuronal synaptic plasticityAlpha-synucleinHomo sapiens (human)
synaptic vesicle endocytosisAlpha-synucleinHomo sapiens (human)
synaptic vesicle transportAlpha-synucleinHomo sapiens (human)
positive regulation of inflammatory responseAlpha-synucleinHomo sapiens (human)
regulation of acyl-CoA biosynthetic processAlpha-synucleinHomo sapiens (human)
protein tetramerizationAlpha-synucleinHomo sapiens (human)
positive regulation of release of sequestered calcium ion into cytosolAlpha-synucleinHomo sapiens (human)
neuron apoptotic processAlpha-synucleinHomo sapiens (human)
dopamine uptake involved in synaptic transmissionAlpha-synucleinHomo sapiens (human)
negative regulation of dopamine uptake involved in synaptic transmissionAlpha-synucleinHomo sapiens (human)
negative regulation of serotonin uptakeAlpha-synucleinHomo sapiens (human)
regulation of norepinephrine uptakeAlpha-synucleinHomo sapiens (human)
negative regulation of norepinephrine uptakeAlpha-synucleinHomo sapiens (human)
excitatory postsynaptic potentialAlpha-synucleinHomo sapiens (human)
long-term synaptic potentiationAlpha-synucleinHomo sapiens (human)
positive regulation of inositol phosphate biosynthetic processAlpha-synucleinHomo sapiens (human)
negative regulation of thrombin-activated receptor signaling pathwayAlpha-synucleinHomo sapiens (human)
response to interleukin-1Alpha-synucleinHomo sapiens (human)
cellular response to copper ionAlpha-synucleinHomo sapiens (human)
cellular response to epinephrine stimulusAlpha-synucleinHomo sapiens (human)
positive regulation of protein serine/threonine kinase activityAlpha-synucleinHomo sapiens (human)
supramolecular fiber organizationAlpha-synucleinHomo sapiens (human)
negative regulation of mitochondrial electron transport, NADH to ubiquinoneAlpha-synucleinHomo sapiens (human)
positive regulation of glutathione peroxidase activityAlpha-synucleinHomo sapiens (human)
positive regulation of hydrogen peroxide catabolic processAlpha-synucleinHomo sapiens (human)
regulation of synaptic vesicle recyclingAlpha-synucleinHomo sapiens (human)
regulation of reactive oxygen species biosynthetic processAlpha-synucleinHomo sapiens (human)
positive regulation of protein localization to cell peripheryAlpha-synucleinHomo sapiens (human)
negative regulation of chaperone-mediated autophagyAlpha-synucleinHomo sapiens (human)
regulation of presynapse assemblyAlpha-synucleinHomo sapiens (human)
amyloid fibril formationAlpha-synucleinHomo sapiens (human)
synapse organizationAlpha-synucleinHomo sapiens (human)
chemical synaptic transmissionAlpha-synucleinHomo sapiens (human)
negative regulation of inflammatory response to antigenic stimulusGuanine nucleotide-binding protein GHomo sapiens (human)
renal water homeostasisGuanine nucleotide-binding protein GHomo sapiens (human)
G protein-coupled receptor signaling pathwayGuanine nucleotide-binding protein GHomo sapiens (human)
regulation of insulin secretionGuanine nucleotide-binding protein GHomo sapiens (human)
cellular response to glucagon stimulusGuanine nucleotide-binding protein GHomo sapiens (human)
negative regulation of protein phosphorylationTAR DNA-binding protein 43Homo sapiens (human)
mRNA processingTAR DNA-binding protein 43Homo sapiens (human)
RNA splicingTAR DNA-binding protein 43Homo sapiens (human)
negative regulation of gene expressionTAR DNA-binding protein 43Homo sapiens (human)
regulation of protein stabilityTAR DNA-binding protein 43Homo sapiens (human)
positive regulation of insulin secretionTAR DNA-binding protein 43Homo sapiens (human)
response to endoplasmic reticulum stressTAR DNA-binding protein 43Homo sapiens (human)
positive regulation of protein import into nucleusTAR DNA-binding protein 43Homo sapiens (human)
regulation of circadian rhythmTAR DNA-binding protein 43Homo sapiens (human)
regulation of apoptotic processTAR DNA-binding protein 43Homo sapiens (human)
negative regulation by host of viral transcriptionTAR DNA-binding protein 43Homo sapiens (human)
rhythmic processTAR DNA-binding protein 43Homo sapiens (human)
regulation of cell cycleTAR DNA-binding protein 43Homo sapiens (human)
3'-UTR-mediated mRNA destabilizationTAR DNA-binding protein 43Homo sapiens (human)
3'-UTR-mediated mRNA stabilizationTAR DNA-binding protein 43Homo sapiens (human)
nuclear inner membrane organizationTAR DNA-binding protein 43Homo sapiens (human)
amyloid fibril formationTAR DNA-binding protein 43Homo sapiens (human)
regulation of gene expressionTAR DNA-binding protein 43Homo sapiens (human)
muscle contractionLeukotriene B4 receptor 1Homo sapiens (human)
inflammatory responseLeukotriene B4 receptor 1Homo sapiens (human)
immune responseLeukotriene B4 receptor 1Homo sapiens (human)
G protein-coupled receptor signaling pathwayLeukotriene B4 receptor 1Homo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayLeukotriene B4 receptor 1Homo sapiens (human)
leukotriene signaling pathwayLeukotriene B4 receptor 1Homo sapiens (human)
neuropeptide signaling pathwayLeukotriene B4 receptor 1Homo sapiens (human)
lipid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
phospholipid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
apoptotic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of cell population proliferationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
positive regulation of macrophage derived foam cell differentiationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
arachidonic acid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of cell migrationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
prostate gland developmentPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
regulation of epithelial cell differentiationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
positive regulation of chemokine productionPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
positive regulation of peroxisome proliferator activated receptor signaling pathwayPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
positive regulation of keratinocyte differentiationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of cell cyclePolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of growthPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
hepoxilin biosynthetic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
endocannabinoid signaling pathwayPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
cannabinoid biosynthetic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipoxin A4 biosynthetic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
linoleic acid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipid oxidationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipoxygenase pathwayPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of low-density lipoprotein receptor activityIntegrin beta-3Homo sapiens (human)
positive regulation of protein phosphorylationIntegrin beta-3Homo sapiens (human)
positive regulation of endothelial cell proliferationIntegrin beta-3Homo sapiens (human)
positive regulation of cell-matrix adhesionIntegrin beta-3Homo sapiens (human)
cell-substrate junction assemblyIntegrin beta-3Homo sapiens (human)
cell adhesionIntegrin beta-3Homo sapiens (human)
cell-matrix adhesionIntegrin beta-3Homo sapiens (human)
integrin-mediated signaling pathwayIntegrin beta-3Homo sapiens (human)
embryo implantationIntegrin beta-3Homo sapiens (human)
blood coagulationIntegrin beta-3Homo sapiens (human)
positive regulation of endothelial cell migrationIntegrin beta-3Homo sapiens (human)
positive regulation of gene expressionIntegrin beta-3Homo sapiens (human)
negative regulation of macrophage derived foam cell differentiationIntegrin beta-3Homo sapiens (human)
positive regulation of fibroblast migrationIntegrin beta-3Homo sapiens (human)
negative regulation of lipid storageIntegrin beta-3Homo sapiens (human)
response to activityIntegrin beta-3Homo sapiens (human)
smooth muscle cell migrationIntegrin beta-3Homo sapiens (human)
positive regulation of smooth muscle cell migrationIntegrin beta-3Homo sapiens (human)
platelet activationIntegrin beta-3Homo sapiens (human)
positive regulation of vascular endothelial growth factor receptor signaling pathwayIntegrin beta-3Homo sapiens (human)
cell-substrate adhesionIntegrin beta-3Homo sapiens (human)
activation of protein kinase activityIntegrin beta-3Homo sapiens (human)
negative regulation of lipid transportIntegrin beta-3Homo sapiens (human)
regulation of protein localizationIntegrin beta-3Homo sapiens (human)
regulation of actin cytoskeleton organizationIntegrin beta-3Homo sapiens (human)
cell adhesion mediated by integrinIntegrin beta-3Homo sapiens (human)
positive regulation of cell adhesion mediated by integrinIntegrin beta-3Homo sapiens (human)
positive regulation of osteoblast proliferationIntegrin beta-3Homo sapiens (human)
heterotypic cell-cell adhesionIntegrin beta-3Homo sapiens (human)
substrate adhesion-dependent cell spreadingIntegrin beta-3Homo sapiens (human)
tube developmentIntegrin beta-3Homo sapiens (human)
wound healing, spreading of epidermal cellsIntegrin beta-3Homo sapiens (human)
cellular response to platelet-derived growth factor stimulusIntegrin beta-3Homo sapiens (human)
apolipoprotein A-I-mediated signaling pathwayIntegrin beta-3Homo sapiens (human)
wound healingIntegrin beta-3Homo sapiens (human)
apoptotic cell clearanceIntegrin beta-3Homo sapiens (human)
regulation of bone resorptionIntegrin beta-3Homo sapiens (human)
positive regulation of angiogenesisIntegrin beta-3Homo sapiens (human)
positive regulation of bone resorptionIntegrin beta-3Homo sapiens (human)
symbiont entry into host cellIntegrin beta-3Homo sapiens (human)
platelet-derived growth factor receptor signaling pathwayIntegrin beta-3Homo sapiens (human)
positive regulation of fibroblast proliferationIntegrin beta-3Homo sapiens (human)
mesodermal cell differentiationIntegrin beta-3Homo sapiens (human)
positive regulation of smooth muscle cell proliferationIntegrin beta-3Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationIntegrin beta-3Homo sapiens (human)
negative regulation of lipoprotein metabolic processIntegrin beta-3Homo sapiens (human)
negative chemotaxisIntegrin beta-3Homo sapiens (human)
regulation of release of sequestered calcium ion into cytosolIntegrin beta-3Homo sapiens (human)
regulation of serotonin uptakeIntegrin beta-3Homo sapiens (human)
angiogenesis involved in wound healingIntegrin beta-3Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeIntegrin beta-3Homo sapiens (human)
platelet aggregationIntegrin beta-3Homo sapiens (human)
cellular response to mechanical stimulusIntegrin beta-3Homo sapiens (human)
cellular response to xenobiotic stimulusIntegrin beta-3Homo sapiens (human)
positive regulation of glomerular mesangial cell proliferationIntegrin beta-3Homo sapiens (human)
blood coagulation, fibrin clot formationIntegrin beta-3Homo sapiens (human)
maintenance of postsynaptic specialization structureIntegrin beta-3Homo sapiens (human)
regulation of postsynaptic neurotransmitter receptor internalizationIntegrin beta-3Homo sapiens (human)
regulation of postsynaptic neurotransmitter receptor diffusion trappingIntegrin beta-3Homo sapiens (human)
positive regulation of substrate adhesion-dependent cell spreadingIntegrin beta-3Homo sapiens (human)
positive regulation of adenylate cyclase-inhibiting opioid receptor signaling pathwayIntegrin beta-3Homo sapiens (human)
regulation of trophoblast cell migrationIntegrin beta-3Homo sapiens (human)
regulation of extracellular matrix organizationIntegrin beta-3Homo sapiens (human)
cellular response to insulin-like growth factor stimulusIntegrin beta-3Homo sapiens (human)
negative regulation of endothelial cell apoptotic processIntegrin beta-3Homo sapiens (human)
positive regulation of T cell migrationIntegrin beta-3Homo sapiens (human)
cell migrationIntegrin beta-3Homo sapiens (human)
positive regulation of leukocyte migrationIntegrin alpha-IIbHomo sapiens (human)
cell-matrix adhesionIntegrin alpha-IIbHomo sapiens (human)
integrin-mediated signaling pathwayIntegrin alpha-IIbHomo sapiens (human)
angiogenesisIntegrin alpha-IIbHomo sapiens (human)
cell-cell adhesionIntegrin alpha-IIbHomo sapiens (human)
cell adhesion mediated by integrinIntegrin alpha-IIbHomo sapiens (human)
prostaglandin biosynthetic processProstaglandin G/H synthase 2Homo sapiens (human)
angiogenesisProstaglandin G/H synthase 2Homo sapiens (human)
response to oxidative stressProstaglandin G/H synthase 2Homo sapiens (human)
embryo implantationProstaglandin G/H synthase 2Homo sapiens (human)
learningProstaglandin G/H synthase 2Homo sapiens (human)
memoryProstaglandin G/H synthase 2Homo sapiens (human)
regulation of blood pressureProstaglandin G/H synthase 2Homo sapiens (human)
negative regulation of cell population proliferationProstaglandin G/H synthase 2Homo sapiens (human)
response to xenobiotic stimulusProstaglandin G/H synthase 2Homo sapiens (human)
response to nematodeProstaglandin G/H synthase 2Homo sapiens (human)
response to fructoseProstaglandin G/H synthase 2Homo sapiens (human)
response to manganese ionProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of vascular endothelial growth factor productionProstaglandin G/H synthase 2Homo sapiens (human)
cyclooxygenase pathwayProstaglandin G/H synthase 2Homo sapiens (human)
bone mineralizationProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of prostaglandin biosynthetic processProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of fever generationProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of synaptic plasticityProstaglandin G/H synthase 2Homo sapiens (human)
negative regulation of synaptic transmission, dopaminergicProstaglandin G/H synthase 2Homo sapiens (human)
prostaglandin secretionProstaglandin G/H synthase 2Homo sapiens (human)
response to estradiolProstaglandin G/H synthase 2Homo sapiens (human)
response to lipopolysaccharideProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of peptidyl-serine phosphorylationProstaglandin G/H synthase 2Homo sapiens (human)
response to vitamin DProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to heatProstaglandin G/H synthase 2Homo sapiens (human)
response to tumor necrosis factorProstaglandin G/H synthase 2Homo sapiens (human)
maintenance of blood-brain barrierProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of protein import into nucleusProstaglandin G/H synthase 2Homo sapiens (human)
hair cycleProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of apoptotic processProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of nitric oxide biosynthetic processProstaglandin G/H synthase 2Homo sapiens (human)
negative regulation of cell cycleProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of vasoconstrictionProstaglandin G/H synthase 2Homo sapiens (human)
negative regulation of smooth muscle contractionProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of smooth muscle contractionProstaglandin G/H synthase 2Homo sapiens (human)
decidualizationProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of smooth muscle cell proliferationProstaglandin G/H synthase 2Homo sapiens (human)
regulation of inflammatory responseProstaglandin G/H synthase 2Homo sapiens (human)
brown fat cell differentiationProstaglandin G/H synthase 2Homo sapiens (human)
response to glucocorticoidProstaglandin G/H synthase 2Homo sapiens (human)
negative regulation of calcium ion transportProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of synaptic transmission, glutamatergicProstaglandin G/H synthase 2Homo sapiens (human)
response to fatty acidProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to mechanical stimulusProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to lead ionProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to ATPProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to hypoxiaProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to non-ionic osmotic stressProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to fluid shear stressProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of transforming growth factor beta productionProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of cell migration involved in sprouting angiogenesisProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of fibroblast growth factor productionProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of brown fat cell differentiationProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of platelet-derived growth factor productionProstaglandin G/H synthase 2Homo sapiens (human)
cellular oxidant detoxificationProstaglandin G/H synthase 2Homo sapiens (human)
regulation of neuroinflammatory responseProstaglandin G/H synthase 2Homo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathway in response to osmotic stressProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to homocysteineProstaglandin G/H synthase 2Homo sapiens (human)
response to angiotensinProstaglandin G/H synthase 2Homo sapiens (human)
calcium ion homeostasisAlpha-synucleinHomo sapiens (human)
negative regulation of transcription by RNA polymerase IIAlpha-synucleinHomo sapiens (human)
microglial cell activationAlpha-synucleinHomo sapiens (human)
positive regulation of receptor recyclingAlpha-synucleinHomo sapiens (human)
positive regulation of neurotransmitter secretionAlpha-synucleinHomo sapiens (human)
negative regulation of protein kinase activityAlpha-synucleinHomo sapiens (human)
fatty acid metabolic processAlpha-synucleinHomo sapiens (human)
neutral lipid metabolic processAlpha-synucleinHomo sapiens (human)
phospholipid metabolic processAlpha-synucleinHomo sapiens (human)
activation of cysteine-type endopeptidase activity involved in apoptotic processAlpha-synucleinHomo sapiens (human)
mitochondrial membrane organizationAlpha-synucleinHomo sapiens (human)
adult locomotory behaviorAlpha-synucleinHomo sapiens (human)
response to xenobiotic stimulusAlpha-synucleinHomo sapiens (human)
response to iron(II) ionAlpha-synucleinHomo sapiens (human)
regulation of phospholipase activityAlpha-synucleinHomo sapiens (human)
negative regulation of platelet-derived growth factor receptor signaling pathwayAlpha-synucleinHomo sapiens (human)
regulation of glutamate secretionAlpha-synucleinHomo sapiens (human)
regulation of dopamine secretionAlpha-synucleinHomo sapiens (human)
synaptic vesicle exocytosisAlpha-synucleinHomo sapiens (human)
synaptic vesicle primingAlpha-synucleinHomo sapiens (human)
regulation of transmembrane transporter activityAlpha-synucleinHomo sapiens (human)
negative regulation of microtubule polymerizationAlpha-synucleinHomo sapiens (human)
receptor internalizationAlpha-synucleinHomo sapiens (human)
protein destabilizationAlpha-synucleinHomo sapiens (human)
response to magnesium ionAlpha-synucleinHomo sapiens (human)
negative regulation of transporter activityAlpha-synucleinHomo sapiens (human)
response to lipopolysaccharideAlpha-synucleinHomo sapiens (human)
negative regulation of monooxygenase activityAlpha-synucleinHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylationAlpha-synucleinHomo sapiens (human)
response to type II interferonAlpha-synucleinHomo sapiens (human)
cellular response to oxidative stressAlpha-synucleinHomo sapiens (human)
SNARE complex assemblyAlpha-synucleinHomo sapiens (human)
positive regulation of SNARE complex assemblyAlpha-synucleinHomo sapiens (human)
regulation of locomotionAlpha-synucleinHomo sapiens (human)
dopamine biosynthetic processAlpha-synucleinHomo sapiens (human)
mitochondrial ATP synthesis coupled electron transportAlpha-synucleinHomo sapiens (human)
regulation of macrophage activationAlpha-synucleinHomo sapiens (human)
positive regulation of apoptotic processAlpha-synucleinHomo sapiens (human)
negative regulation of apoptotic processAlpha-synucleinHomo sapiens (human)
negative regulation of cysteine-type endopeptidase activity involved in apoptotic processAlpha-synucleinHomo sapiens (human)
negative regulation of neuron apoptotic processAlpha-synucleinHomo sapiens (human)
positive regulation of endocytosisAlpha-synucleinHomo sapiens (human)
negative regulation of exocytosisAlpha-synucleinHomo sapiens (human)
positive regulation of exocytosisAlpha-synucleinHomo sapiens (human)
regulation of long-term neuronal synaptic plasticityAlpha-synucleinHomo sapiens (human)
synaptic vesicle endocytosisAlpha-synucleinHomo sapiens (human)
synaptic vesicle transportAlpha-synucleinHomo sapiens (human)
positive regulation of inflammatory responseAlpha-synucleinHomo sapiens (human)
regulation of acyl-CoA biosynthetic processAlpha-synucleinHomo sapiens (human)
protein tetramerizationAlpha-synucleinHomo sapiens (human)
positive regulation of release of sequestered calcium ion into cytosolAlpha-synucleinHomo sapiens (human)
neuron apoptotic processAlpha-synucleinHomo sapiens (human)
dopamine uptake involved in synaptic transmissionAlpha-synucleinHomo sapiens (human)
negative regulation of dopamine uptake involved in synaptic transmissionAlpha-synucleinHomo sapiens (human)
negative regulation of serotonin uptakeAlpha-synucleinHomo sapiens (human)
regulation of norepinephrine uptakeAlpha-synucleinHomo sapiens (human)
negative regulation of norepinephrine uptakeAlpha-synucleinHomo sapiens (human)
excitatory postsynaptic potentialAlpha-synucleinHomo sapiens (human)
long-term synaptic potentiationAlpha-synucleinHomo sapiens (human)
positive regulation of inositol phosphate biosynthetic processAlpha-synucleinHomo sapiens (human)
negative regulation of thrombin-activated receptor signaling pathwayAlpha-synucleinHomo sapiens (human)
response to interleukin-1Alpha-synucleinHomo sapiens (human)
cellular response to copper ionAlpha-synucleinHomo sapiens (human)
cellular response to epinephrine stimulusAlpha-synucleinHomo sapiens (human)
positive regulation of protein serine/threonine kinase activityAlpha-synucleinHomo sapiens (human)
supramolecular fiber organizationAlpha-synucleinHomo sapiens (human)
negative regulation of mitochondrial electron transport, NADH to ubiquinoneAlpha-synucleinHomo sapiens (human)
positive regulation of glutathione peroxidase activityAlpha-synucleinHomo sapiens (human)
positive regulation of hydrogen peroxide catabolic processAlpha-synucleinHomo sapiens (human)
regulation of synaptic vesicle recyclingAlpha-synucleinHomo sapiens (human)
regulation of reactive oxygen species biosynthetic processAlpha-synucleinHomo sapiens (human)
positive regulation of protein localization to cell peripheryAlpha-synucleinHomo sapiens (human)
negative regulation of chaperone-mediated autophagyAlpha-synucleinHomo sapiens (human)
regulation of presynapse assemblyAlpha-synucleinHomo sapiens (human)
amyloid fibril formationAlpha-synucleinHomo sapiens (human)
synapse organizationAlpha-synucleinHomo sapiens (human)
chemical synaptic transmissionAlpha-synucleinHomo sapiens (human)
positive regulation of epidermal growth factor receptor signaling pathwayDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
response to hypoxiaDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
neutrophil mediated immunityDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
germinal center formationDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of leukocyte chemotaxisDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
proteolysisDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
membrane protein ectodomain proteolysisDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
cell adhesionDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
Notch receptor processingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of cell population proliferationDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
response to xenobiotic stimulusDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of T cell chemotaxisDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
protein processingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
signal releaseDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
B cell differentiationDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of cell growthDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of cell migrationDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
response to lipopolysaccharideDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of chemokine productionDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of tumor necrosis factor productionDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
regulation of mast cell apoptotic processDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
T cell differentiation in thymusDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
cell adhesion mediated by integrinDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
wound healing, spreading of epidermal cellsDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
amyloid precursor protein catabolic processDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of blood vessel endothelial cell migrationDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of cyclin-dependent protein serine/threonine kinase activityDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of epidermal growth factor-activated receptor activityDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of epidermal growth factor receptor signaling pathwayDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
spleen developmentDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
cell motilityDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
defense response to Gram-positive bacteriumDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
cellular response to high density lipoprotein particle stimulusDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
commissural neuron axon guidanceDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
negative regulation of cold-induced thermogenesisDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of G1/S transition of mitotic cell cycleDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of tumor necrosis factor-mediated signaling pathwayDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of vascular endothelial cell proliferationDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
Notch signaling pathwayDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
negative regulation of receptor internalizationAtaxin-2Homo sapiens (human)
regulation of translationAtaxin-2Homo sapiens (human)
RNA metabolic processAtaxin-2Homo sapiens (human)
P-body assemblyAtaxin-2Homo sapiens (human)
stress granule assemblyAtaxin-2Homo sapiens (human)
RNA transportAtaxin-2Homo sapiens (human)
mRNA processingSingle-stranded DNA cytosine deaminaseHomo sapiens (human)
cytidine deaminationSingle-stranded DNA cytosine deaminaseHomo sapiens (human)
somatic diversification of immunoglobulinsSingle-stranded DNA cytosine deaminaseHomo sapiens (human)
somatic hypermutation of immunoglobulin genesSingle-stranded DNA cytosine deaminaseHomo sapiens (human)
B cell differentiationSingle-stranded DNA cytosine deaminaseHomo sapiens (human)
regulation of nuclear cell cycle DNA replicationSingle-stranded DNA cytosine deaminaseHomo sapiens (human)
defense response to bacteriumSingle-stranded DNA cytosine deaminaseHomo sapiens (human)
positive regulation of gene expression via chromosomal CpG island demethylationSingle-stranded DNA cytosine deaminaseHomo sapiens (human)
isotype switchingSingle-stranded DNA cytosine deaminaseHomo sapiens (human)
cellular response to lipopolysaccharideSingle-stranded DNA cytosine deaminaseHomo sapiens (human)
DNA cytosine deaminationSingle-stranded DNA cytosine deaminaseHomo sapiens (human)
DNA demethylationSingle-stranded DNA cytosine deaminaseHomo sapiens (human)
cytidine to uridine editingSingle-stranded DNA cytosine deaminaseHomo sapiens (human)
negative regulation of single stranded viral RNA replication via double stranded DNA intermediateSingle-stranded DNA cytosine deaminaseHomo sapiens (human)
defense response to virusSingle-stranded DNA cytosine deaminaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (187)

Processvia Protein(s)Taxonomy
iron ion bindingPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
calcium ion bindingPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
protein bindingPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipid bindingPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
linoleate 13S-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
arachidonate 8(S)-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
arachidonate 15-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
linoleate 9S-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
peroxidase activityProstaglandin G/H synthase 1 Bos taurus (cattle)
heme bindingProstaglandin G/H synthase 1 Bos taurus (cattle)
metal ion bindingProstaglandin G/H synthase 1 Bos taurus (cattle)
peroxidase activityProstaglandin G/H synthase 2 Bos taurus (cattle)
prostaglandin-endoperoxide synthase activityProstaglandin G/H synthase 2 Bos taurus (cattle)
heme bindingProstaglandin G/H synthase 2 Bos taurus (cattle)
metal ion bindingProstaglandin G/H synthase 2 Bos taurus (cattle)
calcium channel activityTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
channel activityTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
intracellularly gated calcium channel activityTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
identical protein bindingTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
temperature-gated cation channel activityTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
guanyl-nucleotide exchange factor activityRap guanine nucleotide exchange factor 3Homo sapiens (human)
protein bindingRap guanine nucleotide exchange factor 3Homo sapiens (human)
protein domain specific bindingRap guanine nucleotide exchange factor 3Homo sapiens (human)
cAMP bindingRap guanine nucleotide exchange factor 3Homo sapiens (human)
transcription cis-regulatory region bindingProto-oncogene c-FosHomo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingProto-oncogene c-FosHomo sapiens (human)
RNA polymerase II core promoter sequence-specific DNA bindingProto-oncogene c-FosHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificProto-oncogene c-FosHomo sapiens (human)
transcription coregulator bindingProto-oncogene c-FosHomo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificProto-oncogene c-FosHomo sapiens (human)
chromatin bindingProto-oncogene c-FosHomo sapiens (human)
DNA-binding transcription factor activityProto-oncogene c-FosHomo sapiens (human)
protein bindingProto-oncogene c-FosHomo sapiens (human)
identical protein bindingProto-oncogene c-FosHomo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingProto-oncogene c-FosHomo sapiens (human)
R-SMAD bindingProto-oncogene c-FosHomo sapiens (human)
sequence-specific double-stranded DNA bindingProto-oncogene c-FosHomo sapiens (human)
hormone activityTransthyretinHomo sapiens (human)
protein bindingTransthyretinHomo sapiens (human)
identical protein bindingTransthyretinHomo sapiens (human)
thyroid hormone bindingTransthyretinHomo sapiens (human)
transcription cis-regulatory region bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
core promoter sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
TFIID-class transcription factor complex bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
protease bindingCellular tumor antigen p53Homo sapiens (human)
p53 bindingCellular tumor antigen p53Homo sapiens (human)
DNA bindingCellular tumor antigen p53Homo sapiens (human)
chromatin bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activityCellular tumor antigen p53Homo sapiens (human)
mRNA 3'-UTR bindingCellular tumor antigen p53Homo sapiens (human)
copper ion bindingCellular tumor antigen p53Homo sapiens (human)
protein bindingCellular tumor antigen p53Homo sapiens (human)
zinc ion bindingCellular tumor antigen p53Homo sapiens (human)
enzyme bindingCellular tumor antigen p53Homo sapiens (human)
receptor tyrosine kinase bindingCellular tumor antigen p53Homo sapiens (human)
ubiquitin protein ligase bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase regulator activityCellular tumor antigen p53Homo sapiens (human)
ATP-dependent DNA/DNA annealing activityCellular tumor antigen p53Homo sapiens (human)
identical protein bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase bindingCellular tumor antigen p53Homo sapiens (human)
protein heterodimerization activityCellular tumor antigen p53Homo sapiens (human)
protein-folding chaperone bindingCellular tumor antigen p53Homo sapiens (human)
protein phosphatase 2A bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingCellular tumor antigen p53Homo sapiens (human)
14-3-3 protein bindingCellular tumor antigen p53Homo sapiens (human)
MDM2/MDM4 family protein bindingCellular tumor antigen p53Homo sapiens (human)
disordered domain specific bindingCellular tumor antigen p53Homo sapiens (human)
general transcription initiation factor bindingCellular tumor antigen p53Homo sapiens (human)
molecular function activator activityCellular tumor antigen p53Homo sapiens (human)
promoter-specific chromatin bindingCellular tumor antigen p53Homo sapiens (human)
transcription cis-regulatory region bindingTranscription factor AP-1Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingTranscription factor AP-1Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificTranscription factor AP-1Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificTranscription factor AP-1Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificTranscription factor AP-1Homo sapiens (human)
DNA bindingTranscription factor AP-1Homo sapiens (human)
DNA-binding transcription factor activityTranscription factor AP-1Homo sapiens (human)
RNA bindingTranscription factor AP-1Homo sapiens (human)
GTPase activator activityTranscription factor AP-1Homo sapiens (human)
protein bindingTranscription factor AP-1Homo sapiens (human)
enzyme bindingTranscription factor AP-1Homo sapiens (human)
ubiquitin protein ligase bindingTranscription factor AP-1Homo sapiens (human)
cAMP response element bindingTranscription factor AP-1Homo sapiens (human)
identical protein bindingTranscription factor AP-1Homo sapiens (human)
ubiquitin-like protein ligase bindingTranscription factor AP-1Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingTranscription factor AP-1Homo sapiens (human)
R-SMAD bindingTranscription factor AP-1Homo sapiens (human)
general transcription initiation factor bindingTranscription factor AP-1Homo sapiens (human)
sequence-specific double-stranded DNA bindingTranscription factor AP-1Homo sapiens (human)
transcription factor bindingTranscription factor AP-1Homo sapiens (human)
G-protein alpha-subunit bindingInsulin-like growth factor 1 receptorHomo sapiens (human)
protein tyrosine kinase activityInsulin-like growth factor 1 receptorHomo sapiens (human)
insulin-like growth factor receptor activityInsulin-like growth factor 1 receptorHomo sapiens (human)
insulin receptor bindingInsulin-like growth factor 1 receptorHomo sapiens (human)
protein bindingInsulin-like growth factor 1 receptorHomo sapiens (human)
insulin-like growth factor bindingInsulin-like growth factor 1 receptorHomo sapiens (human)
ATP bindingInsulin-like growth factor 1 receptorHomo sapiens (human)
insulin-like growth factor I bindingInsulin-like growth factor 1 receptorHomo sapiens (human)
identical protein bindingInsulin-like growth factor 1 receptorHomo sapiens (human)
phosphatidylinositol 3-kinase bindingInsulin-like growth factor 1 receptorHomo sapiens (human)
insulin bindingInsulin-like growth factor 1 receptorHomo sapiens (human)
insulin receptor substrate bindingInsulin-like growth factor 1 receptorHomo sapiens (human)
protein-containing complex bindingInsulin-like growth factor 1 receptorHomo sapiens (human)
protein transporter activityInsulin-like growth factor 1 receptorHomo sapiens (human)
insulin receptor activityInsulin-like growth factor 1 receptorHomo sapiens (human)
arachidonate 5-lipoxygenase activityPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
arachidonate 12(S)-lipoxygenase activityPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
iron ion bindingPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
protein bindingPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
hydrolase activityPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
arachidonate 8(S)-lipoxygenase activityPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
3'-5'-RNA exonuclease activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
RNA-dependent RNA polymerase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
cysteine-type endopeptidase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
mRNA 5'-cap (guanine-N7-)-methyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
mRNA (nucleoside-2'-O-)-methyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
mRNA guanylyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
RNA endonuclease activity, producing 3'-phosphomonoestersReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
ISG15-specific peptidase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
5'-3' RNA helicase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
protein guanylyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
transcription cis-regulatory region bindingAndrogen receptorHomo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingAndrogen receptorHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificAndrogen receptorHomo sapiens (human)
RNA polymerase II general transcription initiation factor bindingAndrogen receptorHomo sapiens (human)
transcription coactivator bindingAndrogen receptorHomo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificAndrogen receptorHomo sapiens (human)
chromatin bindingAndrogen receptorHomo sapiens (human)
DNA-binding transcription factor activityAndrogen receptorHomo sapiens (human)
nuclear receptor activityAndrogen receptorHomo sapiens (human)
G protein-coupled receptor activityAndrogen receptorHomo sapiens (human)
signaling receptor bindingAndrogen receptorHomo sapiens (human)
steroid bindingAndrogen receptorHomo sapiens (human)
androgen bindingAndrogen receptorHomo sapiens (human)
protein bindingAndrogen receptorHomo sapiens (human)
beta-catenin bindingAndrogen receptorHomo sapiens (human)
zinc ion bindingAndrogen receptorHomo sapiens (human)
enzyme bindingAndrogen receptorHomo sapiens (human)
ATPase bindingAndrogen receptorHomo sapiens (human)
molecular adaptor activityAndrogen receptorHomo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingAndrogen receptorHomo sapiens (human)
POU domain bindingAndrogen receptorHomo sapiens (human)
molecular condensate scaffold activityAndrogen receptorHomo sapiens (human)
estrogen response element bindingAndrogen receptorHomo sapiens (human)
iron ion bindingAromataseHomo sapiens (human)
steroid hydroxylase activityAromataseHomo sapiens (human)
electron transfer activityAromataseHomo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenAromataseHomo sapiens (human)
oxygen bindingAromataseHomo sapiens (human)
heme bindingAromataseHomo sapiens (human)
aromatase activityAromataseHomo sapiens (human)
catalytic activity17-beta-hydroxysteroid dehydrogenase type 1Homo sapiens (human)
estradiol 17-beta-dehydrogenase [NAD(P)] activity17-beta-hydroxysteroid dehydrogenase type 1Homo sapiens (human)
steroid binding17-beta-hydroxysteroid dehydrogenase type 1Homo sapiens (human)
protein binding17-beta-hydroxysteroid dehydrogenase type 1Homo sapiens (human)
testosterone dehydrogenase [NAD(P)] activity17-beta-hydroxysteroid dehydrogenase type 1Homo sapiens (human)
dihydrotestosterone 17-beta-dehydrogenase activity17-beta-hydroxysteroid dehydrogenase type 1Homo sapiens (human)
small molecule binding17-beta-hydroxysteroid dehydrogenase type 1Homo sapiens (human)
protein homodimerization activity17-beta-hydroxysteroid dehydrogenase type 1Homo sapiens (human)
testosterone dehydrogenase (NAD+) activity17-beta-hydroxysteroid dehydrogenase type 1Homo sapiens (human)
testosterone 17-beta-dehydrogenase (NADP+) activity17-beta-hydroxysteroid dehydrogenase type 1Homo sapiens (human)
NADP binding17-beta-hydroxysteroid dehydrogenase type 1Homo sapiens (human)
NADP+ binding17-beta-hydroxysteroid dehydrogenase type 1Homo sapiens (human)
17-beta-hydroxysteroid dehydrogenase (NADP+) activity17-beta-hydroxysteroid dehydrogenase type 1Homo sapiens (human)
estradiol binding17-beta-hydroxysteroid dehydrogenase type 1Homo sapiens (human)
arachidonate 12(S)-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
iron ion bindingPolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
protein bindingPolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
phosphatidylinositol-4,5-bisphosphate bindingPolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
linoleate 13S-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
arachidonate 15-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
arachidonate 12(S)-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX12Homo sapiens (human)
iron ion bindingPolyunsaturated fatty acid lipoxygenase ALOX12Homo sapiens (human)
protein bindingPolyunsaturated fatty acid lipoxygenase ALOX12Homo sapiens (human)
linoleate 13S-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX12Homo sapiens (human)
hepoxilin-epoxide hydrolase activityPolyunsaturated fatty acid lipoxygenase ALOX12Homo sapiens (human)
arachidonate 15-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX12Homo sapiens (human)
actin bindingSodium-dependent noradrenaline transporter Homo sapiens (human)
neurotransmitter transmembrane transporter activitySodium-dependent noradrenaline transporter Homo sapiens (human)
neurotransmitter:sodium symporter activitySodium-dependent noradrenaline transporter Homo sapiens (human)
dopamine:sodium symporter activitySodium-dependent noradrenaline transporter Homo sapiens (human)
norepinephrine:sodium symporter activitySodium-dependent noradrenaline transporter Homo sapiens (human)
protein bindingSodium-dependent noradrenaline transporter Homo sapiens (human)
monoamine transmembrane transporter activitySodium-dependent noradrenaline transporter Homo sapiens (human)
alpha-tubulin bindingSodium-dependent noradrenaline transporter Homo sapiens (human)
metal ion bindingSodium-dependent noradrenaline transporter Homo sapiens (human)
beta-tubulin bindingSodium-dependent noradrenaline transporter Homo sapiens (human)
endopeptidase activityCaspase-1Homo sapiens (human)
cysteine-type endopeptidase activityCaspase-1Homo sapiens (human)
protein bindingCaspase-1Homo sapiens (human)
cysteine-type endopeptidase activator activity involved in apoptotic processCaspase-1Homo sapiens (human)
kinase bindingCaspase-1Homo sapiens (human)
cytokine bindingCaspase-1Homo sapiens (human)
identical protein bindingCaspase-1Homo sapiens (human)
CARD domain bindingCaspase-1Homo sapiens (human)
caspase bindingCaspase-1Homo sapiens (human)
peroxidase activityProstaglandin G/H synthase 2Homo sapiens (human)
prostaglandin-endoperoxide synthase activityProstaglandin G/H synthase 2Homo sapiens (human)
protein bindingProstaglandin G/H synthase 2Homo sapiens (human)
enzyme bindingProstaglandin G/H synthase 2Homo sapiens (human)
heme bindingProstaglandin G/H synthase 2Homo sapiens (human)
protein homodimerization activityProstaglandin G/H synthase 2Homo sapiens (human)
metal ion bindingProstaglandin G/H synthase 2Homo sapiens (human)
oxidoreductase activity, acting on single donors with incorporation of molecular oxygen, incorporation of two atoms of oxygenProstaglandin G/H synthase 2Homo sapiens (human)
estradiol 17-beta-dehydrogenase [NAD(P)] activity17-beta-hydroxysteroid dehydrogenase type 2Homo sapiens (human)
17-alpha,20-alpha-dihydroxypregn-4-en-3-one dehydrogenase activity17-beta-hydroxysteroid dehydrogenase type 2Homo sapiens (human)
testosterone dehydrogenase (NAD+) activity17-beta-hydroxysteroid dehydrogenase type 2Homo sapiens (human)
fatty acid bindingAlpha-synucleinHomo sapiens (human)
phospholipase D inhibitor activityAlpha-synucleinHomo sapiens (human)
SNARE bindingAlpha-synucleinHomo sapiens (human)
magnesium ion bindingAlpha-synucleinHomo sapiens (human)
transcription cis-regulatory region bindingAlpha-synucleinHomo sapiens (human)
actin bindingAlpha-synucleinHomo sapiens (human)
protein kinase inhibitor activityAlpha-synucleinHomo sapiens (human)
copper ion bindingAlpha-synucleinHomo sapiens (human)
calcium ion bindingAlpha-synucleinHomo sapiens (human)
protein bindingAlpha-synucleinHomo sapiens (human)
phospholipid bindingAlpha-synucleinHomo sapiens (human)
ferrous iron bindingAlpha-synucleinHomo sapiens (human)
zinc ion bindingAlpha-synucleinHomo sapiens (human)
lipid bindingAlpha-synucleinHomo sapiens (human)
oxidoreductase activityAlpha-synucleinHomo sapiens (human)
kinesin bindingAlpha-synucleinHomo sapiens (human)
Hsp70 protein bindingAlpha-synucleinHomo sapiens (human)
histone bindingAlpha-synucleinHomo sapiens (human)
identical protein bindingAlpha-synucleinHomo sapiens (human)
alpha-tubulin bindingAlpha-synucleinHomo sapiens (human)
cysteine-type endopeptidase inhibitor activity involved in apoptotic processAlpha-synucleinHomo sapiens (human)
tau protein bindingAlpha-synucleinHomo sapiens (human)
phosphoprotein bindingAlpha-synucleinHomo sapiens (human)
molecular adaptor activityAlpha-synucleinHomo sapiens (human)
dynein complex bindingAlpha-synucleinHomo sapiens (human)
cuprous ion bindingAlpha-synucleinHomo sapiens (human)
G protein activityGuanine nucleotide-binding protein GHomo sapiens (human)
adenylate cyclase activator activityGuanine nucleotide-binding protein GHomo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
double-stranded DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
RNA bindingTAR DNA-binding protein 43Homo sapiens (human)
mRNA 3'-UTR bindingTAR DNA-binding protein 43Homo sapiens (human)
protein bindingTAR DNA-binding protein 43Homo sapiens (human)
lipid bindingTAR DNA-binding protein 43Homo sapiens (human)
identical protein bindingTAR DNA-binding protein 43Homo sapiens (human)
pre-mRNA intronic bindingTAR DNA-binding protein 43Homo sapiens (human)
molecular condensate scaffold activityTAR DNA-binding protein 43Homo sapiens (human)
nucleotide bindingLeukotriene B4 receptor 1Homo sapiens (human)
leukotriene receptor activityLeukotriene B4 receptor 1Homo sapiens (human)
G protein-coupled peptide receptor activityLeukotriene B4 receptor 1Homo sapiens (human)
leukotriene B4 receptor activityLeukotriene B4 receptor 1Homo sapiens (human)
iron ion bindingPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
calcium ion bindingPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
protein bindingPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipid bindingPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
linoleate 13S-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
arachidonate 8(S)-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
arachidonate 15-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
linoleate 9S-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
fibroblast growth factor bindingIntegrin beta-3Homo sapiens (human)
C-X3-C chemokine bindingIntegrin beta-3Homo sapiens (human)
insulin-like growth factor I bindingIntegrin beta-3Homo sapiens (human)
neuregulin bindingIntegrin beta-3Homo sapiens (human)
virus receptor activityIntegrin beta-3Homo sapiens (human)
fibronectin bindingIntegrin beta-3Homo sapiens (human)
protease bindingIntegrin beta-3Homo sapiens (human)
protein disulfide isomerase activityIntegrin beta-3Homo sapiens (human)
protein kinase C bindingIntegrin beta-3Homo sapiens (human)
platelet-derived growth factor receptor bindingIntegrin beta-3Homo sapiens (human)
integrin bindingIntegrin beta-3Homo sapiens (human)
protein bindingIntegrin beta-3Homo sapiens (human)
coreceptor activityIntegrin beta-3Homo sapiens (human)
enzyme bindingIntegrin beta-3Homo sapiens (human)
identical protein bindingIntegrin beta-3Homo sapiens (human)
vascular endothelial growth factor receptor 2 bindingIntegrin beta-3Homo sapiens (human)
metal ion bindingIntegrin beta-3Homo sapiens (human)
cell adhesion molecule bindingIntegrin beta-3Homo sapiens (human)
extracellular matrix bindingIntegrin beta-3Homo sapiens (human)
fibrinogen bindingIntegrin beta-3Homo sapiens (human)
protein bindingIntegrin alpha-IIbHomo sapiens (human)
identical protein bindingIntegrin alpha-IIbHomo sapiens (human)
metal ion bindingIntegrin alpha-IIbHomo sapiens (human)
extracellular matrix bindingIntegrin alpha-IIbHomo sapiens (human)
molecular adaptor activityIntegrin alpha-IIbHomo sapiens (human)
fibrinogen bindingIntegrin alpha-IIbHomo sapiens (human)
integrin bindingIntegrin alpha-IIbHomo sapiens (human)
peroxidase activityProstaglandin G/H synthase 2Homo sapiens (human)
prostaglandin-endoperoxide synthase activityProstaglandin G/H synthase 2Homo sapiens (human)
protein bindingProstaglandin G/H synthase 2Homo sapiens (human)
enzyme bindingProstaglandin G/H synthase 2Homo sapiens (human)
heme bindingProstaglandin G/H synthase 2Homo sapiens (human)
protein homodimerization activityProstaglandin G/H synthase 2Homo sapiens (human)
metal ion bindingProstaglandin G/H synthase 2Homo sapiens (human)
oxidoreductase activity, acting on single donors with incorporation of molecular oxygen, incorporation of two atoms of oxygenProstaglandin G/H synthase 2Homo sapiens (human)
fatty acid bindingAlpha-synucleinHomo sapiens (human)
phospholipase D inhibitor activityAlpha-synucleinHomo sapiens (human)
SNARE bindingAlpha-synucleinHomo sapiens (human)
magnesium ion bindingAlpha-synucleinHomo sapiens (human)
transcription cis-regulatory region bindingAlpha-synucleinHomo sapiens (human)
actin bindingAlpha-synucleinHomo sapiens (human)
protein kinase inhibitor activityAlpha-synucleinHomo sapiens (human)
copper ion bindingAlpha-synucleinHomo sapiens (human)
calcium ion bindingAlpha-synucleinHomo sapiens (human)
protein bindingAlpha-synucleinHomo sapiens (human)
phospholipid bindingAlpha-synucleinHomo sapiens (human)
ferrous iron bindingAlpha-synucleinHomo sapiens (human)
zinc ion bindingAlpha-synucleinHomo sapiens (human)
lipid bindingAlpha-synucleinHomo sapiens (human)
oxidoreductase activityAlpha-synucleinHomo sapiens (human)
kinesin bindingAlpha-synucleinHomo sapiens (human)
Hsp70 protein bindingAlpha-synucleinHomo sapiens (human)
histone bindingAlpha-synucleinHomo sapiens (human)
identical protein bindingAlpha-synucleinHomo sapiens (human)
alpha-tubulin bindingAlpha-synucleinHomo sapiens (human)
cysteine-type endopeptidase inhibitor activity involved in apoptotic processAlpha-synucleinHomo sapiens (human)
tau protein bindingAlpha-synucleinHomo sapiens (human)
phosphoprotein bindingAlpha-synucleinHomo sapiens (human)
molecular adaptor activityAlpha-synucleinHomo sapiens (human)
dynein complex bindingAlpha-synucleinHomo sapiens (human)
cuprous ion bindingAlpha-synucleinHomo sapiens (human)
endopeptidase activityDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
metalloendopeptidase activityDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
Notch bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
interleukin-6 receptor bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
integrin bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
protein bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
peptidase activityDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
metallopeptidase activityDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
SH3 domain bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
cytokine bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
PDZ domain bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
tumor necrosis factor bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
metal ion bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
metalloendopeptidase activity involved in amyloid precursor protein catabolic processDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
RNA bindingAtaxin-2Homo sapiens (human)
epidermal growth factor receptor bindingAtaxin-2Homo sapiens (human)
protein bindingAtaxin-2Homo sapiens (human)
mRNA bindingAtaxin-2Homo sapiens (human)
cytidine deaminase activitySingle-stranded DNA cytosine deaminaseHomo sapiens (human)
protein bindingSingle-stranded DNA cytosine deaminaseHomo sapiens (human)
zinc ion bindingSingle-stranded DNA cytosine deaminaseHomo sapiens (human)
ubiquitin protein ligase bindingSingle-stranded DNA cytosine deaminaseHomo sapiens (human)
identical protein bindingSingle-stranded DNA cytosine deaminaseHomo sapiens (human)
RNA bindingSingle-stranded DNA cytosine deaminaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (115)

Processvia Protein(s)Taxonomy
nucleusPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
cytosolPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
cytoskeletonPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
plasma membranePolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
adherens junctionPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
focal adhesionPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
membranePolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
extracellular exosomePolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
endoplasmic reticulum membraneProstaglandin G/H synthase 1 Bos taurus (cattle)
nuclear inner membraneProstaglandin G/H synthase 2 Bos taurus (cattle)
nuclear outer membraneProstaglandin G/H synthase 2 Bos taurus (cattle)
endoplasmic reticulum membraneProstaglandin G/H synthase 2 Bos taurus (cattle)
plasma membraneTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
stereocilium bundleTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
plasma membraneRap guanine nucleotide exchange factor 3Homo sapiens (human)
cortical actin cytoskeletonRap guanine nucleotide exchange factor 3Homo sapiens (human)
plasma membraneRap guanine nucleotide exchange factor 3Homo sapiens (human)
microvillusRap guanine nucleotide exchange factor 3Homo sapiens (human)
endomembrane systemRap guanine nucleotide exchange factor 3Homo sapiens (human)
membraneRap guanine nucleotide exchange factor 3Homo sapiens (human)
lamellipodiumRap guanine nucleotide exchange factor 3Homo sapiens (human)
filopodiumRap guanine nucleotide exchange factor 3Homo sapiens (human)
extracellular exosomeRap guanine nucleotide exchange factor 3Homo sapiens (human)
nucleusProto-oncogene c-FosHomo sapiens (human)
nucleoplasmProto-oncogene c-FosHomo sapiens (human)
endoplasmic reticulumProto-oncogene c-FosHomo sapiens (human)
cytosolProto-oncogene c-FosHomo sapiens (human)
transcription factor AP-1 complexProto-oncogene c-FosHomo sapiens (human)
RNA polymerase II transcription regulator complexProto-oncogene c-FosHomo sapiens (human)
chromatinProto-oncogene c-FosHomo sapiens (human)
protein-DNA complexProto-oncogene c-FosHomo sapiens (human)
nucleusProto-oncogene c-FosHomo sapiens (human)
extracellular regionTransthyretinHomo sapiens (human)
extracellular spaceTransthyretinHomo sapiens (human)
azurophil granule lumenTransthyretinHomo sapiens (human)
extracellular exosomeTransthyretinHomo sapiens (human)
extracellular spaceTransthyretinHomo sapiens (human)
nuclear bodyCellular tumor antigen p53Homo sapiens (human)
nucleusCellular tumor antigen p53Homo sapiens (human)
nucleoplasmCellular tumor antigen p53Homo sapiens (human)
replication forkCellular tumor antigen p53Homo sapiens (human)
nucleolusCellular tumor antigen p53Homo sapiens (human)
cytoplasmCellular tumor antigen p53Homo sapiens (human)
mitochondrionCellular tumor antigen p53Homo sapiens (human)
mitochondrial matrixCellular tumor antigen p53Homo sapiens (human)
endoplasmic reticulumCellular tumor antigen p53Homo sapiens (human)
centrosomeCellular tumor antigen p53Homo sapiens (human)
cytosolCellular tumor antigen p53Homo sapiens (human)
nuclear matrixCellular tumor antigen p53Homo sapiens (human)
PML bodyCellular tumor antigen p53Homo sapiens (human)
transcription repressor complexCellular tumor antigen p53Homo sapiens (human)
site of double-strand breakCellular tumor antigen p53Homo sapiens (human)
germ cell nucleusCellular tumor antigen p53Homo sapiens (human)
chromatinCellular tumor antigen p53Homo sapiens (human)
transcription regulator complexCellular tumor antigen p53Homo sapiens (human)
protein-containing complexCellular tumor antigen p53Homo sapiens (human)
nuclear chromosomeTranscription factor AP-1Homo sapiens (human)
nucleusTranscription factor AP-1Homo sapiens (human)
nucleoplasmTranscription factor AP-1Homo sapiens (human)
transcription factor AP-1 complexTranscription factor AP-1Homo sapiens (human)
RNA polymerase II transcription regulator complexTranscription factor AP-1Homo sapiens (human)
chromatinTranscription factor AP-1Homo sapiens (human)
euchromatinTranscription factor AP-1Homo sapiens (human)
transcription regulator complexTranscription factor AP-1Homo sapiens (human)
plasma membraneInsulin-like growth factor 1 receptorHomo sapiens (human)
caveolaInsulin-like growth factor 1 receptorHomo sapiens (human)
membraneInsulin-like growth factor 1 receptorHomo sapiens (human)
T-tubuleInsulin-like growth factor 1 receptorHomo sapiens (human)
neuronal cell bodyInsulin-like growth factor 1 receptorHomo sapiens (human)
intracellular membrane-bounded organelleInsulin-like growth factor 1 receptorHomo sapiens (human)
alphav-beta3 integrin-IGF-1-IGF1R complexInsulin-like growth factor 1 receptorHomo sapiens (human)
receptor complexInsulin-like growth factor 1 receptorHomo sapiens (human)
protein kinase complexInsulin-like growth factor 1 receptorHomo sapiens (human)
axonInsulin-like growth factor 1 receptorHomo sapiens (human)
plasma membraneInsulin-like growth factor 1 receptorHomo sapiens (human)
insulin receptor complexInsulin-like growth factor 1 receptorHomo sapiens (human)
extracellular regionPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
extracellular spacePolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
nuclear envelopePolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
nuclear envelope lumenPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
nucleoplasmPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
cytosolPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
nuclear matrixPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
nuclear membranePolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
secretory granule lumenPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
perinuclear region of cytoplasmPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
ficolin-1-rich granule lumenPolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
nuclear envelopePolyunsaturated fatty acid 5-lipoxygenaseHomo sapiens (human)
double membrane vesicle viral factory outer membraneReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
plasma membraneAndrogen receptorHomo sapiens (human)
nucleusAndrogen receptorHomo sapiens (human)
nucleoplasmAndrogen receptorHomo sapiens (human)
cytoplasmAndrogen receptorHomo sapiens (human)
cytosolAndrogen receptorHomo sapiens (human)
nuclear speckAndrogen receptorHomo sapiens (human)
chromatinAndrogen receptorHomo sapiens (human)
protein-containing complexAndrogen receptorHomo sapiens (human)
nucleusAndrogen receptorHomo sapiens (human)
endoplasmic reticulumAromataseHomo sapiens (human)
endoplasmic reticulum membraneAromataseHomo sapiens (human)
membraneAromataseHomo sapiens (human)
endoplasmic reticulumAromataseHomo sapiens (human)
cytoplasm17-beta-hydroxysteroid dehydrogenase type 1Homo sapiens (human)
cytosol17-beta-hydroxysteroid dehydrogenase type 1Homo sapiens (human)
cytosol17-beta-hydroxysteroid dehydrogenase type 1Homo sapiens (human)
lipid dropletPolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
cytosolPolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
plasma membranePolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
cytoplasmic side of plasma membranePolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
membranePolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
plasma membranePolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
cytosolPolyunsaturated fatty acid lipoxygenase ALOX15Homo sapiens (human)
cytoplasmPolyunsaturated fatty acid lipoxygenase ALOX12Homo sapiens (human)
cytosolPolyunsaturated fatty acid lipoxygenase ALOX12Homo sapiens (human)
membranePolyunsaturated fatty acid lipoxygenase ALOX12Homo sapiens (human)
sarcolemmaPolyunsaturated fatty acid lipoxygenase ALOX12Homo sapiens (human)
extracellular exosomePolyunsaturated fatty acid lipoxygenase ALOX12Homo sapiens (human)
cytosolPolyunsaturated fatty acid lipoxygenase ALOX12Homo sapiens (human)
sarcolemmaPolyunsaturated fatty acid lipoxygenase ALOX12Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)
plasma membraneSodium-dependent noradrenaline transporter Homo sapiens (human)
cell surfaceSodium-dependent noradrenaline transporter Homo sapiens (human)
membraneSodium-dependent noradrenaline transporter Homo sapiens (human)
neuronal cell body membraneSodium-dependent noradrenaline transporter Homo sapiens (human)
presynaptic membraneSodium-dependent noradrenaline transporter Homo sapiens (human)
plasma membraneSodium-dependent noradrenaline transporter Homo sapiens (human)
axonSodium-dependent noradrenaline transporter Homo sapiens (human)
cytoplasmCaspase-1Homo sapiens (human)
cytosolCaspase-1Homo sapiens (human)
nucleolusCaspase-1Homo sapiens (human)
cytoplasmCaspase-1Homo sapiens (human)
cytosolCaspase-1Homo sapiens (human)
microtubuleCaspase-1Homo sapiens (human)
plasma membraneCaspase-1Homo sapiens (human)
canonical inflammasome complexCaspase-1Homo sapiens (human)
NLRP1 inflammasome complexCaspase-1Homo sapiens (human)
NLRP3 inflammasome complexCaspase-1Homo sapiens (human)
AIM2 inflammasome complexCaspase-1Homo sapiens (human)
protein-containing complexCaspase-1Homo sapiens (human)
IPAF inflammasome complexCaspase-1Homo sapiens (human)
protease inhibitor complexCaspase-1Homo sapiens (human)
nuclear inner membraneProstaglandin G/H synthase 2Homo sapiens (human)
nuclear outer membraneProstaglandin G/H synthase 2Homo sapiens (human)
cytoplasmProstaglandin G/H synthase 2Homo sapiens (human)
endoplasmic reticulumProstaglandin G/H synthase 2Homo sapiens (human)
endoplasmic reticulum lumenProstaglandin G/H synthase 2Homo sapiens (human)
endoplasmic reticulum membraneProstaglandin G/H synthase 2Homo sapiens (human)
caveolaProstaglandin G/H synthase 2Homo sapiens (human)
neuron projectionProstaglandin G/H synthase 2Homo sapiens (human)
protein-containing complexProstaglandin G/H synthase 2Homo sapiens (human)
neuron projectionProstaglandin G/H synthase 2Homo sapiens (human)
cytoplasmProstaglandin G/H synthase 2Homo sapiens (human)
endoplasmic reticulum membrane17-beta-hydroxysteroid dehydrogenase type 2Homo sapiens (human)
intracellular membrane-bounded organelle17-beta-hydroxysteroid dehydrogenase type 2Homo sapiens (human)
platelet alpha granule membraneAlpha-synucleinHomo sapiens (human)
extracellular regionAlpha-synucleinHomo sapiens (human)
extracellular spaceAlpha-synucleinHomo sapiens (human)
nucleusAlpha-synucleinHomo sapiens (human)
cytoplasmAlpha-synucleinHomo sapiens (human)
mitochondrionAlpha-synucleinHomo sapiens (human)
lysosomeAlpha-synucleinHomo sapiens (human)
cytosolAlpha-synucleinHomo sapiens (human)
plasma membraneAlpha-synucleinHomo sapiens (human)
cell cortexAlpha-synucleinHomo sapiens (human)
actin cytoskeletonAlpha-synucleinHomo sapiens (human)
membraneAlpha-synucleinHomo sapiens (human)
inclusion bodyAlpha-synucleinHomo sapiens (human)
axonAlpha-synucleinHomo sapiens (human)
growth coneAlpha-synucleinHomo sapiens (human)
synaptic vesicle membraneAlpha-synucleinHomo sapiens (human)
perinuclear region of cytoplasmAlpha-synucleinHomo sapiens (human)
postsynapseAlpha-synucleinHomo sapiens (human)
supramolecular fiberAlpha-synucleinHomo sapiens (human)
protein-containing complexAlpha-synucleinHomo sapiens (human)
cytoplasmAlpha-synucleinHomo sapiens (human)
axon terminusAlpha-synucleinHomo sapiens (human)
neuronal cell bodyAlpha-synucleinHomo sapiens (human)
virion membraneSpike glycoproteinSevere acute respiratory syndrome-related coronavirus
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)
plasma membraneGuanine nucleotide-binding protein GHomo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)
intracellular non-membrane-bounded organelleTAR DNA-binding protein 43Homo sapiens (human)
nucleusTAR DNA-binding protein 43Homo sapiens (human)
nucleoplasmTAR DNA-binding protein 43Homo sapiens (human)
perichromatin fibrilsTAR DNA-binding protein 43Homo sapiens (human)
mitochondrionTAR DNA-binding protein 43Homo sapiens (human)
cytoplasmic stress granuleTAR DNA-binding protein 43Homo sapiens (human)
nuclear speckTAR DNA-binding protein 43Homo sapiens (human)
interchromatin granuleTAR DNA-binding protein 43Homo sapiens (human)
nucleoplasmTAR DNA-binding protein 43Homo sapiens (human)
chromatinTAR DNA-binding protein 43Homo sapiens (human)
plasma membraneLeukotriene B4 receptor 1Homo sapiens (human)
plasma membraneLeukotriene B4 receptor 1Homo sapiens (human)
nucleusPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
cytosolPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
cytoskeletonPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
plasma membranePolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
adherens junctionPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
focal adhesionPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
membranePolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
extracellular exosomePolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
glutamatergic synapseIntegrin beta-3Homo sapiens (human)
nucleusIntegrin beta-3Homo sapiens (human)
nucleoplasmIntegrin beta-3Homo sapiens (human)
plasma membraneIntegrin beta-3Homo sapiens (human)
cell-cell junctionIntegrin beta-3Homo sapiens (human)
focal adhesionIntegrin beta-3Homo sapiens (human)
external side of plasma membraneIntegrin beta-3Homo sapiens (human)
cell surfaceIntegrin beta-3Homo sapiens (human)
apical plasma membraneIntegrin beta-3Homo sapiens (human)
platelet alpha granule membraneIntegrin beta-3Homo sapiens (human)
lamellipodium membraneIntegrin beta-3Homo sapiens (human)
filopodium membraneIntegrin beta-3Homo sapiens (human)
microvillus membraneIntegrin beta-3Homo sapiens (human)
ruffle membraneIntegrin beta-3Homo sapiens (human)
integrin alphav-beta3 complexIntegrin beta-3Homo sapiens (human)
melanosomeIntegrin beta-3Homo sapiens (human)
synapseIntegrin beta-3Homo sapiens (human)
postsynaptic membraneIntegrin beta-3Homo sapiens (human)
extracellular exosomeIntegrin beta-3Homo sapiens (human)
integrin alphaIIb-beta3 complexIntegrin beta-3Homo sapiens (human)
glycinergic synapseIntegrin beta-3Homo sapiens (human)
integrin complexIntegrin beta-3Homo sapiens (human)
protein-containing complexIntegrin beta-3Homo sapiens (human)
alphav-beta3 integrin-PKCalpha complexIntegrin beta-3Homo sapiens (human)
alphav-beta3 integrin-IGF-1-IGF1R complexIntegrin beta-3Homo sapiens (human)
alphav-beta3 integrin-HMGB1 complexIntegrin beta-3Homo sapiens (human)
receptor complexIntegrin beta-3Homo sapiens (human)
alphav-beta3 integrin-vitronectin complexIntegrin beta-3Homo sapiens (human)
alpha9-beta1 integrin-ADAM8 complexIntegrin beta-3Homo sapiens (human)
focal adhesionIntegrin beta-3Homo sapiens (human)
cell surfaceIntegrin beta-3Homo sapiens (human)
synapseIntegrin beta-3Homo sapiens (human)
plasma membraneIntegrin alpha-IIbHomo sapiens (human)
focal adhesionIntegrin alpha-IIbHomo sapiens (human)
cell surfaceIntegrin alpha-IIbHomo sapiens (human)
platelet alpha granule membraneIntegrin alpha-IIbHomo sapiens (human)
extracellular exosomeIntegrin alpha-IIbHomo sapiens (human)
integrin alphaIIb-beta3 complexIntegrin alpha-IIbHomo sapiens (human)
blood microparticleIntegrin alpha-IIbHomo sapiens (human)
integrin complexIntegrin alpha-IIbHomo sapiens (human)
external side of plasma membraneIntegrin alpha-IIbHomo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)
nuclear inner membraneProstaglandin G/H synthase 2Homo sapiens (human)
nuclear outer membraneProstaglandin G/H synthase 2Homo sapiens (human)
cytoplasmProstaglandin G/H synthase 2Homo sapiens (human)
endoplasmic reticulumProstaglandin G/H synthase 2Homo sapiens (human)
endoplasmic reticulum lumenProstaglandin G/H synthase 2Homo sapiens (human)
endoplasmic reticulum membraneProstaglandin G/H synthase 2Homo sapiens (human)
caveolaProstaglandin G/H synthase 2Homo sapiens (human)
neuron projectionProstaglandin G/H synthase 2Homo sapiens (human)
protein-containing complexProstaglandin G/H synthase 2Homo sapiens (human)
neuron projectionProstaglandin G/H synthase 2Homo sapiens (human)
cytoplasmProstaglandin G/H synthase 2Homo sapiens (human)
platelet alpha granule membraneAlpha-synucleinHomo sapiens (human)
extracellular regionAlpha-synucleinHomo sapiens (human)
extracellular spaceAlpha-synucleinHomo sapiens (human)
nucleusAlpha-synucleinHomo sapiens (human)
cytoplasmAlpha-synucleinHomo sapiens (human)
mitochondrionAlpha-synucleinHomo sapiens (human)
lysosomeAlpha-synucleinHomo sapiens (human)
cytosolAlpha-synucleinHomo sapiens (human)
plasma membraneAlpha-synucleinHomo sapiens (human)
cell cortexAlpha-synucleinHomo sapiens (human)
actin cytoskeletonAlpha-synucleinHomo sapiens (human)
membraneAlpha-synucleinHomo sapiens (human)
inclusion bodyAlpha-synucleinHomo sapiens (human)
axonAlpha-synucleinHomo sapiens (human)
growth coneAlpha-synucleinHomo sapiens (human)
synaptic vesicle membraneAlpha-synucleinHomo sapiens (human)
perinuclear region of cytoplasmAlpha-synucleinHomo sapiens (human)
postsynapseAlpha-synucleinHomo sapiens (human)
supramolecular fiberAlpha-synucleinHomo sapiens (human)
protein-containing complexAlpha-synucleinHomo sapiens (human)
cytoplasmAlpha-synucleinHomo sapiens (human)
axon terminusAlpha-synucleinHomo sapiens (human)
neuronal cell bodyAlpha-synucleinHomo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)
cell-cell junctionDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
focal adhesionDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
ruffle membraneDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
Golgi membraneDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
cytoplasmDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
endoplasmic reticulum lumenDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
cytosolDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
plasma membraneDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
cell surfaceDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
actin cytoskeletonDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
membraneDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
apical plasma membraneDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
membrane raftDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
plasma membraneDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
cytoplasmAtaxin-2Homo sapiens (human)
Golgi apparatusAtaxin-2Homo sapiens (human)
trans-Golgi networkAtaxin-2Homo sapiens (human)
cytosolAtaxin-2Homo sapiens (human)
cytoplasmic stress granuleAtaxin-2Homo sapiens (human)
membraneAtaxin-2Homo sapiens (human)
perinuclear region of cytoplasmAtaxin-2Homo sapiens (human)
ribonucleoprotein complexAtaxin-2Homo sapiens (human)
cytoplasmic stress granuleAtaxin-2Homo sapiens (human)
nucleusSingle-stranded DNA cytosine deaminaseHomo sapiens (human)
cytoplasmSingle-stranded DNA cytosine deaminaseHomo sapiens (human)
cytosolSingle-stranded DNA cytosine deaminaseHomo sapiens (human)
protein-containing complexSingle-stranded DNA cytosine deaminaseHomo sapiens (human)
nucleusSingle-stranded DNA cytosine deaminaseHomo sapiens (human)
cytoplasmSingle-stranded DNA cytosine deaminaseHomo sapiens (human)
P-bodySingle-stranded DNA cytosine deaminaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (463)

Assay IDTitleYearJournalArticle
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID548961Antioxidant activity of the compound assessed as reducing activity of DPPH at 0.1 mM after 60 mins2010Bioorganic & medicinal chemistry, Dec-01, Volume: 18, Issue:23
Does conjugation of antioxidants improve their antioxidative/anti-inflammatory potential?
AID1256769Inhibition of soybean lipoxygenase assessed as reduction in conversion of sodium linoleate to 13-hydroperoxylinoleic acid up to 7 mins2015Bioorganic & medicinal chemistry letters, Nov-15, Volume: 25, Issue:22
Esters of some non-steroidal anti-inflammatory drugs with cinnamyl alcohol are potent lipoxygenase inhibitors with enhanced anti-inflammatory activity.
AID548956Inhibition of soybean lipoxygenase2010Bioorganic & medicinal chemistry, Dec-01, Volume: 18, Issue:23
Does conjugation of antioxidants improve their antioxidative/anti-inflammatory potential?
AID286755Antioxidant activity assessed as DPPH reducing activity at 0.5 mM after 20 mins2007Journal of medicinal chemistry, May-17, Volume: 50, Issue:10
Design and synthesis of novel quinolinone-3-aminoamides and their alpha-lipoic acid adducts as antioxidant and anti-inflammatory agents.
AID1549771Agonist activity at human TRPA1 expressed in HEK293 cells assessed as increase in calcium influx by Fluo-4-AM dye based fluorescence assay2019European journal of medicinal chemistry, May-15, Volume: 170N-Cinnamoylanthranilates as human TRPA1 modulators: Structure-activity relationships and channel binding sites.
AID256507Superoxide radical scavenging activity at 1 mM upon incubation for 2 min at RT in pH 7.4 with PMS, NADH and NBT by nitroblue tetrazolium method; no action2005Journal of medicinal chemistry, Oct-06, Volume: 48, Issue:20
Synthesis and antiinflammatory activity of coumarin derivatives.
AID6790Ability to inhibit 5-lipoxygenase by using a crude preparation of the cytosolic enzyme from the rat basophilic leukemia (RBL-1) cell line1990Journal of medicinal chemistry, Jan, Volume: 33, Issue:1
2-substituted-1-naphthols as potent 5-lipoxygenase inhibitors with topical antiinflammatory activity.
AID609923Antioxidant activity assessed as DPPH radical scavenging activity at 10 uM after 60 mins2011Bioorganic & medicinal chemistry letters, Aug-15, Volume: 21, Issue:16
Thrombin inhibitors with lipid peroxidation and lipoxygenase inhibitory activities.
AID754976Inhibition of N-terminal His6-tagged human platelet 12-LOX pseudoperoxidase activity assessed as reduction of active ferric ion to inactive ferrous state measured decomposition of 13-(S)-HPODE at 40 uM after 30 mins by iron-xylenol orange staining assay2013Bioorganic & medicinal chemistry, Jul-01, Volume: 21, Issue:13
Pseudoperoxidase investigations of hydroperoxides and inhibitors with human lipoxygenases.
AID588219FDA HLAED, gamma-glutamyl transferase (GGT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1169291Inhibition of TTR V30M mutant (unknown origin) expressed in Escherichia coli assessed as inhibition of amyloid fibril formation by fluorescence assay2014Journal of medicinal chemistry, Nov-13, Volume: 57, Issue:21
Inhibitory activities of propolis and its promising component, caffeic acid phenethyl ester, against amyloidogenesis of human transthyretin.
AID1083337Antiviral activity against Vesicular stomatitis virus infected HEL cells assessed as inhibition of virus-induced cytopathicity2011Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents, , Volume: 20, Issue:2
The novel amidocarbamate derivatives of ketoprofen: synthesis and biological activity.
AID761462Inhibition of potato 5-LOX using linoleic acid as substrate assessed as hydroperoxides production after 5 mins by enzyme immuno assay2013European journal of medicinal chemistry, Aug, Volume: 66Syntheses and evaluation of novel isoliquiritigenin derivatives as potential dual inhibitors for amyloid-beta aggregation and 5-lipoxygenase.
AID1083348Antioxidant activity assessed as inhibition of AAPH-induced lipid peroxidation at 1 X 10'-5 M2011Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents, , Volume: 20, Issue:2
The novel amidocarbamate derivatives of ketoprofen: synthesis and biological activity.
AID633579Transcriptional activity at human androgen receptor BF3 site stably transfected in eGFP-expressing human LNCAP cells after 5 days by fluorometric analysis2011Journal of medicinal chemistry, Dec-22, Volume: 54, Issue:24
Targeting the binding function 3 (BF3) site of the human androgen receptor through virtual screening.
AID354434Ratio of IC50 for human 12-lipoxygenase to IC50 for human 15-lipoxygenase2003Journal of natural products, Feb, Volume: 66, Issue:2
Exploring sponge-derived terpenoids for their potency and selectivity against 12-human, 15-human, and 15-soybean lipoxygenases.
AID479369Inhibition of human placental microsome CYP192010Bioorganic & medicinal chemistry letters, May-15, Volume: 20, Issue:10
Pharmacophore modeling strategies for the development of novel nonsteroidal inhibitors of human aromatase (CYP19).
AID1426088Antiproliferative activity against human BGC823 cells after 72 hrs by MTT assay2017European journal of medicinal chemistry, Feb-15, Volume: 127Synthesis, biological evaluation, QSAR and molecular dynamics simulation studies of potential fibroblast growth factor receptor 1 inhibitors for the treatment of gastric cancer.
AID1163380Antioxidant activity assessed as DPPH scavenging activity at 100 uM after 20 mins by spectrophotometry2014European journal of medicinal chemistry, Oct-30, Volume: 86Novel semicarbazides and ureas of primaquine with bulky aryl or hydroxyalkyl substituents: synthesis, cytostatic and antioxidative activity.
AID161166Inhibition of Prostaglandin G/H synthase activity in sheep seminal vesicle was determined1993Journal of medicinal chemistry, Nov-26, Volume: 36, Issue:24
3,4-Dihydroxychalcones as potent 5-lipoxygenase and cyclooxygenase inhibitors.
AID633581Binding affinity to human androgen receptor ligand binding domain expressed in Escherichia coli BL21 cells by surface plasmon resonance analysis2011Journal of medicinal chemistry, Dec-22, Volume: 54, Issue:24
Targeting the binding function 3 (BF3) site of the human androgen receptor through virtual screening.
AID426427In vivo antiinflammatory activity in Fisher 344 rat assessed as inhibition of carrageenan-induced paw edema at 0.01 mmol/kg, ip administered simultaneously with carrageenan measured after 3.5 hrs2009European journal of medicinal chemistry, Jul, Volume: 44, Issue:7
Synthesis and evaluation of the antioxidant and anti-inflammatory activity of novel coumarin-3-aminoamides and their alpha-lipoic acid adducts.
AID724358Antioxidant activity assessed as DPPH radical scavenging activity at 100 uM after 20 mins by spectrophotometric analysis2013European journal of medicinal chemistry, Feb, Volume: 60Syntheses and evaluation of the antioxidant activity of novel methoxypsoralen derivatives.
AID588217FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID588218FDA HLAED, lactate dehydrogenase (LDH) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID3068Inhibitory activity against soybean 1-lipoxygenase (SLO)2002Journal of medicinal chemistry, Jun-06, Volume: 45, Issue:12
Structure-activity relationship studies of nordihydroguaiaretic acid inhibitors toward soybean, 12-human, and 15-human lipoxygenase.
AID322956Inhibition of synthetic amyloid beta42 oligomer formation by Western blot2007The Journal of biological chemistry, Apr-06, Volume: 282, Issue:14
Small molecule inhibitors of aggregation indicate that amyloid beta oligomerization and fibrillization pathways are independent and distinct.
AID354435Ratio of IC50 for human 12-lipoxygenase to IC50 for soybean 15-lipoxygenase2003Journal of natural products, Feb, Volume: 66, Issue:2
Exploring sponge-derived terpenoids for their potency and selectivity against 12-human, 15-human, and 15-soybean lipoxygenases.
AID426431Antioxidant activity assessed as reduction of DPPH activity at 0.1 mM after 60 mins2009European journal of medicinal chemistry, Jul, Volume: 44, Issue:7
Synthesis and evaluation of the antioxidant and anti-inflammatory activity of novel coumarin-3-aminoamides and their alpha-lipoic acid adducts.
AID630143Inhibition of 5-LOX in calcium ionophore A23187-stimulated NMRI mouse macrophage assessed as inhibition of LTC4 production preincubated for 60 mins before stimulation measured after 2 hrs by ELISA2011Bioorganic & medicinal chemistry, Nov-01, Volume: 19, Issue:21
Bioassay-guided identification of an anti-inflammatory prenylated acylphloroglucinol from Melicope ptelefolia and molecular insights into its interaction with 5-lipoxygenase.
AID256503Percent heme protein dependent lipid peroxidation at (0.1 mM) upon incubation for 10 min at 37 degree C. in pH 7.4 with arachidonic acid and H2O22005Journal of medicinal chemistry, Oct-06, Volume: 48, Issue:20
Synthesis and antiinflammatory activity of coumarin derivatives.
AID1549817Agonist activity at human TRPA1 Phe944Ala mutant expressed in HEK293 cells assessed as Ca2+ influx at 30 uM by fluorescence assay2019European journal of medicinal chemistry, May-15, Volume: 170N-Cinnamoylanthranilates as human TRPA1 modulators: Structure-activity relationships and channel binding sites.
AID380424Cytotoxicity against human HL60 cells by XTT assay2006Journal of natural products, Mar, Volume: 69, Issue:3
Schisandrene, a dibenzocyclooctadiene lignan from Schisandra chinensis: structure-antioxidant activity relationships of dibenzocyclooctadiene lignans.
AID597261Antioxidant activity assessed as DPPH free radical scavenging activity after 20 to 60 mins by spectrophotometry2011Bioorganic & medicinal chemistry, May-01, Volume: 19, Issue:9
Synthesis, in silico docking experiments of new 2-pyrrolidinone derivatives and study of their anti-inflammatory activity.
AID1406151Antioxidant activity assessed as trolox equivalent of AAPH-induced radical scavenging activity pretreated for 15 mins followed by APPH challenge measured every minute for 80 mins by ORAC-FL assay2018European journal of medicinal chemistry, Aug-05, Volume: 156Neurogenic and neuroprotective donepezil-flavonoid hybrids with sigma-1 affinity and inhibition of key enzymes in Alzheimer's disease.
AID597262Inhibition of soybean LOX assessed as inhibition of sodium linoleate to 13-hydroperoxylinoleic acid conversion at 0.1 mM by UV-visible spectrophotometry2011Bioorganic & medicinal chemistry, May-01, Volume: 19, Issue:9
Synthesis, in silico docking experiments of new 2-pyrrolidinone derivatives and study of their anti-inflammatory activity.
AID1257019Antioxidant activity assessed as DPPH free radical scavenging activity by measuring reducing activity at 100 uM after 20 mins by spectrophotometry2015Bioorganic & medicinal chemistry, Nov-15, Volume: 23, Issue:22
Synthesis and biological evaluation of new C-10 substituted dithranol pleiotropic hybrids.
AID1624746Inhibition of soybean lipoxygenase using sodium linoleate as substrate by UV-based analysis2019Journal of medicinal chemistry, 02-28, Volume: 62, Issue:4
New Quinolylnitrones for Stroke Therapy: Antioxidant and Neuroprotective ( Z)- N- tert-Butyl-1-(2-chloro-6-methoxyquinolin-3-yl)methanimine Oxide as a New Lead-Compound for Ischemic Stroke Treatment.
AID1083347Antioxidant activity assessed as inhibition of AAPH-induced lipid peroxidation at 1 X 10'-4 M2011Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents, , Volume: 20, Issue:2
The novel amidocarbamate derivatives of ketoprofen: synthesis and biological activity.
AID355095Antiinflammatory activity in NMRI mouse macrophages assessed as inhibition of A23187-induced LTC4 release at 100 uM by Ellman's method relative to control1996Journal of natural products, Dec, Volume: 59, Issue:12
Antiinflammatory activity of coumarins from Santolina oblongifolia.
AID354431Inhibition of soybean 15-lipoxygenase2003Journal of natural products, Feb, Volume: 66, Issue:2
Exploring sponge-derived terpenoids for their potency and selectivity against 12-human, 15-human, and 15-soybean lipoxygenases.
AID1617777Inhibition of human recombinant N-terminal His-tagged 15-LOX2 expressed in Escherichia coli assessed as residual activity at 42 uM using arachidonic acid as substrate preincubated for 5 mins followed by substrate addition measured after 20 mins in dark by2019Journal of natural products, 12-27, Volume: 82, Issue:12
Structure-Activity Relationships of Pentacyclic Triterpenoids as Inhibitors of Cyclooxygenase and Lipoxygenase Enzymes.
AID1083350Antioxidant activity assessed as DPPH radical scavenging activity at 1 X 10'-4 M after 60 min2011Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents, , Volume: 20, Issue:2
The novel amidocarbamate derivatives of ketoprofen: synthesis and biological activity.
AID402473Inhibition of recombinant human TNF-alpha-induced cytotoxicity of mouse L929 cells assessed as survivality preincubated for 15 mins before TNFalpha addition measured after 24 hrs by crystal violet staining1997Journal of natural products, Aug, Volume: 60, Issue:8
Flavonoids as inhibitors or enhancers of the cytotoxicity of tumor necrosis factor-alpha in L-929 tumor cells.
AID625356Inhibition of soybean lipoxygenase assessed as conversion of sodium linoleate to 13-hydroperoxylinoleic acid at 100 uM2011European journal of medicinal chemistry, Dec, Volume: 46, Issue:12
Synthesis and biological evaluation of (2,5-dihydro-1H-pyrrol-1-yl)-2H-chromen-2-ones as free radical scavengers.
AID379835Prooxidant activity assessed as hydroxyl radical formation at 75 uM measured as malondialdehyde per mmol of deoxyribose by deoxyribose assay1999Journal of natural products, Jun, Volume: 62, Issue:6
Lichen metabolites. 1. Inhibitory action against leukotriene B4 biosynthesis by a non-redox mechanism.
AID308043Inhibition of IGF1 mediated cell growth in MCF7 cells2007Bioorganic & medicinal chemistry letters, Jul-15, Volume: 17, Issue:14
Inhibition of IGF-1R and lipoxygenase by nordihydroguaiaretic acid (NDGA) analogs.
AID1071747Inhibition of soybean lipoxygenase assessed as conversion of sodium linoleate to 13-hydroperoxylinoleic acid at 100 uM by UV absorbance assay2014European journal of medicinal chemistry, Mar-03, Volume: 74Toxicological and pharmacological evaluation, antioxidant, ADMET and molecular modeling of selected racemic chromenotacrines {11-amino-12-aryl-8,9,10,12-tetrahydro-7H-chromeno[2,3-b]quinolin-3-ols} for the potential prevention and treatment of Alzheimer's
AID588216FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID6882Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL).1993Journal of medicinal chemistry, Dec-10, Volume: 36, Issue:25
Antipsoriatic anthrones with modulated redox properties. 1. Novel 10-substituted 1,8-dihydroxy-9(10H)-anthracenones as inhibitors of 5-lipoxygenase.
AID179759In vitro inhibition of PGE-2 production was measured in rat blood1991Journal of medicinal chemistry, Mar, Volume: 34, Issue:3
Indazolinones, a new series of redox-active 5-lipoxygenase inhibitors with built-in selectivity and oral activity.
AID641626Inhibition of Mycobacterium tuberculosis RmlD assessed as inhibition of dTDP-beta-6-deoxy-L-lyxo-4-hexulose to dTDP-beta-L-rhamnose conversion at 10 ug/ml2011Bioorganic & medicinal chemistry letters, Dec-01, Volume: 21, Issue:23
Novel inhibitors of Mycobacterium tuberculosis dTDP-6-deoxy-L-lyxo-4-hexulose reductase (RmlD) identified by virtual screening.
AID442506Antioxidant activity assessed as DPPH radical scavenging activity at 100 uM after 20 mins by spectrophotometry2010European journal of medicinal chemistry, Jan, Volume: 45, Issue:1
Syntheses and evaluation of the antioxidant activity of acitretin analogs with amide bond(s) in the polyene spacer.
AID609917Antioxidant activity assessed as DPPH radical scavenging activity at 50 uM after 20 mins2011Bioorganic & medicinal chemistry letters, Aug-15, Volume: 21, Issue:16
Thrombin inhibitors with lipid peroxidation and lipoxygenase inhibitory activities.
AID485950Inhibition of human reticulocyte N-terminal His6-tagged 15-lipoxygenase by UV-vis spectrometry2009Journal of natural products, Oct, Volume: 72, Issue:10
Using enzyme assays to evaluate the structure and bioactivity of sponge-derived meroterpenes.
AID3638The compound was tested for inhibitory activity against 5-Lipoxygenase in rat blood1992Journal of medicinal chemistry, Jul-10, Volume: 35, Issue:14
5-lipoxygenase: properties, pharmacology, and the quinolinyl(bridged)aryl class of inhibitors.
AID549590Antiinflammatory activity in CD1 mouse assessed as inhibition of croton oil-induced ear edema per cm'2 administered topically2011Bioorganic & medicinal chemistry letters, Jan-15, Volume: 21, Issue:2
Topical anti-inflammatory activity of boropinic acid and its natural and semi-synthetic derivatives.
AID347223Inhibition of 5LOX in bovine polymorphonuclear leucocytes assessed as leukotriene B4 formation2009Bioorganic & medicinal chemistry, Jan-15, Volume: 17, Issue:2
Diaryl-dithiolanes and -isothiazoles: COX-1/COX-2 and 5-LOX-inhibitory, *OH scavenging and anti-adhesive activities.
AID6825In vitro inhibition of RBL-1 5-lipoxygenase1987Journal of medicinal chemistry, Dec, Volume: 30, Issue:12
Novel 1H-benzimidazol-4-ols with potent 5-lipoxygenase inhibitory activity.
AID6820In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined1993Journal of medicinal chemistry, Nov-26, Volume: 36, Issue:24
3,4-Dihydroxychalcones as potent 5-lipoxygenase and cyclooxygenase inhibitors.
AID452855Inhibition of soybean 5-lipoxygenase by UV-absorbance based enzyme assay2009Bioorganic & medicinal chemistry, Dec-01, Volume: 17, Issue:23
Natural and synthetic 2'-hydroxy-chalcones and aurones: synthesis, characterization and evaluation of the antioxidant and soybean lipoxygenase inhibitory activity.
AID630141Inhibition of soybean 15-LOX type 1-B assessed as inhibition of conversion of linoleic acid to (9Z,11E)-(13S)-13-hydroperoxyoctadeca-9,11-dienoate preincubated for 10 mins before substrate addition measured after 6 mins by spectrophotometry2011Bioorganic & medicinal chemistry, Nov-01, Volume: 19, Issue:21
Bioassay-guided identification of an anti-inflammatory prenylated acylphloroglucinol from Melicope ptelefolia and molecular insights into its interaction with 5-lipoxygenase.
AID286751Inhibition of soybean lipoxygenase at 0.1 mM2007Journal of medicinal chemistry, May-17, Volume: 50, Issue:10
Design and synthesis of novel quinolinone-3-aminoamides and their alpha-lipoic acid adducts as antioxidant and anti-inflammatory agents.
AID723699Inhibition of soybean lipoxygenase assessed as inhibition of sodium linolate conversion to 13-hydroperoxylinoleic acid after 4 mins by spectrophotometry2013Bioorganic & medicinal chemistry, Jan-15, Volume: 21, Issue:2
Synthesis and biological evaluation of some 5-arylidene-2-(1,3-thiazol-2-ylimino)-1,3-thiazolidin-4-ones as dual anti-inflammatory/antimicrobial agents.
AID309801Inhibition of 15-hLO22007Bioorganic & medicinal chemistry, Dec-01, Volume: 15, Issue:23
Structure-activity relationship studies of flavonoids as potent inhibitors of human platelet 12-hLO, reticulocyte 15-hLO-1, and prostate epithelial 15-hLO-2.
AID485949Inhibition of human platelet N-terminal His6-tagged 12-lipoxygenase by UV-vis spectrometry2009Journal of natural products, Oct, Volume: 72, Issue:10
Using enzyme assays to evaluate the structure and bioactivity of sponge-derived meroterpenes.
AID471735Antioxidant activity assessed as DPPH free radical scavenging activity at 0.05 mM after 60 mins2009Bioorganic & medicinal chemistry letters, Nov-15, Volume: 19, Issue:22
Synthesis of modified homo-N-nucleosides from the reactions of mesityl nitrile oxide with 9-allylpurines and their influence on lipid peroxidation and thrombin inhibition.
AID471736Antioxidant activity assessed as DPPH free radical scavenging activity at 0.1 mM after 20 mins2009Bioorganic & medicinal chemistry letters, Nov-15, Volume: 19, Issue:22
Synthesis of modified homo-N-nucleosides from the reactions of mesityl nitrile oxide with 9-allylpurines and their influence on lipid peroxidation and thrombin inhibition.
AID256361Percent inhibition of carrageenan 2% (0.1 mL intradermal) induced paw edema at the i.p. dose of 0.01 m mol/kg in fisher 344 rats; n=5; not tested2005Journal of medicinal chemistry, Oct-06, Volume: 48, Issue:20
Synthesis and antiinflammatory activity of coumarin derivatives.
AID303034Antioxidant activity assessed as DPPH radical scavenging activity at 0.1 mM after 20 mins2007Bioorganic & medicinal chemistry letters, Dec-01, Volume: 17, Issue:23
Synthesis and anti-inflammatory/antioxidant activities of some new ring substituted 3-phenyl-1-(1,4-di-N-oxide quinoxalin-2-yl)-2-propen-1-one derivatives and of their 4,5-dihydro-(1H)-pyrazole analogues.
AID519608Selectivity index, ratio of TC50 for hepatocytes to IC50 for Plasmodium yoelii 2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
New active drugs against liver stages of Plasmodium predicted by molecular topology.
AID516450Inhibition of potato 5-lipoxygenase by enzyme immunoassay2010Bioorganic & medicinal chemistry letters, Oct-01, Volume: 20, Issue:19
Synthesis and biological evaluation of indomethacin analogs possessing a N-difluoromethyl-1,2-dihydropyrid-2-one ring system: a search for novel cyclooxygenase and lipoxygenase inhibitors.
AID456268Antiallergic activity in Ca(2+)-stimulated differentiated human HeLa cells assessed as inhibition of cys-leukotriene release after 6 days by ELISA2010Bioorganic & medicinal chemistry, Jan-01, Volume: 18, Issue:1
Inhibitory activity of Brazilian green propolis components and their derivatives on the release of cys-leukotrienes.
AID566096Inhibition of soybean LOX at 0.01 mM2011European journal of medicinal chemistry, Jan, Volume: 46, Issue:1
One-pot microwave assisted synthesis under green chemistry conditions, antioxidant screening, and cytotoxicity assessments of benzimidazole Schiff bases and pyrimido[1,2-a]benzimidazol-3(4H)-ones.
AID653291Antioxidant activity assessed as DPPH free radical scavenging activity at 100 uM after 20 mins by spectrophotometric analysis2012European journal of medicinal chemistry, May, Volume: 51Novel NSAID 1-acyl-4-cycloalkyl/arylsemicarbazides and 1-acyl-5-benzyloxy/hydroxy carbamoylcarbazides as potential anticancer agents and antioxidants.
AID717165Antioxidant activity of compound assessed as DPPH radical scavenging activity by colorimetric method2012Bioorganic & medicinal chemistry, Dec-15, Volume: 20, Issue:24
Synthesis and SAR study of 4,5-diaryl-1H-imidazole-2(3H)-thione derivatives, as potent 15-lipoxygenase inhibitors.
AID345786Inhibition of COX22008Bioorganic & medicinal chemistry, Dec-15, Volume: 16, Issue:24
Characterization of novel furan compounds on the basis of their radical scavenging activity and cytoprotective effects against glutamate- and lipopolysaccharide-induced insults.
AID363803Inhibition of human COX2 at 10 uM2008European journal of medicinal chemistry, Jun, Volume: 43, Issue:6
Investigations concerning the COX/5-LOX inhibiting and hydroxyl radical scavenging potencies of novel 4,5-diaryl isoselenazoles.
AID1169297Inhibition of TTR L55P mutant (unknown origin) expressed in Escherichia coli assessed as inhibition of amyloid fibril formation by fluorescence assay2014Journal of medicinal chemistry, Nov-13, Volume: 57, Issue:21
Inhibitory activities of propolis and its promising component, caffeic acid phenethyl ester, against amyloidogenesis of human transthyretin.
AID261407Inhibitory activity against soybean 15LOX2006Journal of medicinal chemistry, Mar-09, Volume: 49, Issue:5
Synthesis and structure-activity relationship studies of 1,3-diarylprop-2-yn-1-ones: dual inhibitors of cyclooxygenases and lipoxygenases.
AID1071732Inhibition of soybean lipoxygenase2014Bioorganic & medicinal chemistry letters, Mar-01, Volume: 24, Issue:5
Lipoxygenase inhibitors derived from marine macroalgae.
AID489921Antioxidant activity assessed as DPPH radical scavenging activity at 50 uM after 20 mins2010Bioorganic & medicinal chemistry letters, Jul-01, Volume: 20, Issue:13
A novel synthesis of 3-aryl coumarins and evaluation of their antioxidant and lipoxygenase inhibitory activity.
AID1083349Inhibition of Glycine max (soybean) lipoxygenase using sodium linoleate as substrate at 1 X 10'-42011Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents, , Volume: 20, Issue:2
The novel amidocarbamate derivatives of ketoprofen: synthesis and biological activity.
AID745287Antioxidant activity assessed as DPPH free radical scavenging activity at 100 uM after 60 mins by spectrophotometry2013European journal of medicinal chemistry, May, Volume: 63Analysis of the antioxidant properties of differently substituted 2- and 3-indolyl carbohydrazides and related derivatives.
AID392745Antioxidant activity assessed as DPPH radical scavenging activity at 0.01 mM after 60 mins2009Bioorganic & medicinal chemistry letters, Feb-15, Volume: 19, Issue:4
Synthesis of hydroxycoumarins and hydroxybenzo[f]- or [h]coumarins as lipid peroxidation inhibitors.
AID1083341Antiviral activity against Sindbis virus infected Hela cells assessed as inhibition of virus-induced cytopathicity2011Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents, , Volume: 20, Issue:2
The novel amidocarbamate derivatives of ketoprofen: synthesis and biological activity.
AID489924Inhibition of soybean lipoxygenase at 100 uM2010Bioorganic & medicinal chemistry letters, Jul-01, Volume: 20, Issue:13
A novel synthesis of 3-aryl coumarins and evaluation of their antioxidant and lipoxygenase inhibitory activity.
AID676990Inhibition of soybean lipoxygenase using sodium linoleate substrate at 100 uM2012Bioorganic & medicinal chemistry, Sep-01, Volume: 20, Issue:17
Synthesis of sulfur containing dihydro-pyrrolo derivatives and their biological evaluation as antioxidants.
AID566093Antioxidant activity assessed as DPPH radical scavenging activity at 0.05 mM after 60 mins2011European journal of medicinal chemistry, Jan, Volume: 46, Issue:1
One-pot microwave assisted synthesis under green chemistry conditions, antioxidant screening, and cytotoxicity assessments of benzimidazole Schiff bases and pyrimido[1,2-a]benzimidazol-3(4H)-ones.
AID754977Inhibition of human leukocyte 5-LOX pseudoperoxidase activity assessed as reduction of active ferric ion to inactive ferrous state measured decomposition of 13-(S)-HPODE at 40 uM after 30 mins by iron-xylenol orange staining assay2013Bioorganic & medicinal chemistry, Jul-01, Volume: 21, Issue:13
Pseudoperoxidase investigations of hydroperoxides and inhibitors with human lipoxygenases.
AID541255Antioxidant activity assessed as DPPH radical scavenging activity at 100 uM after 20 mins2010Journal of medicinal chemistry, Dec-09, Volume: 53, Issue:23
1,5-Benzoxazepines vs 1,5-benzodiazepines. one-pot microwave-assisted synthesis and evaluation for antioxidant activity and lipid peroxidation inhibition.
AID1335586Antioxidant activity assessed as DPPH radical scavenging activity at 100 uM after 60 mins relative to control2016European journal of medicinal chemistry, Nov-29, Volume: 124Novel urea and bis-urea primaquine derivatives with hydroxyphenyl or halogenphenyl substituents: Synthesis and biological evaluation.
AID633582Displacement of [3H]DHT from human androgen receptor expressed in Escherichia coli BL21 cells2011Journal of medicinal chemistry, Dec-22, Volume: 54, Issue:24
Targeting the binding function 3 (BF3) site of the human androgen receptor through virtual screening.
AID475504Binding affinity to amyloid beta (1 to 42) fibrils by change in fluorescence at 100 uM after 10 mins2009Bioorganic & medicinal chemistry letters, Sep-01, Volume: 19, Issue:17
A chemical screening approach reveals that indole fluorescence is quenched by pre-fibrillar but not fibrillar amyloid-beta.
AID723695Competitive inhibition of human recombinant COX2 assessed as inhibition of PGF2a production at 200 uM by enzyme immunoassay2013Bioorganic & medicinal chemistry, Jan-15, Volume: 21, Issue:2
Synthesis and biological evaluation of some 5-arylidene-2-(1,3-thiazol-2-ylimino)-1,3-thiazolidin-4-ones as dual anti-inflammatory/antimicrobial agents.
AID754972Inhibition of N-terminal His6-tagged human reticulocyte 15-LOX1 pseudoperoxidase activity assessed as decomposition of 13-(S)-HPODE at 20 uM measured over 30 mins by UV-vis spectrophotometric analysis2013Bioorganic & medicinal chemistry, Jul-01, Volume: 21, Issue:13
Pseudoperoxidase investigations of hydroperoxides and inhibitors with human lipoxygenases.
AID723697Antiinflammatory activity in AKR mouse assessed as inhibition of carrageenan-induced paw edema at 0.01 mmol/kg, ip measured after 3.5 hrs of carrageenan-challenge2013Bioorganic & medicinal chemistry, Jan-15, Volume: 21, Issue:2
Synthesis and biological evaluation of some 5-arylidene-2-(1,3-thiazol-2-ylimino)-1,3-thiazolidin-4-ones as dual anti-inflammatory/antimicrobial agents.
AID697065Inhibition of duck liver FASN ketoreductase activity2011Journal of medicinal chemistry, Aug-25, Volume: 54, Issue:16
The lipogenesis pathway as a cancer target.
AID363806Antioxidant activity assessed as hydroxyl radical scavenging activity2008European journal of medicinal chemistry, Jun, Volume: 43, Issue:6
Investigations concerning the COX/5-LOX inhibiting and hydroxyl radical scavenging potencies of novel 4,5-diaryl isoselenazoles.
AID754968Inhibition of N-terminal His6-tagged human prostate epithelial 15-LOX2 using arachidonic acid as substrate assessed as residual activity at 20 uM measured 2 mins post initiation of pseudoperoxidase assay by UV/vis spectrophotometric analysis in presence o2013Bioorganic & medicinal chemistry, Jul-01, Volume: 21, Issue:13
Pseudoperoxidase investigations of hydroperoxides and inhibitors with human lipoxygenases.
AID309800Selectivity for 12h-LO over 15-hLO2007Bioorganic & medicinal chemistry, Dec-01, Volume: 15, Issue:23
Structure-activity relationship studies of flavonoids as potent inhibitors of human platelet 12-hLO, reticulocyte 15-hLO-1, and prostate epithelial 15-hLO-2.
AID548098Antioxidant activity assessed as DPPH free radical scavenging activity at 100 uM after 20 mins2010European journal of medicinal chemistry, Dec, Volume: 45, Issue:12
Convenient synthesis and biological profile of 5-amino-substituted 1,2,4-oxadiazole derivatives.
AID392742Antioxidant activity assessed as DPPH radical scavenging activity at 0.05 mM after 20 mins2009Bioorganic & medicinal chemistry letters, Feb-15, Volume: 19, Issue:4
Synthesis of hydroxycoumarins and hydroxybenzo[f]- or [h]coumarins as lipid peroxidation inhibitors.
AID1169300Displacement of ANS from TTR V30M mutant (unknown origin) expressed in Escherichia coli at 1 to 50 uM after 5 mins by fluorescence assay2014Journal of medicinal chemistry, Nov-13, Volume: 57, Issue:21
Inhibitory activities of propolis and its promising component, caffeic acid phenethyl ester, against amyloidogenesis of human transthyretin.
AID1083334Antiviral activity against Human coxsackievirus B4 infected VERO cells assessed as inhibition of virus-induced cytopathicity2011Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents, , Volume: 20, Issue:2
The novel amidocarbamate derivatives of ketoprofen: synthesis and biological activity.
AID1163381Antioxidant activity assessed as DPPH scavenging activity at 100 uM after 60 mins by spectrophotometry2014European journal of medicinal chemistry, Oct-30, Volume: 86Novel semicarbazides and ureas of primaquine with bulky aryl or hydroxyalkyl substituents: synthesis, cytostatic and antioxidative activity.
AID1253356Stability of compound in 0.5M phosphate citric acid buffer assessed as autoxidative conversion at 0.1 mM at pH 7.4 at 37 degC for 90 mins by HPLC-UV analysis2015Bioorganic & medicinal chemistry, Nov-01, Volume: 23, Issue:21
Ring substitution influences oxidative cyclisation and reactive metabolite formation of nordihydroguaiaretic acid analogues.
AID1163384Inhibition of soybean LOX using sodium linoleate as substrate by spectrophotometry2014European journal of medicinal chemistry, Oct-30, Volume: 86Novel semicarbazides and ureas of primaquine with bulky aryl or hydroxyalkyl substituents: synthesis, cytostatic and antioxidative activity.
AID426422Antioxidant activity against hydroxyl radical assessed as inhibition of formaldehyde production at 0.1 mM after 30 mins relative to DMSO2009European journal of medicinal chemistry, Jul, Volume: 44, Issue:7
Synthesis and evaluation of the antioxidant and anti-inflammatory activity of novel coumarin-3-aminoamides and their alpha-lipoic acid adducts.
AID1253362Stability of compound assessed as level of dibenzocyclooctadiene derivative at 37 degC for 6 hrs in absence of glutathione2015Bioorganic & medicinal chemistry, Nov-01, Volume: 23, Issue:21
Ring substitution influences oxidative cyclisation and reactive metabolite formation of nordihydroguaiaretic acid analogues.
AID1253353Drug degradation in 0.5M phosphate citric acid buffer at 0.5 mM at pH 7.4 at 37 degC by HPLC-UV analysis2015Bioorganic & medicinal chemistry, Nov-01, Volume: 23, Issue:21
Ring substitution influences oxidative cyclisation and reactive metabolite formation of nordihydroguaiaretic acid analogues.
AID433936Cytotoxicity against human MCF7 cells after 5 days by MTT assay2009Bioorganic & medicinal chemistry letters, Aug-15, Volume: 19, Issue:16
Synthesis, characterization, and anti-melanoma activity of tetra-O-substituted analogs of nordihydroguaiaretic acid.
AID548101Inhibition of soybean lipoxygenase at 100 uM by UV spectrophotometry2010European journal of medicinal chemistry, Dec, Volume: 45, Issue:12
Convenient synthesis and biological profile of 5-amino-substituted 1,2,4-oxadiazole derivatives.
AID588214FDA HLAED, liver enzyme composite activity2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID541260Inhibition of soybean lipoxygenase at 100 uM by UV absorbance based assay2010Journal of medicinal chemistry, Dec-09, Volume: 53, Issue:23
1,5-Benzoxazepines vs 1,5-benzodiazepines. one-pot microwave-assisted synthesis and evaluation for antioxidant activity and lipid peroxidation inhibition.
AID1549787Agonist activity at human TRPA1 expressed in HEK293 cells assessed as increase in calcium influx by Calcium-5 dye based fluorescence assay2019European journal of medicinal chemistry, May-15, Volume: 170N-Cinnamoylanthranilates as human TRPA1 modulators: Structure-activity relationships and channel binding sites.
AID549589Antiinflammatory activity in CD1 mouse assessed as inhibition of croton oil-induced ear edema at 0.1 umol administered topically per cm'2 of ear relative to control2011Bioorganic & medicinal chemistry letters, Jan-15, Volume: 21, Issue:2
Topical anti-inflammatory activity of boropinic acid and its natural and semi-synthetic derivatives.
AID354433Inhibition of His-tagged human platelet 12-lipoxygenase2003Journal of natural products, Feb, Volume: 66, Issue:2
Exploring sponge-derived terpenoids for their potency and selectivity against 12-human, 15-human, and 15-soybean lipoxygenases.
AID54297Tested for the inhibition of lipid peroxidation in bovine brain phospholipid liposomes1993Journal of medicinal chemistry, Dec-10, Volume: 36, Issue:25
Antipsoriatic anthrones with modulated redox properties. 1. Novel 10-substituted 1,8-dihydroxy-9(10H)-anthracenones as inhibitors of 5-lipoxygenase.
AID308042Inhibition of IGF1R2007Bioorganic & medicinal chemistry letters, Jul-15, Volume: 17, Issue:14
Inhibition of IGF-1R and lipoxygenase by nordihydroguaiaretic acid (NDGA) analogs.
AID261409Anti-inflammatory activity against carrageenan-induced edema in Sprague-Dawley rat paw after 3 hrs of 30 mg/kg, po2006Journal of medicinal chemistry, Mar-09, Volume: 49, Issue:5
Synthesis and structure-activity relationship studies of 1,3-diarylprop-2-yn-1-ones: dual inhibitors of cyclooxygenases and lipoxygenases.
AID490949Antioxidant activity assessed as inhibition of lipid peroxidation at 100 uM2010European journal of medicinal chemistry, Jul, Volume: 45, Issue:7
Synthesis and biological screening of some novel amidocarbamate derivatives of ketoprofen.
AID7096In vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells1991Journal of medicinal chemistry, Jul, Volume: 34, Issue:7
4-hydroxythiazole inhibitors of 5-lipoxygenase.
AID379834Antioxidant activity assessed as DPPH radical scavenging activity at equimolar amount of compound1999Journal of natural products, Jun, Volume: 62, Issue:6
Lichen metabolites. 1. Inhibitory action against leukotriene B4 biosynthesis by a non-redox mechanism.
AID1169298Inhibition of TTR I84T mutant (unknown origin) expressed in Escherichia coli assessed as inhibition of amyloid fibril formation by fluorescence assay2014Journal of medicinal chemistry, Nov-13, Volume: 57, Issue:21
Inhibitory activities of propolis and its promising component, caffeic acid phenethyl ester, against amyloidogenesis of human transthyretin.
AID354436Ratio of IC50 for soybean 15-lipoxygenase to IC50 for human 15-lipoxygenase2003Journal of natural products, Feb, Volume: 66, Issue:2
Exploring sponge-derived terpenoids for their potency and selectivity against 12-human, 15-human, and 15-soybean lipoxygenases.
AID633580Cytotoxicity against human LNCAP cells assessed as cell viability after 3 days by MTS assay2011Journal of medicinal chemistry, Dec-22, Volume: 54, Issue:24
Targeting the binding function 3 (BF3) site of the human androgen receptor through virtual screening.
AID1083340Antiviral activity against Human simplex virus 1 KOS infected in human HEL cells assessed as inhibition of virus-induced cytopathicity2011Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents, , Volume: 20, Issue:2
The novel amidocarbamate derivatives of ketoprofen: synthesis and biological activity.
AID286752Inhibition of carrageenan-induced Fischer 344 rat paw edema at 0.01 mmol/kg, ip2007Journal of medicinal chemistry, May-17, Volume: 50, Issue:10
Design and synthesis of novel quinolinone-3-aminoamides and their alpha-lipoic acid adducts as antioxidant and anti-inflammatory agents.
AID499651Inhibition of 5-lipoxygenase2010Bioorganic & medicinal chemistry, Aug-15, Volume: 18, Issue:16
Design, synthesis, and biological evaluation of prenylated chalcones as 5-LOX inhibitors.
AID548097Antioxidant activity assessed as DPPH free radical scavenging activity at 50 uM after 20 mins2010European journal of medicinal chemistry, Dec, Volume: 45, Issue:12
Convenient synthesis and biological profile of 5-amino-substituted 1,2,4-oxadiazole derivatives.
AID1253354Half life of the compound in 0.5M phosphate citric acid buffer at 0.5 mM at pH 7.4 at 37 degC by HPLC-UV analysis2015Bioorganic & medicinal chemistry, Nov-01, Volume: 23, Issue:21
Ring substitution influences oxidative cyclisation and reactive metabolite formation of nordihydroguaiaretic acid analogues.
AID489922Antioxidant activity assessed as DPPH radical scavenging activity at 50 uM after 60 mins2010Bioorganic & medicinal chemistry letters, Jul-01, Volume: 20, Issue:13
A novel synthesis of 3-aryl coumarins and evaluation of their antioxidant and lipoxygenase inhibitory activity.
AID682748Antioxidant activity assessed as inhibition of DPPH radical scavenging activity after 30 mins by spectrophotometry2012Bioorganic & medicinal chemistry, Sep-15, Volume: 20, Issue:18
Synthesis and SAR studies of 3-allyl-4-prenyloxyaniline amides as potent 15-lipoxygenase inhibitors.
AID1180076Inhibition of soybean lipoxygenase after 5 mins by colorimetric assay2014Bioorganic & medicinal chemistry, Aug-01, Volume: 22, Issue:15
Pharmacological evaluation and docking studies of α,β-unsaturated carbonyl based synthetic compounds as inhibitors of secretory phospholipase A₂, cyclooxygenases, lipoxygenase and proinflammatory cytokines.
AID524791Antiplasmodial activity against Plasmodium falciparum 7G8 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID461117Antiinflammatory activity against carrageenan-induced paw edema in rat at 30 mg/kg, po2010Bioorganic & medicinal chemistry letters, Feb-01, Volume: 20, Issue:3
Phenylacetic acid regioisomers possessing a N-difluoromethyl-1,2-dihydropyrid-2-one pharmacophore: evaluation as dual inhibitors of cyclooxygenases and 5-lipoxygenase with anti-inflammatory activity.
AID101295Ex vivo inhibition of LTB4 production was measured in dog blood1991Journal of medicinal chemistry, Mar, Volume: 34, Issue:3
Indazolinones, a new series of redox-active 5-lipoxygenase inhibitors with built-in selectivity and oral activity.
AID255240Percent inhibition of soybean lipoxygenase upon incubation with sodium linoleate (1.0 mM) at RT2005Journal of medicinal chemistry, Oct-06, Volume: 48, Issue:20
Synthesis and antiinflammatory activity of coumarin derivatives.
AID1253360Stability of compound assessed as level of adduct at 37 degC for 6 hrs in presence of 20 fold excess of glutathione2015Bioorganic & medicinal chemistry, Nov-01, Volume: 23, Issue:21
Ring substitution influences oxidative cyclisation and reactive metabolite formation of nordihydroguaiaretic acid analogues.
AID566092Antioxidant activity assessed as DPPH radical scavenging activity at 0.05 mM after 20 mins2011European journal of medicinal chemistry, Jan, Volume: 46, Issue:1
One-pot microwave assisted synthesis under green chemistry conditions, antioxidant screening, and cytotoxicity assessments of benzimidazole Schiff bases and pyrimido[1,2-a]benzimidazol-3(4H)-ones.
AID433940Cytotoxicity against human A375 cells assessed as inhibition of RNA synthesis at 50 uM2009Bioorganic & medicinal chemistry letters, Aug-15, Volume: 19, Issue:16
Synthesis, characterization, and anti-melanoma activity of tetra-O-substituted analogs of nordihydroguaiaretic acid.
AID1083353Antioxidant activity assessed as DPPH radical scavenging activity at 5 X 10'-5 M after 20 min2011Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents, , Volume: 20, Issue:2
The novel amidocarbamate derivatives of ketoprofen: synthesis and biological activity.
AID1695730Inhibition of alpha-synuclein fibril formation (unknown origin) incubated for 24 hrs to 7 days by thioflavin S based fluorescence assay2019European journal of medicinal chemistry, Apr-01, Volume: 167Toward the discovery and development of effective modulators of α-synuclein amyloid aggregation.
AID1184082Inhibition of 12-LO-mediated 12-HPETE formation in human platelets using arachidonic acid as substrate assessed as residual activity at 100 uM preincubated for 15 mins before substrate addition measured after 10 mins2014European journal of medicinal chemistry, Sep-12, Volume: 84Multi-dimensional target profiling of N,4-diaryl-1,3-thiazole-2-amines as potent inhibitors of eicosanoid metabolism.
AID611386Antioxidant activity assessed as DPPH radical scavenging activity at 5 uM2011Journal of medicinal chemistry, Aug-11, Volume: 54, Issue:15
Discovery of potent and selective inhibitors of human platelet-type 12- lipoxygenase.
AID303033Antioxidant activity assessed as DPPH radical scavenging activity at 0.05 mM after 60 mins2007Bioorganic & medicinal chemistry letters, Dec-01, Volume: 17, Issue:23
Synthesis and anti-inflammatory/antioxidant activities of some new ring substituted 3-phenyl-1-(1,4-di-N-oxide quinoxalin-2-yl)-2-propen-1-one derivatives and of their 4,5-dihydro-(1H)-pyrazole analogues.
AID1655441Inhibition of HIV1 Nucleocapsid protein (11 to 55 residues) assessed as reduction in NC-induced cTAR DNA destabilization by measuring intrinsic fluorescence using Alexa488-5'-cTAR-3'-Dabcyl oligonucleotide as substrate at 20 degree C incubated for 15 mins2020ACS medicinal chemistry letters, May-14, Volume: 11, Issue:5
5,6-Dihydroxypyrimidine Scaffold to Target HIV-1 Nucleocapsid Protein.
AID633798Inhibition of soybean LOX type 1 pre-incubated for 4 mins at 7x10'-7 w/v concentration assessed as inhibition of sodium linoleate to 13-hydroperoxylinoleic acid2012European journal of medicinal chemistry, Jan, Volume: 47, Issue:1
Fragment-based design, docking, synthesis, biological evaluation and structure-activity relationships of 2-benzo/benzisothiazolimino-5-aryliden-4-thiazolidinones as cycloxygenase/lipoxygenase inhibitors.
AID567044DPPH radical scavenging activity assessed as reducing ability at 0.05 mM after 60 mins2011European journal of medicinal chemistry, Jan, Volume: 46, Issue:1
Design, synthesis and pharmacobiological evaluation of novel acrylic acid derivatives acting as lipoxygenase and cyclooxygenase-1 inhibitors with antioxidant and anti-inflammatory activities.
AID6855In vitro inhibition of 5-lipoxygenase in rat (peritoneal assay)1990Journal of medicinal chemistry, Oct, Volume: 33, Issue:10
Penta- and hexadienoic acid derivatives: a novel series of 5-lipoxygenase inhibitors.
AID1406145Inhibition of human 5-lipoxygenase using arachidonic acid as substrate pretreated for 10 mins followed by substrate and ATP addition and measured after 20 mins by H2DCFDA probe based fluorescence assay2018European journal of medicinal chemistry, Aug-05, Volume: 156Neurogenic and neuroprotective donepezil-flavonoid hybrids with sigma-1 affinity and inhibition of key enzymes in Alzheimer's disease.
AID490948Antioxidant activity assessed as inhibition of lipid peroxidation at 10 uM2010European journal of medicinal chemistry, Jul, Volume: 45, Issue:7
Synthesis and biological screening of some novel amidocarbamate derivatives of ketoprofen.
AID347222Inhibition of COX2 in LPS-stimulated human blood2009Bioorganic & medicinal chemistry, Jan-15, Volume: 17, Issue:2
Diaryl-dithiolanes and -isothiazoles: COX-1/COX-2 and 5-LOX-inhibitory, *OH scavenging and anti-adhesive activities.
AID485953Selectivity ratio of IC50 for human reticulocyte 15-lipoxygenase to IC50 for human 5-lipoxygenase2009Journal of natural products, Oct, Volume: 72, Issue:10
Using enzyme assays to evaluate the structure and bioactivity of sponge-derived meroterpenes.
AID754970Inhibition of N-terminal His6-tagged human platelet 12-LOX using arachidonic acid as substrate assessed as residual activity at 20 uM measured 2 mins post initiation of pseudoperoxidase assay by UV/vis spectrophotometric analysis in presence of 13-(S)-HPO2013Bioorganic & medicinal chemistry, Jul-01, Volume: 21, Issue:13
Pseudoperoxidase investigations of hydroperoxides and inhibitors with human lipoxygenases.
AID426426Inhibition of soybean lipoxygenase assessed as conversion of sodium linoleate to 13-hydroperoxylinoleic acid at 0.1 mM2009European journal of medicinal chemistry, Jul, Volume: 44, Issue:7
Synthesis and evaluation of the antioxidant and anti-inflammatory activity of novel coumarin-3-aminoamides and their alpha-lipoic acid adducts.
AID308044Inhibition of 15 LOX2007Bioorganic & medicinal chemistry letters, Jul-15, Volume: 17, Issue:14
Inhibition of IGF-1R and lipoxygenase by nordihydroguaiaretic acid (NDGA) analogs.
AID426430Antioxidant activity assessed as reduction of DPPH activity at 0.1 mM after 20 mins2009European journal of medicinal chemistry, Jul, Volume: 44, Issue:7
Synthesis and evaluation of the antioxidant and anti-inflammatory activity of novel coumarin-3-aminoamides and their alpha-lipoic acid adducts.
AID609921Antioxidant activity assessed as DPPH radical scavenging activity at 50 uM after 60 mins2011Bioorganic & medicinal chemistry letters, Aug-15, Volume: 21, Issue:16
Thrombin inhibitors with lipid peroxidation and lipoxygenase inhibitory activities.
AID588215FDA HLAED, alkaline phosphatase increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1257023Anti-inflammatory activity in Fisher 344 rat assessed as inhibition of carrageenan-induced paw edema at 0.01 mmol/kg, ip after 3.5 hrs2015Bioorganic & medicinal chemistry, Nov-15, Volume: 23, Issue:22
Synthesis and biological evaluation of new C-10 substituted dithranol pleiotropic hybrids.
AID431299Antioxidant activity assessed as DPPH radical scavenging activity at 0.1 mM after 20 mins2009Bioorganic & medicinal chemistry, Aug-01, Volume: 17, Issue:15
Urea and carbamate derivatives of primaquine: synthesis, cytostatic and antioxidant activities.
AID284858Inhibition of soybean lipoxygenase after 7 mins2007Bioorganic & medicinal chemistry, Jan-15, Volume: 15, Issue:2
Design and study of some novel ibuprofen derivatives with potential nootropic and neuroprotective properties.
AID471734Antioxidant activity assessed as DPPH free radical scavenging activity at 0.05 mM after 20 mins2009Bioorganic & medicinal chemistry letters, Nov-15, Volume: 19, Issue:22
Synthesis of modified homo-N-nucleosides from the reactions of mesityl nitrile oxide with 9-allylpurines and their influence on lipid peroxidation and thrombin inhibition.
AID242641Inhibitory concentration against isolated rabbit reticulocyte 15-lipoxygenase measured in the presence of linoleic acid2005Bioorganic & medicinal chemistry letters, Mar-01, Volume: 15, Issue:5
Tryptamine and homotryptamine-based sulfonamides as potent and selective inhibitors of 15-lipoxygenase.
AID309799Inhibition of 15-hLO12007Bioorganic & medicinal chemistry, Dec-01, Volume: 15, Issue:23
Structure-activity relationship studies of flavonoids as potent inhibitors of human platelet 12-hLO, reticulocyte 15-hLO-1, and prostate epithelial 15-hLO-2.
AID452848Antioxidant activity assessed as DPPH radical scavenging activity at 50 uM after 60 mins2009Bioorganic & medicinal chemistry, Dec-01, Volume: 17, Issue:23
Natural and synthetic 2'-hydroxy-chalcones and aurones: synthesis, characterization and evaluation of the antioxidant and soybean lipoxygenase inhibitory activity.
AID1335585Antioxidant activity assessed as DPPH radical scavenging activity at 100 uM after 20 mins relative to control2016European journal of medicinal chemistry, Nov-29, Volume: 124Novel urea and bis-urea primaquine derivatives with hydroxyphenyl or halogenphenyl substituents: Synthesis and biological evaluation.
AID1083343Antiviral activity against Vesicular stomatitis virus infected Hela cells assessed as inhibition of virus-induced cytopathicity2011Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents, , Volume: 20, Issue:2
The novel amidocarbamate derivatives of ketoprofen: synthesis and biological activity.
AID431297Antioxidant activity assessed as DPPH radical scavenging activity at 0.1 mM after 60 mins2009Bioorganic & medicinal chemistry, Aug-01, Volume: 17, Issue:15
Urea and carbamate derivatives of primaquine: synthesis, cytostatic and antioxidant activities.
AID754975Inhibition of N-terminal His6-tagged human reticulocyte 15-LOX1 pseudoperoxidase activity assessed as reduction of active ferric ion to inactive ferrous state measured decomposition of 13-(S)-HPODE at 40 uM after 30 mins by iron-xylenol orange staining as2013Bioorganic & medicinal chemistry, Jul-01, Volume: 21, Issue:13
Pseudoperoxidase investigations of hydroperoxides and inhibitors with human lipoxygenases.
AID490946Antioxidant activity assessed as DPPH radical scavenging activity at 100 uM after 60 mins2010European journal of medicinal chemistry, Jul, Volume: 45, Issue:7
Synthesis and biological screening of some novel amidocarbamate derivatives of ketoprofen.
AID452850Antioxidant activity assessed as DPPH radical scavenging activity at 100 uM after 60 mins2009Bioorganic & medicinal chemistry, Dec-01, Volume: 17, Issue:23
Natural and synthetic 2'-hydroxy-chalcones and aurones: synthesis, characterization and evaluation of the antioxidant and soybean lipoxygenase inhibitory activity.
AID347225Antioxidant activity assessed as hydroxyl radical scavenging activity2009Bioorganic & medicinal chemistry, Jan-15, Volume: 17, Issue:2
Diaryl-dithiolanes and -isothiazoles: COX-1/COX-2 and 5-LOX-inhibitory, *OH scavenging and anti-adhesive activities.
AID286228Inhibition of 5LOX in human PBMC by EIA assay2007Journal of natural products, May, Volume: 70, Issue:5
Lipoxygenase inhibitory constituents of the fruits of noni (Morinda citrifolia) collected in Tahiti.
AID1253358Stability of compound assessed as level of starting material at 37 degC for 6 hrs in presence of 20 fold excess of glutathione2015Bioorganic & medicinal chemistry, Nov-01, Volume: 23, Issue:21
Ring substitution influences oxidative cyclisation and reactive metabolite formation of nordihydroguaiaretic acid analogues.
AID261411Inhibitory activity against 4% NaCl-induced abdominal constriction in Sprague-Dawley rat after 60 min of 30 mg/kg, po2006Journal of medicinal chemistry, Mar-09, Volume: 49, Issue:5
Synthesis and structure-activity relationship studies of 1,3-diarylprop-2-yn-1-ones: dual inhibitors of cyclooxygenases and lipoxygenases.
AID1257021Inhibition of soybean LOX assessed as reduction in conversion of sodium linoleate to 13-hydroperoxylinoleic acid by UV analysis2015Bioorganic & medicinal chemistry, Nov-15, Volume: 23, Issue:22
Synthesis and biological evaluation of new C-10 substituted dithranol pleiotropic hybrids.
AID228686Deoxyribose-damaging property as a measure of hydroxyl-radical formation (uM of malondialdehyde/mmol of deoxyribose released by 75 uM test compound)1993Journal of medicinal chemistry, Dec-10, Volume: 36, Issue:25
Antipsoriatic anthrones with modulated redox properties. 1. Novel 10-substituted 1,8-dihydroxy-9(10H)-anthracenones as inhibitors of 5-lipoxygenase.
AID303035Antioxidant activity assessed as DPPH radical scavenging activity at 0.1 mM after 60 mins2007Bioorganic & medicinal chemistry letters, Dec-01, Volume: 17, Issue:23
Synthesis and anti-inflammatory/antioxidant activities of some new ring substituted 3-phenyl-1-(1,4-di-N-oxide quinoxalin-2-yl)-2-propen-1-one derivatives and of their 4,5-dihydro-(1H)-pyrazole analogues.
AID524790Antiplasmodial activity against Plasmodium falciparum 3D7 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID548960Antioxidant activity of the compound assessed as reducing activity of DPPH at 0.1 mM after 20 mins2010Bioorganic & medicinal chemistry, Dec-01, Volume: 18, Issue:23
Does conjugation of antioxidants improve their antioxidative/anti-inflammatory potential?
AID1364656Inhibition of human 17beta-HSD1 expressed in HEK293 cell lysates incubated for 10 mins using [2,4,6,7-3H]-estrone and NADPH by scintillation counting method2017Journal of natural products, 04-28, Volume: 80, Issue:4
Potential Antiosteoporotic Natural Product Lead Compounds That Inhibit 17β-Hydroxysteroid Dehydrogenase Type 2.
AID433941Cytotoxicity against human A375 cells assessed as inhibition of protein synthesis at 50 uM2009Bioorganic & medicinal chemistry letters, Aug-15, Volume: 19, Issue:16
Synthesis, characterization, and anti-melanoma activity of tetra-O-substituted analogs of nordihydroguaiaretic acid.
AID485951Inhibition of human N-terminal His6-tagged 5-lipoxygenase arachidonic acid by UV-vis spectrometry2009Journal of natural products, Oct, Volume: 72, Issue:10
Using enzyme assays to evaluate the structure and bioactivity of sponge-derived meroterpenes.
AID6809In vitro inhibitory activity against RBL-1 5-LO1987Journal of medicinal chemistry, Mar, Volume: 30, Issue:3
Hydroxamic acid inhibitors of 5-lipoxygenase.
AID477295Octanol-water partition coefficient, log P of the compound2010European journal of medicinal chemistry, Apr, Volume: 45, Issue:4
QSPR modeling of octanol/water partition coefficient of antineoplastic agents by balance of correlations.
AID1138903Inhibition of human reticulocyte 12/15-lipoxygenase using arachidonic acid/linoleic acid as substrate by fluorescence assay2014Journal of medicinal chemistry, May-22, Volume: 57, Issue:10
Potent and selective inhibitors of human reticulocyte 12/15-lipoxygenase as anti-stroke therapies.
AID440883Antioxidant activity assessed as DPPH free radical scavenging activity at 0.1 mM after 60 mins2009European journal of medicinal chemistry, Dec, Volume: 44, Issue:12
Synthesis and anti-inflammatory evaluation of novel angularly or linearly fused coumarins.
AID380429Cytotoxicity against human BT549 cells upto 48 uM2006Journal of natural products, Mar, Volume: 69, Issue:3
Schisandrene, a dibenzocyclooctadiene lignan from Schisandra chinensis: structure-antioxidant activity relationships of dibenzocyclooctadiene lignans.
AID1253368Dissociation constant, pKa of compound2015Bioorganic & medicinal chemistry, Nov-01, Volume: 23, Issue:21
Ring substitution influences oxidative cyclisation and reactive metabolite formation of nordihydroguaiaretic acid analogues.
AID490944Antioxidant activity assessed as DPPH radical scavenging activity at 50 uM after 60 mins2010European journal of medicinal chemistry, Jul, Volume: 45, Issue:7
Synthesis and biological screening of some novel amidocarbamate derivatives of ketoprofen.
AID1083330Antiviral activity against Unidentified Influenza A virus (H1N2) infected MDCK cells assessed as inhibition of virus-induced cytopathicity2011Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents, , Volume: 20, Issue:2
The novel amidocarbamate derivatives of ketoprofen: synthesis and biological activity.
AID355098Antiinflammatory activity in NMRI mouse macrophages assessed as inhibition of A23187-induced LTC4 release by Ellman's method1996Journal of natural products, Dec, Volume: 59, Issue:12
Antiinflammatory activity of coumarins from Santolina oblongifolia.
AID1624741Antioxidant activity assessed as DPPH free radical scavenging activity at 0.1 mM measured after 20 to 60 mins2019Journal of medicinal chemistry, 02-28, Volume: 62, Issue:4
New Quinolylnitrones for Stroke Therapy: Antioxidant and Neuroprotective ( Z)- N- tert-Butyl-1-(2-chloro-6-methoxyquinolin-3-yl)methanimine Oxide as a New Lead-Compound for Ischemic Stroke Treatment.
AID780275Cytotoxicity against human H69 cells2013Bioorganic & medicinal chemistry letters, Nov-15, Volume: 23, Issue:22
Restraining the flexibility of the central linker in terameprocol results in constrained analogs with improved growth inhibitory activity.
AID179757In vitro inhibition of LTB4 production was measured in rat blood1991Journal of medicinal chemistry, Mar, Volume: 34, Issue:3
Indazolinones, a new series of redox-active 5-lipoxygenase inhibitors with built-in selectivity and oral activity.
AID440882Antioxidant activity assessed as DPPH free radical scavenging activity at 0.05 mM after 60 mins2009European journal of medicinal chemistry, Dec, Volume: 44, Issue:12
Synthesis and anti-inflammatory evaluation of novel angularly or linearly fused coumarins.
AID452849Antioxidant activity assessed as DPPH radical scavenging activity at 100 uM after 20 mins2009Bioorganic & medicinal chemistry, Dec-01, Volume: 17, Issue:23
Natural and synthetic 2'-hydroxy-chalcones and aurones: synthesis, characterization and evaluation of the antioxidant and soybean lipoxygenase inhibitory activity.
AID161024In vitro for prostaglandin G/H synthase inhibitory activity against rat basophil leukemia type 1 cell homogenates, by measuring the radioactivity of [14C]-PGD21990Journal of medicinal chemistry, Oct, Volume: 33, Issue:10
Penta- and hexadienoic acid derivatives: a novel series of 5-lipoxygenase inhibitors.
AID697064Inhibition of duck liver FASN2011Journal of medicinal chemistry, Aug-25, Volume: 54, Issue:16
The lipogenesis pathway as a cancer target.
AID653295Inhibition of soybean LOX assessed as conversion of sodium linoleate to 13- hydroperoxylinoleic acid2012European journal of medicinal chemistry, May, Volume: 51Novel NSAID 1-acyl-4-cycloalkyl/arylsemicarbazides and 1-acyl-5-benzyloxy/hydroxy carbamoylcarbazides as potential anticancer agents and antioxidants.
AID490945Antioxidant activity assessed as DPPH radical scavenging activity at 100 uM after 20 mins2010European journal of medicinal chemistry, Jul, Volume: 45, Issue:7
Synthesis and biological screening of some novel amidocarbamate derivatives of ketoprofen.
AID261406Inhibitory activity against potato 5LOX2006Journal of medicinal chemistry, Mar-09, Volume: 49, Issue:5
Synthesis and structure-activity relationship studies of 1,3-diarylprop-2-yn-1-ones: dual inhibitors of cyclooxygenases and lipoxygenases.
AID461116Antiinflammatory activity against carrageenan-induced paw edema in po dosed rat2010Bioorganic & medicinal chemistry letters, Feb-01, Volume: 20, Issue:3
Phenylacetic acid regioisomers possessing a N-difluoromethyl-1,2-dihydropyrid-2-one pharmacophore: evaluation as dual inhibitors of cyclooxygenases and 5-lipoxygenase with anti-inflammatory activity.
AID625352Antioxidant activity assessed as DPPH free radical scavenging activity at 100 uM after 20 mins2011European journal of medicinal chemistry, Dec, Volume: 46, Issue:12
Synthesis and biological evaluation of (2,5-dihydro-1H-pyrrol-1-yl)-2H-chromen-2-ones as free radical scavengers.
AID1083351Antioxidant activity assessed as DPPH radical scavenging activity at 1 X 10'-4 M after 20 min2011Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents, , Volume: 20, Issue:2
The novel amidocarbamate derivatives of ketoprofen: synthesis and biological activity.
AID7079Iin vitro inhibition of 5-lipoxygenase activity in rat basophil leukemia type 1(RBL1) cell homogenates, (reduction of [14C]-5-HETE formation)1990Journal of medicinal chemistry, Oct, Volume: 33, Issue:10
Penta- and hexadienoic acid derivatives: a novel series of 5-lipoxygenase inhibitors.
AID309802Reductive inhibition of 15-hLO12007Bioorganic & medicinal chemistry, Dec-01, Volume: 15, Issue:23
Structure-activity relationship studies of flavonoids as potent inhibitors of human platelet 12-hLO, reticulocyte 15-hLO-1, and prostate epithelial 15-hLO-2.
AID754969Inhibition of N-terminal His6-tagged human reticulocyte 15-LOX1 using arachidonic acid as substrate assessed as residual activity at 20 uM measured 2 mins post initiation of pseudoperoxidase assay by UV/vis spectrophotometric analysis in presence of 13-(S2013Bioorganic & medicinal chemistry, Jul-01, Volume: 21, Issue:13
Pseudoperoxidase investigations of hydroperoxides and inhibitors with human lipoxygenases.
AID426432Antioxidant activity assessed as reduction of DPPH activity at 0.5 mM after 20 mins2009European journal of medicinal chemistry, Jul, Volume: 44, Issue:7
Synthesis and evaluation of the antioxidant and anti-inflammatory activity of novel coumarin-3-aminoamides and their alpha-lipoic acid adducts.
AID754973Inhibition of N-terminal His6-tagged human platelet 12-LOX pseudoperoxidase activity assessed as decomposition of 13-(S)-HPODE at 20 uM measured over 30 mins by UV-vis spectrophotometric analysis2013Bioorganic & medicinal chemistry, Jul-01, Volume: 21, Issue:13
Pseudoperoxidase investigations of hydroperoxides and inhibitors with human lipoxygenases.
AID433938Cytotoxicity against human A375 cells after 5 days by MTT assay2009Bioorganic & medicinal chemistry letters, Aug-15, Volume: 19, Issue:16
Synthesis, characterization, and anti-melanoma activity of tetra-O-substituted analogs of nordihydroguaiaretic acid.
AID490947Inhibition of soybean LOX at 100 uM2010European journal of medicinal chemistry, Jul, Volume: 45, Issue:7
Synthesis and biological screening of some novel amidocarbamate derivatives of ketoprofen.
AID204319Effect of compound at 100 uM concentration on ABA accumulation in spinachleaf slices determined as fresh weight of leaves (Experiment 1)2004Bioorganic & medicinal chemistry letters, Jun-21, Volume: 14, Issue:12
A new lead compound for abscisic acid biosynthesis inhibitors targeting 9-cis-epoxycarotenoid dioxygenase.
AID2919Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO)2002Journal of medicinal chemistry, Jun-06, Volume: 45, Issue:12
Structure-activity relationship studies of nordihydroguaiaretic acid inhibitors toward soybean, 12-human, and 15-human lipoxygenase.
AID401061Antioxidant activity assessed as DPPH free radical scavenging activity1998Journal of natural products, May, Volume: 61, Issue:5
Antioxidant flavonoid glycosides from Daphniphyllum calycinum.
AID1178344Inhibition of Fos-Jun dimer formation (unknown origin)2014Journal of medicinal chemistry, Aug-28, Volume: 57, Issue:16
Small molecule inhibitors targeting activator protein 1 (AP-1).
AID286756Antioxidant activity assessed as DPPH reducing activity at 0.5 mM after 60 mins2007Journal of medicinal chemistry, May-17, Volume: 50, Issue:10
Design and synthesis of novel quinolinone-3-aminoamides and their alpha-lipoic acid adducts as antioxidant and anti-inflammatory agents.
AID524795Antiplasmodial activity against Plasmodium falciparum HB3 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID609922Antioxidant activity assessed as DPPH radical scavenging activity at 10 uM after 20 mins2011Bioorganic & medicinal chemistry letters, Aug-15, Volume: 21, Issue:16
Thrombin inhibitors with lipid peroxidation and lipoxygenase inhibitory activities.
AID433935Cytotoxicity against human HT-29 cells after 5 days by MTT assay2009Bioorganic & medicinal chemistry letters, Aug-15, Volume: 19, Issue:16
Synthesis, characterization, and anti-melanoma activity of tetra-O-substituted analogs of nordihydroguaiaretic acid.
AID1169294Inhibition of TTR V30M mutant (unknown origin) expressed in Escherichia coli assessed as inhibition of amyloid fibril formation at 20 uM by fluorescence assay2014Journal of medicinal chemistry, Nov-13, Volume: 57, Issue:21
Inhibitory activities of propolis and its promising component, caffeic acid phenethyl ester, against amyloidogenesis of human transthyretin.
AID1695728Inhibition of alpha-synuclein aggregation (unknown origin) incubated for 8 days by thioflavin S based fluorescence assay2019European journal of medicinal chemistry, Apr-01, Volume: 167Toward the discovery and development of effective modulators of α-synuclein amyloid aggregation.
AID433948Cytotoxicity against human A375 cells assessed as inhibition of DNA synthesis at 50 uM2009Bioorganic & medicinal chemistry letters, Aug-15, Volume: 19, Issue:16
Synthesis, characterization, and anti-melanoma activity of tetra-O-substituted analogs of nordihydroguaiaretic acid.
AID475505Binding affinity to amyloid beta (1 to 42) oligomers by change in fluorescence at 100 uM after 10 mins2009Bioorganic & medicinal chemistry letters, Sep-01, Volume: 19, Issue:17
A chemical screening approach reveals that indole fluorescence is quenched by pre-fibrillar but not fibrillar amyloid-beta.
AID334023Antiinflammatory activity against Arachidonic acid-induced ear edema in Swiss mouse assessed as reduction in ear thickness at 2 mg/ear1997Journal of natural products, Nov, Volume: 60, Issue:11
Zanhasaponins A and B, antiphospholipase A2 saponins from an antiinflammatory extract of Zanha africana root bark.
AID630132Inhibition of recombinant human 5-LOX in human PBML assessed as inhibition of A23187-induced LTB4 production preincubated for 15 mins measured after 15 mins by enzyme immunoassay2011Bioorganic & medicinal chemistry, Nov-01, Volume: 19, Issue:21
Design, synthesis and biological evaluation of benzo[1.3.2]dithiazolium ylide 1,1-dioxide derivatives as potential dual cyclooxygenase-2/5-lipoxygenase inhibitors.
AID683742Inhibition of soybean lipoxygenase assessed as conversion of sodium linoleate to 13-hydroperoxylinoleic acid at 0.1 mM by competitive inhibition assay2012Journal of medicinal chemistry, Jan-12, Volume: 55, Issue:1
Α-aryl-N-alkyl nitrones, as potential agents for stroke treatment: synthesis, theoretical calculations, antioxidant, anti-inflammatory, neuroprotective, and brain-blood barrier permeability properties.
AID524796Antiplasmodial activity against Plasmodium falciparum W2 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID1173941Antioxidant activity assessed as DPPH radical scavenging activity at 100 uM after 60 mins by spectrophotometry2014Bioorganic & medicinal chemistry, Dec-01, Volume: 22, Issue:23
Structural modifications of coumarin derivatives: Determination of antioxidant and lipoxygenase (LOX) inhibitory activity.
AID625353Antioxidant activity assessed as DPPH free radical scavenging activity at 100 uM after 60 mins2011European journal of medicinal chemistry, Dec, Volume: 46, Issue:12
Synthesis and biological evaluation of (2,5-dihydro-1H-pyrrol-1-yl)-2H-chromen-2-ones as free radical scavengers.
AID524792Antiplasmodial activity against Plasmodium falciparum D10 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID380423Antioxidant activity in human HL60 cells assessed as inhibition of TPA-stimulated hydrogen peroxide induced DCFH-DA oxidation by fluorometric microplate assay2006Journal of natural products, Mar, Volume: 69, Issue:3
Schisandrene, a dibenzocyclooctadiene lignan from Schisandra chinensis: structure-antioxidant activity relationships of dibenzocyclooctadiene lignans.
AID7141Percent inhibition of rat neutrophil 5-lipoxygenase (5-LO)1987Journal of medicinal chemistry, Jan, Volume: 30, Issue:1
Substituted arylmethyl phenyl ethers. 1. A novel series of 5-lipoxygenase inhibitors and leukotriene antagonists.
AID303032Antioxidant activity assessed as DPPH radical scavenging activity at 0.05 mM after 20 mins2007Bioorganic & medicinal chemistry letters, Dec-01, Volume: 17, Issue:23
Synthesis and anti-inflammatory/antioxidant activities of some new ring substituted 3-phenyl-1-(1,4-di-N-oxide quinoxalin-2-yl)-2-propen-1-one derivatives and of their 4,5-dihydro-(1H)-pyrazole analogues.
AID1083338Antiviral activity against Vaccinia virus infected human HEL cells assessed as inhibition of virus-induced cytopathicity2011Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents, , Volume: 20, Issue:2
The novel amidocarbamate derivatives of ketoprofen: synthesis and biological activity.
AID1364654Inhibition of human 17beta-HSD2 expressed in HEK293 cell lysates incubated for 10 mins using [2,4,6,7-3H]-estradiol and NAD+ by scintillation counting method2017Journal of natural products, 04-28, Volume: 80, Issue:4
Potential Antiosteoporotic Natural Product Lead Compounds That Inhibit 17β-Hydroxysteroid Dehydrogenase Type 2.
AID611380Inhibition of human 15-lipoxygenase2011Journal of medicinal chemistry, Aug-11, Volume: 54, Issue:15
Discovery of potent and selective inhibitors of human platelet-type 12- lipoxygenase.
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID440880Antioxidant activity assessed as DPPH free radical scavenging activity at 0.05 mM after 20 mins2009European journal of medicinal chemistry, Dec, Volume: 44, Issue:12
Synthesis and anti-inflammatory evaluation of novel angularly or linearly fused coumarins.
AID1426087Antiproliferative activity against human MGC803 cells after 72 hrs by MTT assay2017European journal of medicinal chemistry, Feb-15, Volume: 127Synthesis, biological evaluation, QSAR and molecular dynamics simulation studies of potential fibroblast growth factor receptor 1 inhibitors for the treatment of gastric cancer.
AID400125Inhibition of 5-lipoxygenase1998Journal of natural products, Mar, Volume: 61, Issue:3
5-Lipoxygenase and cyclooxygenase-1 inhibitory active compounds from Atractylodes lancea.
AID132251Inhibition of arachidonic acid oedema in mouse ear.1996Journal of medicinal chemistry, Jan-05, Volume: 39, Issue:1
Dibenzoxepinone hydroxylamines and hydroxamic acids: dual inhibitors of cyclooxygenase and 5-lipoxygenase with potent topical antiinflammatory activity.
AID1083329Antiviral activity against Unidentified Influenza A virus (H1N2) infected MDCK cells assessed as inhibition of virus-induced cytopathicity2011Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents, , Volume: 20, Issue:2
The novel amidocarbamate derivatives of ketoprofen: synthesis and biological activity.
AID160519Concentration required for 50 % inhibition of leukotriene B4 production in human PMN compared with controls in the absence of compound1989Journal of medicinal chemistry, Jun, Volume: 32, Issue:6
Synthesis and structure-activity relationships of a novel class of 5-lipoxygenase inhibitors. 2-(Phenylmethyl)-4-hydroxy-3,5-dialkylbenzofurans: the development of L-656,224.
AID363804Inhibition of bovine 5LOX2008European journal of medicinal chemistry, Jun, Volume: 43, Issue:6
Investigations concerning the COX/5-LOX inhibiting and hydroxyl radical scavenging potencies of novel 4,5-diaryl isoselenazoles.
AID3108Inhibitory activity against human platelet 12-lipoxygenase (12-HLO)2002Journal of medicinal chemistry, Jun-06, Volume: 45, Issue:12
Structure-activity relationship studies of nordihydroguaiaretic acid inhibitors toward soybean, 12-human, and 15-human lipoxygenase.
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1335588Inhibition of soybean LOX assessed as reduction in conversion of sodium linoleate to 13-hydroperoxylinoleic acid at 1 x 10'-4 M relative to control2016European journal of medicinal chemistry, Nov-29, Volume: 124Novel urea and bis-urea primaquine derivatives with hydroxyphenyl or halogenphenyl substituents: Synthesis and biological evaluation.
AID745289Antioxidant activity assessed as DPPH free radical scavenging activity at 100 uM after 20 mins by spectrophotometry2013European journal of medicinal chemistry, May, Volume: 63Analysis of the antioxidant properties of differently substituted 2- and 3-indolyl carbohydrazides and related derivatives.
AID653294Inhibition of soybean LOX assessed as conversion of sodium linoleate to 13- hydroperoxylinoleic acid at 100 uM2012European journal of medicinal chemistry, May, Volume: 51Novel NSAID 1-acyl-4-cycloalkyl/arylsemicarbazides and 1-acyl-5-benzyloxy/hydroxy carbamoylcarbazides as potential anticancer agents and antioxidants.
AID494206Antioxidant activity assessed as DPPH free radical scavenging activity after 30 mins2010European journal of medicinal chemistry, Aug, Volume: 45, Issue:8
Structure-activity relationship studies of acridones as potential antipsoriatic agents. 1. Synthesis and antiproliferative activity of simple N-unsubstituted 10H-acridin-9-ones against human keratinocyte growth.
AID611381Inhibition of human platelet-type 12-lipoxygenase2011Journal of medicinal chemistry, Aug-11, Volume: 54, Issue:15
Discovery of potent and selective inhibitors of human platelet-type 12- lipoxygenase.
AID7125In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 10 uM concentration2001Bioorganic & medicinal chemistry letters, Mar-26, Volume: 11, Issue:6
N-Aminoindoline derivatives as inhibitors of 5-lipoxygenase.
AID254899In vitro inhibitory activity against 5-lipoxygenase obtained from potato2005Bioorganic & medicinal chemistry letters, Nov-01, Volume: 15, Issue:21
Synthesis and biological evaluation of 1,3-diphenylprop-2-yn-1-ones as dual inhibitors of cyclooxygenases and lipoxygenases.
AID521220Inhibition of neurosphere proliferation of mouse neural precursor cells by MTT assay2007Nature chemical biology, May, Volume: 3, Issue:5
Chemical genetics reveals a complex functional ground state of neural stem cells.
AID1163383Inhibition of soybean LOX using sodium linoleate as substrate at 100 uM by spectrophotometry2014European journal of medicinal chemistry, Oct-30, Volume: 86Novel semicarbazides and ureas of primaquine with bulky aryl or hydroxyalkyl substituents: synthesis, cytostatic and antioxidative activity.
AID630142Inhibition of human 5-LOX in human peripheral blood mononuclear leukocytes assessed as inhibition of calymycin A23187-stimulated LTB4 production preincubated for 15 mins before stimulation measured after 15 mins by enzyme immunoassay2011Bioorganic & medicinal chemistry, Nov-01, Volume: 19, Issue:21
Bioassay-guided identification of an anti-inflammatory prenylated acylphloroglucinol from Melicope ptelefolia and molecular insights into its interaction with 5-lipoxygenase.
AID653292Antioxidant activity assessed as DPPH free radical scavenging activity at 100 uM after 60 mins by spectrophotometric analysis2012European journal of medicinal chemistry, May, Volume: 51Novel NSAID 1-acyl-4-cycloalkyl/arylsemicarbazides and 1-acyl-5-benzyloxy/hydroxy carbamoylcarbazides as potential anticancer agents and antioxidants.
AID1592997Inhibition of soya bean 15-LOX by colorimetric lipoxygenase inhibitor screening assay kit method2019European journal of medicinal chemistry, Apr-01, Volume: 167Shooting three inflammatory targets with a single bullet: Novel multi-targeting anti-inflammatory glitazones.
AID567047DPPH radical scavenging activity assessed as reducing ability at 0.2 mM after 20 mins2011European journal of medicinal chemistry, Jan, Volume: 46, Issue:1
Design, synthesis and pharmacobiological evaluation of novel acrylic acid derivatives acting as lipoxygenase and cyclooxygenase-1 inhibitors with antioxidant and anti-inflammatory activities.
AID322957Inhibition of synthetic amyloid beta-42 fibrillation by ThT fluorescence analysis relative to control2007The Journal of biological chemistry, Apr-06, Volume: 282, Issue:14
Small molecule inhibitors of aggregation indicate that amyloid beta oligomerization and fibrillization pathways are independent and distinct.
AID1141993Antioxidant activity assessed as reduction of DPPH free radical formation at 100 uM after 20 mins relative to control2014European journal of medicinal chemistry, Jun-10, Volume: 80Synthesis of stable aromatic and heteroaromatic sulfonyl-amidoximes and evaluation of their antioxidant and lipid peroxidation activity.
AID567043DPPH radical scavenging activity assessed as reducing ability at 0.05 mM after 20 mins2011European journal of medicinal chemistry, Jan, Volume: 46, Issue:1
Design, synthesis and pharmacobiological evaluation of novel acrylic acid derivatives acting as lipoxygenase and cyclooxygenase-1 inhibitors with antioxidant and anti-inflammatory activities.
AID548100Antioxidant activity assessed as DPPH free radical scavenging activity at 100 uM after 60 mins2010European journal of medicinal chemistry, Dec, Volume: 45, Issue:12
Convenient synthesis and biological profile of 5-amino-substituted 1,2,4-oxadiazole derivatives.
AID184031In vivo activity against the release of SRS(slow releasing substance)-A in a rat passive intraperitoneally1987Journal of medicinal chemistry, Dec, Volume: 30, Issue:12
Novel 1H-benzimidazol-4-ols with potent 5-lipoxygenase inhibitory activity.
AID333730Inhibition of 5-lipoxygenase activity at 100 uM by ferric-xylenol orange peroxide assay relative to control2004Journal of natural products, Dec, Volume: 67, Issue:12
New acylated iridoid glucosides from Vitex altissima.
AID548099Antioxidant activity assessed as DPPH free radical scavenging activity at 50 uM after 60 mins2010European journal of medicinal chemistry, Dec, Volume: 45, Issue:12
Convenient synthesis and biological profile of 5-amino-substituted 1,2,4-oxadiazole derivatives.
AID1335589Inhibition of soybean LOX assessed as reduction in conversion of sodium linoleate to 13-hydroperoxylinoleic acid2016European journal of medicinal chemistry, Nov-29, Volume: 124Novel urea and bis-urea primaquine derivatives with hydroxyphenyl or halogenphenyl substituents: Synthesis and biological evaluation.
AID1405921Antioxidant activity assessed as DPPH radical scavenging activity relative to control2018European journal of medicinal chemistry, Aug-05, Volume: 156Current progress on antioxidants incorporating the pyrazole core.
AID362172Stability assessed as conversion to (6R,7S)-2,3,10,11-Tetrahydroxy-6,7-dimethyl-5,6,7,8-tetrahydrodibenzo[a,c]cyclooctene) at pH 8.02008Journal of natural products, Sep, Volume: 71, Issue:9
Nordihydroguaiaretic acid autoxidation produces a schisandrin-like dibenzocyclooctadiene lignan.
AID1169299Competitive binding to TTR V30M mutant (unknown origin) expressed in Escherichia coli at 1 to 80 uM by fluorescence assay2014Journal of medicinal chemistry, Nov-13, Volume: 57, Issue:21
Inhibitory activities of propolis and its promising component, caffeic acid phenethyl ester, against amyloidogenesis of human transthyretin.
AID1406148Inhibition of recombinant human MAO-B expressed in baculovirus infected BTI insect cells using p-tyramine as substrate pretreated for 15 mins followed by substrate addition by horse-radish peroxidase/amplex red-based fluorescence method2018European journal of medicinal chemistry, Aug-05, Volume: 156Neurogenic and neuroprotective donepezil-flavonoid hybrids with sigma-1 affinity and inhibition of key enzymes in Alzheimer's disease.
AID1083339Antiviral activity against Human herpesvirus 2 strain G infected human HEL cells assessed as inhibition of virus-induced cytopathicity2011Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents, , Volume: 20, Issue:2
The novel amidocarbamate derivatives of ketoprofen: synthesis and biological activity.
AID452847Antioxidant activity assessed as DPPH radical scavenging activity at 50 uM after 20 mins2009Bioorganic & medicinal chemistry, Dec-01, Volume: 17, Issue:23
Natural and synthetic 2'-hydroxy-chalcones and aurones: synthesis, characterization and evaluation of the antioxidant and soybean lipoxygenase inhibitory activity.
AID101297The compound was tested for its inhibitory activity against LTB4 in human PMN1992Journal of medicinal chemistry, Apr-03, Volume: 35, Issue:7
Development of 2,3-dihydro-6-(3-phenoxypropyl)-2-(2-phenylethyl)-5-benzofuranol (L-670,630) as a potent and orally active inhibitor of 5-lipoxygenase.
AID433937Cytotoxicity against human HepG2 cells after 5 days by MTT assay2009Bioorganic & medicinal chemistry letters, Aug-15, Volume: 19, Issue:16
Synthesis, characterization, and anti-melanoma activity of tetra-O-substituted analogs of nordihydroguaiaretic acid.
AID1083352Antioxidant activity assessed as DPPH radical scavenging activity at 5 X 10'-5 M after 60 min2011Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents, , Volume: 20, Issue:2
The novel amidocarbamate derivatives of ketoprofen: synthesis and biological activity.
AID567045DPPH radical scavenging activity assessed as reducing ability at 0.1 mM after 20 mins2011European journal of medicinal chemistry, Jan, Volume: 46, Issue:1
Design, synthesis and pharmacobiological evaluation of novel acrylic acid derivatives acting as lipoxygenase and cyclooxygenase-1 inhibitors with antioxidant and anti-inflammatory activities.
AID379833Inhibition of LTB4 biosynthesis in A-23187-stimulated bovine PMNL cells1999Journal of natural products, Jun, Volume: 62, Issue:6
Lichen metabolites. 1. Inhibitory action against leukotriene B4 biosynthesis by a non-redox mechanism.
AID567048DPPH radical scavenging activity assessed as reducing ability at 0.2 mM after 60 mins2011European journal of medicinal chemistry, Jan, Volume: 46, Issue:1
Design, synthesis and pharmacobiological evaluation of novel acrylic acid derivatives acting as lipoxygenase and cyclooxygenase-1 inhibitors with antioxidant and anti-inflammatory activities.
AID379832Inhibition of AAPH-induced lipid peroxidation in bovine brain phospholipid liposome1999Journal of natural products, Jun, Volume: 62, Issue:6
Lichen metabolites. 1. Inhibitory action against leukotriene B4 biosynthesis by a non-redox mechanism.
AID1253364Stability of compound assessed as formation of cNDGA in phosphate citric acid buffer at pH 7.4 at 37 degC by HPLC-UV analysis2015Bioorganic & medicinal chemistry, Nov-01, Volume: 23, Issue:21
Ring substitution influences oxidative cyclisation and reactive metabolite formation of nordihydroguaiaretic acid analogues.
AID566097Inhibition of soybean LOX at 0.1 mM2011European journal of medicinal chemistry, Jan, Volume: 46, Issue:1
One-pot microwave assisted synthesis under green chemistry conditions, antioxidant screening, and cytotoxicity assessments of benzimidazole Schiff bases and pyrimido[1,2-a]benzimidazol-3(4H)-ones.
AID519606Antimicrobial activity against Plasmodium yoelii 265 liver infected in mammalian hepatocytes after 48 hrs2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
New active drugs against liver stages of Plasmodium predicted by molecular topology.
AID25770Reducing activity against 2,2-diphenyl-1-picrylhydrazyl1993Journal of medicinal chemistry, Dec-10, Volume: 36, Issue:25
Antipsoriatic anthrones with modulated redox properties. 1. Novel 10-substituted 1,8-dihydroxy-9(10H)-anthracenones as inhibitors of 5-lipoxygenase.
AID104137Inhibition of 2,2'-azobis(2-aminopropane)hydrochloride (AAPH) induced lipid peroxidation in bovine brain phospholipid liposomes1994Journal of medicinal chemistry, May-27, Volume: 37, Issue:11
Antipsoriatic anthrones with modulated redox properties. 2. Novel derivatives of chrysarobin and isochrysarobin--antiproliferative activity and 5-lipoxygenase inhibition.
AID255239Percent inhibition of soybean lipoxygenase upon incubation with sodium linoleate (0.1 mM) at RT2005Journal of medicinal chemistry, Oct-06, Volume: 48, Issue:20
Synthesis and antiinflammatory activity of coumarin derivatives.
AID256502Percent heme protein dependent lipid peroxidation at (1 mM) upon incubation for 10 min at 37 degree C. in pH 7.4 with arachidonic acid and H2O22005Journal of medicinal chemistry, Oct-06, Volume: 48, Issue:20
Synthesis and antiinflammatory activity of coumarin derivatives.
AID8440Inhibitory activity was determined against 9-cis-epoxycarotenoid dioxygenase (NCED) expressed in Escherichia coli in presence of 9''-cis-neo-xanthin2004Bioorganic & medicinal chemistry letters, Jun-21, Volume: 14, Issue:12
A new lead compound for abscisic acid biosynthesis inhibitors targeting 9-cis-epoxycarotenoid dioxygenase.
AID6859In vitro inhibitory concentration against 5-lipoxygenase in RBL-1 cells2001Bioorganic & medicinal chemistry letters, Mar-26, Volume: 11, Issue:6
N-Aminoindoline derivatives as inhibitors of 5-lipoxygenase.
AID363801Inhibition of bovine COX1 at 10 uM2008European journal of medicinal chemistry, Jun, Volume: 43, Issue:6
Investigations concerning the COX/5-LOX inhibiting and hydroxyl radical scavenging potencies of novel 4,5-diaryl isoselenazoles.
AID724355Inhibition of soybean LOX using sodium linoleate as substrate by spectrophotometric analysis2013European journal of medicinal chemistry, Feb, Volume: 60Syntheses and evaluation of the antioxidant activity of novel methoxypsoralen derivatives.
AID1736439Inhibition of human 5-Lipoxygenase using H2DCFDA as substrate preincubated for 5 mins and measured by Spectrophotometric assay2020European journal of medicinal chemistry, Mar-15, Volume: 190Tuning melatonin receptor subtype selectivity in oxadiazolone-based analogues: Discovery of QR2 ligands and NRF2 activators with neurogenic properties.
AID1253361Stability of compound assessed as level of starting material at 37 degC for 6 hrs in absence of glutathione2015Bioorganic & medicinal chemistry, Nov-01, Volume: 23, Issue:21
Ring substitution influences oxidative cyclisation and reactive metabolite formation of nordihydroguaiaretic acid analogues.
AID1542244Inhibition of soya bean 15-LOX by colorimetric lipoxygenase inhibitor screening assay kit method2019European journal of medicinal chemistry, Apr-01, Volume: 167Tackling neuroinflammation and cholinergic deficit in Alzheimer's disease: Multi-target inhibitors of cholinesterases, cyclooxygenase-2 and 15-lipoxygenase.
AID309798Inhibition of 12-hLO2007Bioorganic & medicinal chemistry, Dec-01, Volume: 15, Issue:23
Structure-activity relationship studies of flavonoids as potent inhibitors of human platelet 12-hLO, reticulocyte 15-hLO-1, and prostate epithelial 15-hLO-2.
AID625358Antioxidant activity assessed as DPPH free radical scavenging activity at 100 uM2011European journal of medicinal chemistry, Dec, Volume: 46, Issue:12
Synthesis and biological evaluation of (2,5-dihydro-1H-pyrrol-1-yl)-2H-chromen-2-ones as free radical scavengers.
AID392743Antioxidant activity assessed as DPPH radical scavenging activity at 0.05 mM after 60 mins2009Bioorganic & medicinal chemistry letters, Feb-15, Volume: 19, Issue:4
Synthesis of hydroxycoumarins and hydroxybenzo[f]- or [h]coumarins as lipid peroxidation inhibitors.
AID160706In vitro inhibition of Prostaglandin G/H synthase in BSV cell line.1990Journal of medicinal chemistry, Jan, Volume: 33, Issue:1
2-substituted-1-naphthols as potent 5-lipoxygenase inhibitors with topical antiinflammatory activity.
AID519607Cytotoxicity against Hepatocyte cells assessed as cell viability by MTT assay2008Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4
New active drugs against liver stages of Plasmodium predicted by molecular topology.
AID1617776Inhibition of human recombinant N-terminal His-tagged 15-LOX2 expressed in Escherichia coli using arachidonic acid as substrate preincubated for 5 mins followed by substrate addition measured after 20 mins in dark by ferric ion oxidation-xylenol orange as2019Journal of natural products, 12-27, Volume: 82, Issue:12
Structure-Activity Relationships of Pentacyclic Triterpenoids as Inhibitors of Cyclooxygenase and Lipoxygenase Enzymes.
AID524793Antiplasmodial activity against Plasmodium falciparum Dd2 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID1083333Antiviral activity against Human coxsackievirus B4 infected human HeLa cells assessed as inhibition of virus-induced cytopathicity2011Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents, , Volume: 20, Issue:2
The novel amidocarbamate derivatives of ketoprofen: synthesis and biological activity.
AID524794Antiplasmodial activity against Plasmodium falciparum GB4 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID286754Antioxidant activity assessed as DPPH reducing activity at 0.1 mM after 60 mins2007Journal of medicinal chemistry, May-17, Volume: 50, Issue:10
Design and synthesis of novel quinolinone-3-aminoamides and their alpha-lipoic acid adducts as antioxidant and anti-inflammatory agents.
AID567038Inhibition of soybean LOX2011European journal of medicinal chemistry, Jan, Volume: 46, Issue:1
Design, synthesis and pharmacobiological evaluation of novel acrylic acid derivatives acting as lipoxygenase and cyclooxygenase-1 inhibitors with antioxidant and anti-inflammatory activities.
AID471737Antioxidant activity assessed as DPPH free radical scavenging activity at 0.1 mM after 60 mins2009Bioorganic & medicinal chemistry letters, Nov-15, Volume: 19, Issue:22
Synthesis of modified homo-N-nucleosides from the reactions of mesityl nitrile oxide with 9-allylpurines and their influence on lipid peroxidation and thrombin inhibition.
AID1083342Antiviral activity against Punta Toro virus infected Hela cells assessed as inhibition of virus-induced cytopathicity2011Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents, , Volume: 20, Issue:2
The novel amidocarbamate derivatives of ketoprofen: synthesis and biological activity.
AID345785Inhibition of COX12008Bioorganic & medicinal chemistry, Dec-15, Volume: 16, Issue:24
Characterization of novel furan compounds on the basis of their radical scavenging activity and cytoprotective effects against glutamate- and lipopolysaccharide-induced insults.
AID442512Antioxidant activity assessed as DPPH radical scavenging activity at 100 uM after 60 mins by spectrophotometry2010European journal of medicinal chemistry, Jan, Volume: 45, Issue:1
Syntheses and evaluation of the antioxidant activity of acitretin analogs with amide bond(s) in the polyene spacer.
AID132224In vivo inhibition of AA induced ear oedema in mice following topical administration.1990Journal of medicinal chemistry, Oct, Volume: 33, Issue:10
Penta- and hexadienoic acid derivatives: a novel series of 5-lipoxygenase inhibitors.
AID1173943Inhibition of soybean LOX assessed as reduction in conversion of sodium linoleate to 13-hydroperoxylinoleic acid by UV spectroscopy2014Bioorganic & medicinal chemistry, Dec-01, Volume: 22, Issue:23
Structural modifications of coumarin derivatives: Determination of antioxidant and lipoxygenase (LOX) inhibitory activity.
AID132112In vivo inhibition of ear oedema in mice following p.o. administration.1990Journal of medicinal chemistry, Oct, Volume: 33, Issue:10
Penta- and hexadienoic acid derivatives: a novel series of 5-lipoxygenase inhibitors.
AID1071731Inhibition of soybean lipoxygenase at 100 uM2014Bioorganic & medicinal chemistry letters, Mar-01, Volume: 24, Issue:5
Lipoxygenase inhibitors derived from marine macroalgae.
AID1257018Antioxidant activity assessed as increase of DPPH free radical scavenging activity by measuring reducing activity at 100 uM after 60 mins by spectrophotometry2015Bioorganic & medicinal chemistry, Nov-15, Volume: 23, Issue:22
Synthesis and biological evaluation of new C-10 substituted dithranol pleiotropic hybrids.
AID490943Antioxidant activity assessed as DPPH radical scavenging activity at 50 uM after 20 mins2010European journal of medicinal chemistry, Jul, Volume: 45, Issue:7
Synthesis and biological screening of some novel amidocarbamate derivatives of ketoprofen.
AID1083332Antiviral activity against Respiratory syncytial virus infected human HeLa cells assessed as inhibition of virus-induced cytopathicity2011Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents, , Volume: 20, Issue:2
The novel amidocarbamate derivatives of ketoprofen: synthesis and biological activity.
AID549588Antiinflammatory activity in CD1 mouse assessed as inhibition of croton oil-induced ear edema at 0.3 umol administered topically per cm'2 of ear relative to control2011Bioorganic & medicinal chemistry letters, Jan-15, Volume: 21, Issue:2
Topical anti-inflammatory activity of boropinic acid and its natural and semi-synthetic derivatives.
AID322955Inhibition of synthetic amyloid beta-42 oligomerization by ELISA2007The Journal of biological chemistry, Apr-06, Volume: 282, Issue:14
Small molecule inhibitors of aggregation indicate that amyloid beta oligomerization and fibrillization pathways are independent and distinct.
AID354432Inhibition of His-tagged human reticulocyte 15-lipoxygenase2003Journal of natural products, Feb, Volume: 66, Issue:2
Exploring sponge-derived terpenoids for their potency and selectivity against 12-human, 15-human, and 15-soybean lipoxygenases.
AID745283Inhibition of soybean lipoxygenase2013European journal of medicinal chemistry, May, Volume: 63Analysis of the antioxidant properties of differently substituted 2- and 3-indolyl carbohydrazides and related derivatives.
AID286753Antioxidant activity assessed as DPPH reducing activity at 0.1 mM after 20 mins2007Journal of medicinal chemistry, May-17, Volume: 50, Issue:10
Design and synthesis of novel quinolinone-3-aminoamides and their alpha-lipoic acid adducts as antioxidant and anti-inflammatory agents.
AID485952Selectivity ratio of IC50 for human platelet 12-lipoxygenase to IC50 for human 5-lipoxygenase2009Journal of natural products, Oct, Volume: 72, Issue:10
Using enzyme assays to evaluate the structure and bioactivity of sponge-derived meroterpenes.
AID147684Compound is evaluated for inhibitory effect on the generation of Leukotriene B4 (LTB4) from human neutrophils1987Journal of medicinal chemistry, Nov, Volume: 30, Issue:11
Synthesis and antiinflammatory activities of 3-(3,5-di-tert-butyl-4-hydroxybenzylidene)pyrrolidin-2-ones.
AID1551036Inhibition of soybean 15-LOX using arachidonic acid or linoleic acid as substrate incubated for 10 mins by colorimetric lipoxygenase inhibitor screening assay kit method
AID676989Antioxidant activity assessed as reduction of DPPH radical generation at 50 uM incubated for 20 mins at room temperature2012Bioorganic & medicinal chemistry, Sep-01, Volume: 20, Issue:17
Synthesis of sulfur containing dihydro-pyrrolo derivatives and their biological evaluation as antioxidants.
AID204321Effect of compound at 100 uM concentration on ABA accumulation in spinachleaf slices determined as fresh weight of leaves (Experiment 3)2004Bioorganic & medicinal chemistry letters, Jun-21, Volume: 14, Issue:12
A new lead compound for abscisic acid biosynthesis inhibitors targeting 9-cis-epoxycarotenoid dioxygenase.
AID724357Antioxidant activity assessed as DPPH radical scavenging activity at 100 uM after 60 mins by spectrophotometric analysis2013European journal of medicinal chemistry, Feb, Volume: 60Syntheses and evaluation of the antioxidant activity of novel methoxypsoralen derivatives.
AID204320Effect of compound at 100 uM concentration on ABA accumulation in spinachleaf slices determined as fresh weight of leaves (Experiment 2)2004Bioorganic & medicinal chemistry letters, Jun-21, Volume: 14, Issue:12
A new lead compound for abscisic acid biosynthesis inhibitors targeting 9-cis-epoxycarotenoid dioxygenase.
AID392744Antioxidant activity assessed as DPPH radical scavenging activity at 0.01 mM after 20 mins2009Bioorganic & medicinal chemistry letters, Feb-15, Volume: 19, Issue:4
Synthesis of hydroxycoumarins and hydroxybenzo[f]- or [h]coumarins as lipid peroxidation inhibitors.
AID347221Inhibition of COX1 in bovine platelets assessed as formation of 12-hydroxyheptadecatrienoic acid by HPLC2009Bioorganic & medicinal chemistry, Jan-15, Volume: 17, Issue:2
Diaryl-dithiolanes and -isothiazoles: COX-1/COX-2 and 5-LOX-inhibitory, *OH scavenging and anti-adhesive activities.
AID6951Inhibition against 5-lipoxygenase from guinea pig polymorphonuclear lymphocytes1990Journal of medicinal chemistry, Apr, Volume: 33, Issue:4
Development of a novel series of (2-quinolinylmethoxy)phenyl-containing compounds as high-affinity leukotriene receptor antagonists. 1. Initial structure-activity relationships.
AID1173940Antioxidant activity assessed as DPPH radical scavenging activity at 100 uM after 20 mins by spectrophotometry2014Bioorganic & medicinal chemistry, Dec-01, Volume: 22, Issue:23
Structural modifications of coumarin derivatives: Determination of antioxidant and lipoxygenase (LOX) inhibitory activity.
AID339217Inhibition of lipoxygenase-5 in human ED273b-BT cells assessed as amount of cysteinyl leukotriene secreted after 24 hrs by immunoassay2008Bioorganic & medicinal chemistry letters, Jul-15, Volume: 18, Issue:14
Synthesis and biological evaluation of 1-(benzenesulfonamido)-2-[5-(N-hydroxypyridin-2(1H)-one)]acetylene regioisomers: a novel class of 5-lipoxygenase inhibitors.
AID567046DPPH radical scavenging activity assessed as reducing ability at 0.1 mM after 60 mins2011European journal of medicinal chemistry, Jan, Volume: 46, Issue:1
Design, synthesis and pharmacobiological evaluation of novel acrylic acid derivatives acting as lipoxygenase and cyclooxygenase-1 inhibitors with antioxidant and anti-inflammatory activities.
AID345787Inhibition of 5LOX2008Bioorganic & medicinal chemistry, Dec-15, Volume: 16, Issue:24
Characterization of novel furan compounds on the basis of their radical scavenging activity and cytoprotective effects against glutamate- and lipopolysaccharide-induced insults.
AID362171Stability assessed as half life at pH 7.42008Journal of natural products, Sep, Volume: 71, Issue:9
Nordihydroguaiaretic acid autoxidation produces a schisandrin-like dibenzocyclooctadiene lignan.
AID754971Inhibition of N-terminal His6-tagged human prostate epithelial 15-LOX2 pseudoperoxidase activity assessed as decomposition of 13-(S)-HPODE at 20 uM measured over 30 mins by UV-vis spectrophotometric analysis2013Bioorganic & medicinal chemistry, Jul-01, Volume: 21, Issue:13
Pseudoperoxidase investigations of hydroperoxides and inhibitors with human lipoxygenases.
AID322958Inhibition of synthetic amyloid beta-42 fibrillation by light scattering analysis relative to control2007The Journal of biological chemistry, Apr-06, Volume: 282, Issue:14
Small molecule inhibitors of aggregation indicate that amyloid beta oligomerization and fibrillization pathways are independent and distinct.
AID254906In vitro inhibitory activity against 15-lipoxygenase obtained from soybean2005Bioorganic & medicinal chemistry letters, Nov-01, Volume: 15, Issue:21
Synthesis and biological evaluation of 1,3-diphenylprop-2-yn-1-ones as dual inhibitors of cyclooxygenases and lipoxygenases.
AID1426086Antiproliferative activity against human SGC7901 cells after 72 hrs by MTT assay2017European journal of medicinal chemistry, Feb-15, Volume: 127Synthesis, biological evaluation, QSAR and molecular dynamics simulation studies of potential fibroblast growth factor receptor 1 inhibitors for the treatment of gastric cancer.
AID433939Cytotoxicity against human A375 cells assessed as inhibition of DNA synthesis in at 50 uM2009Bioorganic & medicinal chemistry letters, Aug-15, Volume: 19, Issue:16
Synthesis, characterization, and anti-melanoma activity of tetra-O-substituted analogs of nordihydroguaiaretic acid.
AID1184083Inhibition of 15-LO1-mediated 15-HPETE formation in human eosinophil using arachidonic acid as substrate assessed as residual activity at 100 uM preincubated for 15 mins before substrate addition measured after 10 mins2014European journal of medicinal chemistry, Sep-12, Volume: 84Multi-dimensional target profiling of N,4-diaryl-1,3-thiazole-2-amines as potent inhibitors of eicosanoid metabolism.
AID754974Inhibition of N-terminal His6-tagged human prostate epithelial 15-LOX2 pseudoperoxidase activity assessed as reduction of active ferric ion to inactive ferrous state measured decomposition of 13-(S)-HPODE at 40 uM after 30 mins by iron-xylenol orange stai2013Bioorganic & medicinal chemistry, Jul-01, Volume: 21, Issue:13
Pseudoperoxidase investigations of hydroperoxides and inhibitors with human lipoxygenases.
AID630140Inhibition of soybean 15-LOX type 1-B assessed as inhibition of conversion of linoleic acid to (9Z,11E)-(13S)-13-hydroperoxyoctadeca-9,11-dienoate at 25 ug/ml preincubated for 10 mins before substrate addition measured after 6 mins by spectrophotometry2011Bioorganic & medicinal chemistry, Nov-01, Volume: 19, Issue:21
Bioassay-guided identification of an anti-inflammatory prenylated acylphloroglucinol from Melicope ptelefolia and molecular insights into its interaction with 5-lipoxygenase.
AID1083335Antiviral activity against Mammalian orthoreovirus 1 infected VERO cells assessed as inhibition of virus-induced cytopathicity2011Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents, , Volume: 20, Issue:2
The novel amidocarbamate derivatives of ketoprofen: synthesis and biological activity.
AID1406147Inhibition of recombinant human MAO-A expressed in baculovirus infected BTI insect cells using p-tyramine as substrate pretreated for 15 mins followed by substrate addition by horse-radish peroxidase/amplex red-based fluorescence method2018European journal of medicinal chemistry, Aug-05, Volume: 156Neurogenic and neuroprotective donepezil-flavonoid hybrids with sigma-1 affinity and inhibition of key enzymes in Alzheimer's disease.
AID549591Antiinflammatory activity in CD1 mouse assessed as inhibition of croton oil-induced ear edema at 1 umol administered topically per cm'2 of ear relative to control2011Bioorganic & medicinal chemistry letters, Jan-15, Volume: 21, Issue:2
Topical anti-inflammatory activity of boropinic acid and its natural and semi-synthetic derivatives.
AID261410Inhibitory activity against 4% NaCl-induced abdominal constriction in Sprague-Dawley rat after 30 min of 30 mg/kg, po2006Journal of medicinal chemistry, Mar-09, Volume: 49, Issue:5
Synthesis and structure-activity relationship studies of 1,3-diarylprop-2-yn-1-ones: dual inhibitors of cyclooxygenases and lipoxygenases.
AID1141994Antioxidant activity assessed as reduction of DPPH free radical formation at 100 uM after 60 mins relative to control2014European journal of medicinal chemistry, Jun-10, Volume: 80Synthesis of stable aromatic and heteroaromatic sulfonyl-amidoximes and evaluation of their antioxidant and lipid peroxidation activity.
AID723698Inhibition of ovine COX1 assessed as inhibition of PGF2a production by enzyme immunoassay2013Bioorganic & medicinal chemistry, Jan-15, Volume: 21, Issue:2
Synthesis and biological evaluation of some 5-arylidene-2-(1,3-thiazol-2-ylimino)-1,3-thiazolidin-4-ones as dual anti-inflammatory/antimicrobial agents.
AID289267Reduction of DPPH radical activity at 0.1 mM after 20 mins2007Bioorganic & medicinal chemistry, Sep-01, Volume: 15, Issue:17
Synthesis and pharmacochemical evaluation of novel aryl-acetic acid inhibitors of lipoxygenase, antioxidants, and anti-inflammatory agents.
AID6804Inhibition of 5-lipoxygenase by measuring 5-HETE levels in RBL-1 cell-free supernatant1996Journal of medicinal chemistry, Jan-05, Volume: 39, Issue:1
Dibenzoxepinone hydroxylamines and hydroxamic acids: dual inhibitors of cyclooxygenase and 5-lipoxygenase with potent topical antiinflammatory activity.
AID440881Antioxidant activity assessed as DPPH free radical scavenging activity at 0.1 mM after 20 mins2009European journal of medicinal chemistry, Dec, Volume: 44, Issue:12
Synthesis and anti-inflammatory evaluation of novel angularly or linearly fused coumarins.
AID133223Percentage inhibition of the mouse arachidonic acid induced ear edema assay (AA) at a dose of 100 ug/ear1990Journal of medicinal chemistry, Jan, Volume: 33, Issue:1
2-substituted-1-naphthols as potent 5-lipoxygenase inhibitors with topical antiinflammatory activity.
AID286757Antioxidant activity assessed as DMSO hydroxyl radical scavenging activity at 0.1 mM2007Journal of medicinal chemistry, May-17, Volume: 50, Issue:10
Design and synthesis of novel quinolinone-3-aminoamides and their alpha-lipoic acid adducts as antioxidant and anti-inflammatory agents.
AID402475Inhibition of recombinant human TNF-alpha-induced cytotoxicity of mouse L929 cells assessed as survivality preincubated for 15 mins before TNFalpha addition measured after 24 hrs by [methyl-3H]thymidine incorporation assay1997Journal of natural products, Aug, Volume: 60, Issue:8
Flavonoids as inhibitors or enhancers of the cytotoxicity of tumor necrosis factor-alpha in L-929 tumor cells.
AID433953Toxicity in ip dosed mouse2009Bioorganic & medicinal chemistry letters, Aug-15, Volume: 19, Issue:16
Synthesis, characterization, and anti-melanoma activity of tetra-O-substituted analogs of nordihydroguaiaretic acid.
AID1083336Antiviral activity against Human parainfluenza virus 3 infected Vero cells assessed as inhibition of virus-induced cytopathicity2011Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents, , Volume: 20, Issue:2
The novel amidocarbamate derivatives of ketoprofen: synthesis and biological activity.
AID426433Antioxidant activity assessed as reduction of DPPH activity at 0.5 mM after 60 mins2009European journal of medicinal chemistry, Jul, Volume: 44, Issue:7
Synthesis and evaluation of the antioxidant and anti-inflammatory activity of novel coumarin-3-aminoamides and their alpha-lipoic acid adducts.
AID1083331Antiviral activity against Feline coronavirus infected feline kidney crandell cells assessed as inhibition of virus-induced cytopathicity2011Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents, , Volume: 20, Issue:2
The novel amidocarbamate derivatives of ketoprofen: synthesis and biological activity.
AID541257Antioxidant activity assessed as DPPH radical scavenging activity at 100 uM after 60 mins2010Journal of medicinal chemistry, Dec-09, Volume: 53, Issue:23
1,5-Benzoxazepines vs 1,5-benzodiazepines. one-pot microwave-assisted synthesis and evaluation for antioxidant activity and lipid peroxidation inhibition.
AID1498922Inhibition of soybean lipoxygenase2018Bioorganic & medicinal chemistry, 07-30, Volume: 26, Issue:13
Developing hybrid molecule therapeutics for diverse enzyme inhibitory action: Active role of coumarin-based structural leads in drug discovery.
AID1364657Selectivity index, ratio of inhibition of human 17beta-HSD1 expressed in HEK293 cell lysates to inhibition of human 17beta-HSD2 expressed in HEK293 cell lysates2017Journal of natural products, 04-28, Volume: 80, Issue:4
Potential Antiosteoporotic Natural Product Lead Compounds That Inhibit 17β-Hydroxysteroid Dehydrogenase Type 2.
AID1063903Inhibition of 5-LOX-mediated LTB4 production in human neutrophils using arachidonic acid as substrate at 1 uM preincubated for 10 mins followed by substrate addition measured after 8 mins by enzyme immunoassay relative to control2014European journal of medicinal chemistry, Jan-24, Volume: 72Inhibition of LOX by flavonoids: a structure-activity relationship study.
AID1549812Agonist activity at human TRPA1 Phe909Ala mutant expressed in HEK293 cells assessed as Ca2+ influx at 30 uM by fluorescence assay2019European journal of medicinal chemistry, May-15, Volume: 170N-Cinnamoylanthranilates as human TRPA1 modulators: Structure-activity relationships and channel binding sites.
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1488290Antioxidant activity assessed as DPPH radical scavenging activity after 30 mins in absence of light2017Bioorganic & medicinal chemistry letters, 08-15, Volume: 27, Issue:16
Synthesis, antioxidant and antiproliferative activities of 1,3,4-thiadiazoles derived from phenolic acids.
AID289268Reduction of DPPH radical activity at 0.1 mM after 60 mins2007Bioorganic & medicinal chemistry, Sep-01, Volume: 15, Issue:17
Synthesis and pharmacochemical evaluation of novel aryl-acetic acid inhibitors of lipoxygenase, antioxidants, and anti-inflammatory agents.
AID633583Displacement of 5-iodoacetamidofluorescein labeled SRC23 peptide CKENALLRYLLDKDD human androgen receptor AF2 site expressed in Escherichia coli BL21 cells by fluorescence polarization assay2011Journal of medicinal chemistry, Dec-22, Volume: 54, Issue:24
Targeting the binding function 3 (BF3) site of the human androgen receptor through virtual screening.
AID493017Wombat Data for BeliefDocking1991Journal of medicinal chemistry, Mar, Volume: 34, Issue:3
Indazolinones, a new series of redox-active 5-lipoxygenase inhibitors with built-in selectivity and oral activity.
AID1801850LoxA Selectivity Assay from Article 10.1021/acs.biochem.6b00338: \\Biochemical and Cellular Characterization and Inhibitor Discovery of Pseudomonas aeruginosa 15-Lipoxygenase.\\2016Biochemistry, 06-14, Volume: 55, Issue:23
Biochemical and Cellular Characterization and Inhibitor Discovery of Pseudomonas aeruginosa 15-Lipoxygenase.
AID1801388Inhibition Assay from Article 10.1111/cbdd.12572: \\Lazaroids U83836E and U74389G are potent, time-dependent inhibitors of caspase-1.\\2015Chemical biology & drug design, Nov, Volume: 86, Issue:5
Lazaroids U83836E and U74389G are potent, time-dependent inhibitors of caspase-1.
AID1802593In Vitro Soybean Lipoxygenase (SLO) Inhibition Assay from Article 10.1016/j.bioorg.2017.01.016: \\Substituted furans as potent lipoxygenase inhibitors: Synthesis, in vitro and molecular docking studies.\\2017Bioorganic chemistry, 04, Volume: 71Substituted furans as potent lipoxygenase inhibitors: Synthesis, in vitro and molecular docking studies.
AID1802594Molecular Docking from Article 10.1016/j.bioorg.2017.01.016: \\Substituted furans as potent lipoxygenase inhibitors: Synthesis, in vitro and molecular docking studies.\\2017Bioorganic chemistry, 04, Volume: 71Substituted furans as potent lipoxygenase inhibitors: Synthesis, in vitro and molecular docking studies.
AID1800286Lipo-oxygenase activity assay from Article 10.1111/cbdd.12280: \\Effects of novel diarylpentanoid analogues of curcumin on secretory phospholipase A2 cyclooxygenases, lipo-oxygenase, and microsomal prostaglandin E synthase-1.\\2014Chemical biology & drug design, Jun, Volume: 83, Issue:6
Effects of novel diarylpentanoid analogues of curcumin on secretory phospholipase A2 , cyclooxygenases, lipo-oxygenase, and microsomal prostaglandin E synthase-1.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID504836Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation2002The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16
Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347049Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588378qHTS for Inhibitors of ATXN expression: Validation
AID1347045Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1508628Confirmatory qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347050Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1508627Counterscreen qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: GLuc-NoTag assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID588349qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID1508629Cell Viability qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347059CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347151Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347410qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library2019Cellular signalling, 08, Volume: 60A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID1347058CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347405qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347057CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1687920Inhibition of AcrB in Escherichia coli BW25113 assessed as potentiation of rifampicin induced antibacterial activity by measuring rifampicin MIC at 256 ug/ml measured after 18 hrs by checkerboard titration method (Rvb = 16 ug/ml)2020European journal of medicinal chemistry, Jan-15, Volume: 186Structural optimization of natural product nordihydroguaretic acid to discover novel analogues as AcrB inhibitors.
AID1687893Inhibition of AcrB in Escherichia coli BW25113 assessed as potentiation of chloramphenicol induced antibacterial activity by measuring chloramphenicol MIC at 32 ug/ml measured after 18 hrs by checkerboard titration method (Rvb = 8 ug/ml)2020European journal of medicinal chemistry, Jan-15, Volume: 186Structural optimization of natural product nordihydroguaretic acid to discover novel analogues as AcrB inhibitors.
AID1687912Inhibition of AcrB in Escherichia coli BW25113 assessed as potentiation of levofloxacin induced antibacterial activity by measuring levofloxacin MIC at 64 ug/ml measured after 18 hrs by checkerboard titration method (Rvb = 0.06 ug/ml)2020European journal of medicinal chemistry, Jan-15, Volume: 186Structural optimization of natural product nordihydroguaretic acid to discover novel analogues as AcrB inhibitors.
AID1687928Inhibition of AcrB in Escherichia coli BW25113 assessed as reduction in glucose-induced nile red efflux at 50 to 100 uM preincubated for 15 mins followed by nile red addition and incubated for 3 hrs in shaker in presence of CCCP by fluorimetric analysis2020European journal of medicinal chemistry, Jan-15, Volume: 186Structural optimization of natural product nordihydroguaretic acid to discover novel analogues as AcrB inhibitors.
AID1687894Inhibition of AcrB in Escherichia coli BW25113 assessed as potentiation of chloramphenicol induced antibacterial activity by measuring chloramphenicol MIC at 64 ug/ml measured after 18 hrs by checkerboard titration method (Rvb = 8 ug/ml)2020European journal of medicinal chemistry, Jan-15, Volume: 186Structural optimization of natural product nordihydroguaretic acid to discover novel analogues as AcrB inhibitors.
AID1687908Inhibition of AcrB in Escherichia coli BW25113 assessed as potentiation of tetraphenylphosphonium induced antibacterial activity by measuring tetraphenylphosphonium MIC at 256 ug/ml measured after 18 hrs by checkerboard titration method (Rvb = 1024 ug/ml)2020European journal of medicinal chemistry, Jan-15, Volume: 186Structural optimization of natural product nordihydroguaretic acid to discover novel analogues as AcrB inhibitors.
AID1687901Inhibition of AcrB in Escherichia coli BW25113 assessed as potentiation of erythromycin induced antibacterial activity by measuring erythromycin MIC at 128 ug/ml measured after 18 hrs by checkerboard titration method (Rvb = 64 ug/ml)2020European journal of medicinal chemistry, Jan-15, Volume: 186Structural optimization of natural product nordihydroguaretic acid to discover novel analogues as AcrB inhibitors.
AID1687919Inhibition of AcrB in Escherichia coli BW25113 assessed as potentiation of rifampicin induced antibacterial activity by measuring rifampicin MIC at 128 ug/ml measured after 18 hrs by checkerboard titration method (Rvb = 16 ug/ml)2020European journal of medicinal chemistry, Jan-15, Volume: 186Structural optimization of natural product nordihydroguaretic acid to discover novel analogues as AcrB inhibitors.
AID1687914Inhibition of AcrB in Escherichia coli BW25113 assessed as potentiation of levofloxacin induced antibacterial activity by measuring levofloxacin MIC at 256 ug/ml measured after 18 hrs by checkerboard titration method (Rvb = 0.06 ug/ml)2020European journal of medicinal chemistry, Jan-15, Volume: 186Structural optimization of natural product nordihydroguaretic acid to discover novel analogues as AcrB inhibitors.
AID1687931Induction of outer membrane permeabilization in wild type Escherichia coli BW25113 assessed as increase in nitrocefin hydrolysis at 256 ug/ml by spectrophotometry analysis2020European journal of medicinal chemistry, Jan-15, Volume: 186Structural optimization of natural product nordihydroguaretic acid to discover novel analogues as AcrB inhibitors.
AID1687899Inhibition of AcrB in Escherichia coli BW25113 assessed as potentiation of erythromycin induced antibacterial activity by measuring erythromycin MIC at 32 ug/ml measured after 18 hrs by checkerboard titration method (Rvb = 64 ug/ml)2020European journal of medicinal chemistry, Jan-15, Volume: 186Structural optimization of natural product nordihydroguaretic acid to discover novel analogues as AcrB inhibitors.
AID1687895Inhibition of AcrB in Escherichia coli BW25113 assessed as potentiation of chloramphenicol induced antibacterial activity by measuring chloramphenicol MIC at 128 ug/ml measured after 18 hrs by checkerboard titration method (Rvb = 8 ug/ml)2020European journal of medicinal chemistry, Jan-15, Volume: 186Structural optimization of natural product nordihydroguaretic acid to discover novel analogues as AcrB inhibitors.
AID1687906Inhibition of AcrB in Escherichia coli BW25113 assessed as potentiation of tetraphenylphosphonium induced antibacterial activity by measuring tetraphenylphosphonium MIC at 64 ug/ml measured after 18 hrs by checkerboard titration method (Rvb = 1024 ug/ml)2020European journal of medicinal chemistry, Jan-15, Volume: 186Structural optimization of natural product nordihydroguaretic acid to discover novel analogues as AcrB inhibitors.
AID1687902Inhibition of AcrB in Escherichia coli BW25113 assessed as potentiation of erythromycin induced antibacterial activity by measuring erythromycin MIC at 256 ug/ml measured after 18 hrs by checkerboard titration method (Rvb = 64 ug/ml)2020European journal of medicinal chemistry, Jan-15, Volume: 186Structural optimization of natural product nordihydroguaretic acid to discover novel analogues as AcrB inhibitors.
AID1401189Cytoprotective activity against H2O2-induced damage in rat PC12 cells assessed as increase in cell viability at 5 uM preincubated for 1 hr followed by H2O2 challenge measured after 24 hrs by MTT assay2018European journal of medicinal chemistry, Jan-01, Volume: 143Design, synthesis, and evaluation of NDGA analogues as potential anti-ischemic stroke agents.
AID1687907Inhibition of AcrB in Escherichia coli BW25113 assessed as potentiation of tetraphenylphosphonium induced antibacterial activity by measuring tetraphenylphosphonium MIC at 128 ug/ml measured after 18 hrs by checkerboard titration method (Rvb = 1024 ug/ml)2020European journal of medicinal chemistry, Jan-15, Volume: 186Structural optimization of natural product nordihydroguaretic acid to discover novel analogues as AcrB inhibitors.
AID1401187Antioxidant activity assessed as DPPH radical scavenging activity at 20 mg/ml after 30 mins2018European journal of medicinal chemistry, Jan-01, Volume: 143Design, synthesis, and evaluation of NDGA analogues as potential anti-ischemic stroke agents.
AID1687905Inhibition of AcrB in Escherichia coli BW25113 assessed as potentiation of tetraphenylphosphonium induced antibacterial activity by measuring tetraphenylphosphonium MIC at 32 ug/ml measured after 18 hrs by checkerboard titration method (Rvb = 1024 ug/ml)2020European journal of medicinal chemistry, Jan-15, Volume: 186Structural optimization of natural product nordihydroguaretic acid to discover novel analogues as AcrB inhibitors.
AID1687900Inhibition of AcrB in Escherichia coli BW25113 assessed as potentiation of erythromycin induced antibacterial activity by measuring erythromycin MIC at 64 ug/ml measured after 18 hrs by checkerboard titration method (Rvb = 64 ug/ml)2020European journal of medicinal chemistry, Jan-15, Volume: 186Structural optimization of natural product nordihydroguaretic acid to discover novel analogues as AcrB inhibitors.
AID1401195Induction of Nrf2 translocation in nucleus of rat PC12 cells at 5 uM after 6 hrs by DAPI staining-based fluorescence microscopic method2018European journal of medicinal chemistry, Jan-01, Volume: 143Design, synthesis, and evaluation of NDGA analogues as potential anti-ischemic stroke agents.
AID1687911Inhibition of AcrB in Escherichia coli BW25113 assessed as potentiation of levofloxacin induced antibacterial activity by measuring levofloxacin MIC at 32 ug/ml measured after 18 hrs by checkerboard titration method (Rvb = 0.06 ug/ml)2020European journal of medicinal chemistry, Jan-15, Volume: 186Structural optimization of natural product nordihydroguaretic acid to discover novel analogues as AcrB inhibitors.
AID1687913Inhibition of AcrB in Escherichia coli BW25113 assessed as potentiation of levofloxacin induced antibacterial activity by measuring levofloxacin MIC at 128 ug/ml measured after 18 hrs by checkerboard titration method (Rvb = 0.06 ug/ml)2020European journal of medicinal chemistry, Jan-15, Volume: 186Structural optimization of natural product nordihydroguaretic acid to discover novel analogues as AcrB inhibitors.
AID1687896Inhibition of AcrB in Escherichia coli BW25113 assessed as potentiation of chloramphenicol induced antibacterial activity by measuring chloramphenicol MIC at 256 ug/ml measured after 18 hrs by checkerboard titration method (Rvb = 8 ug/ml)2020European journal of medicinal chemistry, Jan-15, Volume: 186Structural optimization of natural product nordihydroguaretic acid to discover novel analogues as AcrB inhibitors.
AID1687918Inhibition of AcrB in Escherichia coli BW25113 assessed as potentiation of rifampicin induced antibacterial activity by measuring rifampicin MIC at 64 ug/ml measured after 18 hrs by checkerboard titration method (Rvb = 16 ug/ml)2020European journal of medicinal chemistry, Jan-15, Volume: 186Structural optimization of natural product nordihydroguaretic acid to discover novel analogues as AcrB inhibitors.
AID1687933Induction of inner membrane permeabilization in CCCP treated wild type Escherichia coli BW25113 at 64 to 256 ug/ml measured after 10 mins by Di0C2(3) probe based fluorimetric method2020European journal of medicinal chemistry, Jan-15, Volume: 186Structural optimization of natural product nordihydroguaretic acid to discover novel analogues as AcrB inhibitors.
AID1687917Inhibition of AcrB in Escherichia coli BW25113 assessed as potentiation of rifampicin induced antibacterial activity by measuring rifampicin MIC at 32 ug/ml measured after 18 hrs by checkerboard titration method (Rvb = 16 ug/ml)2020European journal of medicinal chemistry, Jan-15, Volume: 186Structural optimization of natural product nordihydroguaretic acid to discover novel analogues as AcrB inhibitors.
AID1401197Induction of Nrf2 translocation in nucleus of rat PC12 cells assessed as upregulation of HO-1 protein expression at 10 uM after 24 hrs by Western blot method2018European journal of medicinal chemistry, Jan-01, Volume: 143Design, synthesis, and evaluation of NDGA analogues as potential anti-ischemic stroke agents.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1798182COX Inhibitor Screening Assay from Article 10.1021/jm0510474: \\Synthesis and structure-activity relationship studies of 1,3-diarylprop-2-yn-1-ones: dual inhibitors of cyclooxygenases and lipoxygenases.\\2006Journal of medicinal chemistry, Mar-09, Volume: 49, Issue:5
Synthesis and structure-activity relationship studies of 1,3-diarylprop-2-yn-1-ones: dual inhibitors of cyclooxygenases and lipoxygenases.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (1,586)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990440 (27.74)18.7374
1990's580 (36.57)18.2507
2000's309 (19.48)29.6817
2010's215 (13.56)24.3611
2020's42 (2.65)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 27.35

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index27.35 (24.57)
Research Supply Index4.93 (2.92)
Research Growth Index5.10 (4.65)
Search Engine Demand Index34.37 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (27.35)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Trials8 (0.52%)5.53%
Reviews4 (2.90%)6.00%
Reviews17 (1.11%)6.00%
Case Studies0 (0.00%)4.05%
Case Studies5 (0.33%)4.05%
Observational0 (0.00%)0.25%
Observational0 (0.00%)0.25%
Other134 (97.10%)84.16%
Other1,497 (98.04%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (7)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Phase 1 Study of Terameprocol (EM-1421) a Survivin and Cyclin-Dependent Kinase-1 (Cdc2) Inhibitor, in Patients With Leukemia [NCT00664677]Phase 116 participants (Actual)Interventional2007-08-31Terminated(stopped due to Funding constraints)
Phase 1 Dose Escalation and Drug Distribution Study of Oral Terameprocol in Patients With Recurrent High Grade Glioma [NCT02575794]Phase 120 participants (Actual)Interventional2018-05-03Completed
A Phase 1 Continuous Intravenous Infusion Study of Terameprocol (EM-1421) in Subjects With Refractory Solid Tumors. [NCT00664586]Phase 121 participants (Actual)Interventional2007-05-31Terminated(stopped due to Funding constraints)
Open-Label Phase 1 Dose Escalation Study of Intralesional Injection of M4N in Patients With Refractory Malignant Tumors of the Head and Neck [NCT00057512]Phase 19 participants (Actual)Interventional2003-01-31Completed
A Phase I Study of NDGA in Patients With Non-Metastatic Biochemically Relapsed Prostate Cancer [NCT00313534]Phase 115 participants (Actual)Interventional2005-06-30Terminated(stopped due to Ran out of drug)
A Pilot Translational Study of Tetra-O-Methyl Nordihydroguaiaretic Acid (EM-1421) for the Treatment of Cervical Intraepithelial Neoplasia Induced by Human Papilloma Virus [NCT00154089]Phase 1/Phase 28 participants (Actual)Interventional2004-11-30Completed
A Phase II Pharmacokinetic and Efficacy Study of Nordihydroguaiaretic Acid (NDGA) in Non-Metastatic Recurrent Prostate Cancer [NCT00678015]Phase 212 participants (Actual)Interventional2008-05-31Terminated(stopped due to Per protocol - interim analysis showed no significant PSA declines among the first 12 patients after 3 cycles of treatment)
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00678015 (4) [back to overview]Change in Prostate Specific Antigen Doubling Time (PSADT)
NCT00678015 (4) [back to overview]Disease Progression at End of Study
NCT00678015 (4) [back to overview]Prostate Specific Antigen (PSA) Response According to Consensus Criteria
NCT00678015 (4) [back to overview]PSA Decline

Change in Prostate Specific Antigen Doubling Time (PSADT)

PSADT was calculated using the formula natural log 2 divided by the slope of the natural log of the PSA versus time. Pretreatment PSADT was calculated using a minimum of 3 values; end of study PSADT incorporated all measured PSA values on study starting Cycle 2-Day 1 until the patient was removed from the study. (NCT00678015)
Timeframe: Cycle 2 through end of treatment (up to 29 months)

Interventionpercentage change (Median)
NDGA17

[back to top]

Disease Progression at End of Study

End-of-study imaging was assessed for disease progression per Response Evaluation Criteria In Solid Tumors (RECIST) criteria: * Progressive Disease (PD)=At least a 20% increase in the sum of the largest diameter (LD) of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions. (NCT00678015)
Timeframe: Baseline, End of treatment (2-19 cycles)

Interventionparticipants (Number)
NDGA0

[back to top]

Prostate Specific Antigen (PSA) Response According to Consensus Criteria

Participants who experienced a PSA decline of at least 50%, confirmed by a second PSA value 4 or more weeks later. The reference PSA for decline was a PSA measured within 2 weeks of beginning study treatment. If at most 1 PSA response was observed among the first 12 patients, then accrual would stop and the trial would close for futility. (NCT00678015)
Timeframe: Monthly, up to 29 months

Interventionparticipants (Number)
NDGA0

[back to top]

PSA Decline

Number of participants experiencing PSA decline during the first 3 treatment cycles (NCT00678015)
Timeframe: Baseline; Monthly, up to 29 months after beginning treatment

Interventionparticipants (Number)
NDGA7

[back to top]